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Abstract
Pharmaceutical product claim and help-seeking advertisements have prompted the types
and purposes of medical dermatology service(s) that patients have used in the United
States. Indeed, researchers have demonstrated that 94% of working nurse practitioners
affirmed receiving from their patients a request for a cancer drug advertised. However,
adult dermatology patients members of Saint Nicholas Catholic Church or/and patients at
MedStar Clinic in Houston, Texas, have not been of interest for any study so far. The
purpose of this quantitative study was to assess the relationship between product claim,
help-seeking, types, and purposes of medical dermatology services used amongst males
and females aged at least18 years. Prospect theory (PT) was the theoretical framework
used to analyze the purpose of this study. A cross-sectional survey approach permitted to
collect primary data from 120 participants who were members of Saint Nicholas Catholic
Church or/and patients at MedStar Clinic. The results, based on a forced entry multiple
regression analysis at 95% confidence interval, indicated that product claim and helpseeking significantly explained (p ≤ .05) the variances of certain types and purposes of
medical dermatology services used. Thus, product claim and help-seeking predicted the
types and purposes of medical services used by the study population. Pharmaceutical
announcers may benefit from the results of this study by using the study results to create
new direct-to-consumers advertisements for the dermatology health promotion. The study
population may benefit healthy skin, hairs, and nails by using medical dermatology
services after exposure to the new pharmaceutical direct-to-consumer advertisements.
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Chapter 1: Introduction to the Study
Introduction
This section addresses the concepts of Direct-To-Consumer Advertisements
(DTCAs) and the utilization (use) of medical services as the variables of the study.
Analysis of the Concept of DTCA
The pharmaceutical DTCAs are device, drug, and disease information that
pharmaceutical companies and distributors convey directly to consumers, without any
health professional mediation. The DTCAs are marketing or promotion efforts in the
United States of America. According to the United States Food and Drug Administration
(FDA) (2012c), doctors and pharmacists were the information link between drug
manufacturers and consumers until 1980. Indeed, they received drug information from
the manufacturers, and if convenient, passed the information over to the consumers.
However, in the mid-1980s, a sudden change occurred: Some manufacturers started
passing the drug related information via advertising directly to consumers without any
health professional intervention (FDA, 2012c). That was the beginning of the DTCAs of
prescription drug. The phenomenon continued from year to year (FDA, 2012c). Then, in
1997, the development of DTCAs became significant after the FDA (2012a), the
regulatory authority, revised its policy concerning drug firms (Frosch, Grande, Tarn, &
Kravitz, 2010). In addition, the FDA published the federal food, drug, and cosmetic act in
1999, where sections 502 and 503 set the setting to advertise prescription medicines
(FDA, 2012a). The act established that prescription drug advertisement has to be accurate
and avoid misleading the public (FDA, 2012a).
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According to Arney, Street Jr., and Naik (2013), Al-Dmour, Al-Zu’bi, and
Fahmawi (2013), and Van de Pol and De Bakker (2010), the DTCAs reached target
consumers via television, radios, newspapers, magazines, the Internet, and outdoors
media to promote prescription drug and devices and to inform patients about conditions.
The supporting marketing tool of the DTCAs spread was advertising or direct-toconsumer advertising of prescription drug, diseases, and devices (Arney et al., 2013;
Limbu, Huhmann, & Peterson, 2012).
In addition, pharmaceutical research and manufacturers of America (PhRMA) is
the consortium of pharmaceutical companies, leading new drug and biotechnology
research in the United States of America. The group initiated the DTCAs in the 1980s,
passing drug and disease information directly to consumers. That was a breakthrough
given that before the 1980s, pharmaceutical companies were passing drug information to
the physicians and pharmacists who were responsible for determining the necessity of
passing that information to the patients and costumers or not (Dieringer, Kukkamma,
Somes, & Shorr, 2011; Faerber & Kreling, 2012; FDA, 2012c; Van de Pol & De Bakker,
2010). Indeed, PhRMA (2011) claimed that the DTCAs created a medical environment
where patients and care providers did have an informed conversation regarding drug,
diseases, new treatment options, or a particular health concern. Furthermore, PhRMA
thought that the DTCAs of prescription drug and diseases informed people concerning
conditions, provided training to patients on the various treatments available, prompted
patients to discuss health issues with the providers, and prompted patients to stick to the
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drug therapy plan. However, The DTCAs’ roles encounter divergent appreciations in the
public opinion.
A diversified opinion on DTCAs roles. The general opinion about the DTCAs’
role is very divergent. Those who are in favor of the DTCAs think that DTCAs have an
educational value for the target audience. The DTCAs inform patients about prescription
drug, diseases, and possible treatments in a practical way (Arney et al., 2013; Van de Pol
& De Bakker, 2010). The DTCAs empower patients to have a sound medical discussion
with the provider, bring drug prices down through competition stimulation, help patients
better follow their treatment, and enable a better physician-patient relationship in the
process of care delivery (Arney et al., 2013; Van de Pol & De Bakker, 2010).
Conversely, the opponents think that the DTCAs are partial in terms of the
product’s risk and benefits disclosure (more detailed benefits appear in the
advertisement). In addition, the DTCAs costs are part of and increase drug price and lead
to unnecessary prescriptions and test requests as well as the wrong autodiagnosis by
costumers (Arney et al., 2013; Van de Pol & De Bakker, 2010). Moreover, the DTCAs
communicate more curative than preventive medicines and can provoke an unnecessary
prescription of a more expensive new drug compare to an existing cheap one (Arney et
al., 2013; Van de Pol & De Bakker, 2010). The preceding advantages and disadvantages
of the DTCAs continue to nourish the debates whether to ban the practice of the DTCAs
in the United States of America (Lee-Wingate & Xie, 2010; Wellington, 2010). The
practice of the DTCAs is legal in only two countries around the world: the United States
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and New Zealand (Dave & Saffer, 2012; Faerber & Kreling, 2012; Taylor, Bell, &
Kravitz, 2011).
The DTCAs generated spending from the marketers in the United States of
America. In fact, from 2003 through 2006, marketers increased the DTCAs spending. In
2003, pharmaceutical companies invested 3.8 billion dollars in the DTCAs in the United
States of America. The same marketers, increasing the 2003 spending (around 111%
increase), paid 4.2 billion U.S. dollars to support the DTCAs activities in 2005 and 5.6
billion in 2006 (133% increase from 2005; Dave & Saffer, 2012; Lee-Wingate & Xie,
2010; Limbu et al., 2012). In 2009, the DTCAs through all media were $4.6 billion
(Limbu et al., 2012) versus $4,371,000 in 2010 (Kornfield, Donohue, Berndt, &
Alexander, 2013). Some scholars and practitioners correlated the health care cost increase
to the DTCAs spending increase regarding the three types of the DTCAs.
Brief presentation of types of DTCAs and regulation. The three types of
DTCAs that the United States’ FDA recognizes are the focus of this analysis. The FDA
has distinguished three types of DTCAs and has partially regulated the practice of
DTCAs in the United States since 1962 (FDA, 2012a, 2012b; Lee-Wingate & Xie, 2010;
Mulligan, 2011). According to the FDA (2012b) and Lee-Wingate and Xie (2010), the
three forms of DTCAs are product claim, help-seeking, and reminder. Product claim
refers to the advertisement that contains a drug name and the use, the treated condition,
and the associated risks and benefits of the drug use. Help-seeking focuses only on the
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disease without any drug recommendation for treatment. Reminder communicates the
drug name and does not discuss the drug use (FDA, 2012b; Lee-Wingate and Xie, 2010).
In terms of regulation, the FDA is the legal regulatory agency of the DTCAs
(product claim) in the United States. The authority to regulate the DTCAs since 1962 has
been the food, drug, and cosmetic act (FDCA) of 1938 (FD A, 2012e) and its
amendment, namely the food and drug administration amendments act (FDAAA) of 2007
(Abrams, 2011; S. Res. 110-85, 2007). Product claim is the only type of the DTCAs
under FDA regulation (FDA, 2012b; La Barbera, 2012; Rollins, King, Zinkhan, & Perri,
2010). Help-seeking is under Federal Trade Commission regulation. When a help-seeking
advertisement mentions a drug name, it becomes a product claim and consequently falls
under FDA regulations. Reminder advertisement is not under any regulation and is for
experienced patients (FDA, 2012b; La Barbera, 2012).
Product claim and help-seeking advertisements are the two independent variables
of this study. The regulation of the DTCAs in the United States limits the risk of the
consumer being misled by the advertisement. In addition, putting the regulations in place
is not enough. The FDA has to use measures to gain compliance from advertisers or
pharmaceutical companies. At this point, the utilization of medical services as the
dependent variable of this study deserves an attention.
Analysis of the Concept of Utilization of Medical Services
The utilization of medical services is one of the variables of the access to health
services. Health services refer to what a human being undertakes to affect human health
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in terms of keeping a healthy life or condition, shifting from poor to excellent health, or
curing a disease completely (Barton, 2010; Shi & Singh, 2008). The examples of medical
care services are to go to the emergency room, to stay in a hospital, or to use an injury
care in a medical facility (French, Fang, & Balsa, 2011).
The utilization of health services belongs to the types of access to medical care
(Aday & Anderson, 1974; Shi & Singh, 2008). Amongst the different types of access, the
utilization of medical care services is the realization of the access to care. The realization
can encompass four variants: type, site, purpose, and frequency of utilization (Aday &
Anderson, 1974; Shi & Singh, 2008). The type of health care services is the particular
care service and the care provider that can be a hospital, surgeon, nurse, or a physical
therapist (Aday & Anderson, 1974; Shi & Singh, 2008). Then, the site is the venue or
physical place where patient uses or receives medical care services. Moreover, the
purpose represents the reason why the care seeker uses medical care: to prevent, to treat,
to monitor, to stay well, to protect, or to alleviate (Aday & Anderson, 1974; Barton,
2010; Shi & Singh, 2008). Finally, the frequency of the utilization refers to the number of
times the care seeker uses the medical care services during certain time, the quantity of
medical services used in a time frame, and the returning aspect of the patient to use more
medical care services in accordance with influencing factors (Aday & Anderson, 1974).
The medical services utilization occurs when a patient receives medical treatment or
services. The service received varies depending on the place, the outcome, the regularity
of the reception, and the influencing factors.
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Factors influencing the utilization of medical services. Many factors impact the
utilization of medical services. The personal characteristics that influence health services
utilization are age, gender, race, education, religion, ethnic groups, and the number of
family members (Aday & Anderson, 1974; Barton, 2010; Shi & Singh, 2008). The social
factors that determine the use or not of medical care services are the revenue, the price,
the employment status, the mean of payment, and the patient’s job type (Aday &
Anderson, 1974; Barton, 2010; Shi & Singh, 2008).
Conclusion of the Section and Contents of Chapter 1
The FDA differentiates three types of the DTCAs: product claim, help-seeking,
and reminder. Product claim is the only one under FDA’s regulations. Public opinions are
conflicting about the value of the DTCAs. The DTCAs facilitate a sound conversation
between care provider and seeker. Additionally, the DTCAs contribute to the increase in
the costs of the care. The utilization of medical services is the realization of the access to
health care. This realization has four dimensions: types, site, purpose, and frequency of
the utilization. The gender, age, race, education, revenue, price, and job are some factors
that prompt the utilization of medical services.
The analysis of the DTCAs and the utilization of medical care services has led to
the question of a statistically significant relationship between the two concepts. The
answer of this question will follow in the next section in order to identify the gap in the
literature that represents the source of this study. Chapter 1, in addition to the
background, contains the problem statement, purpose of the study, research question(s)
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and hypotheses, theoretical framework, the nature of the study, the operational
definitions, assumptions, scope and delimitations, limitations, significance, and a
summary of the chapter.
Background of the Study
Past researchers have claimed there is a relationship between the pharmaceutical
DTCAs and the utilization of medical services amongst the American population in
general. In the background of the study, I summarize the key literature on the topic,
underline the gap, and justify the need of undertaking this study.
PhRMA Influence
PhRMA has impacted the progress of the DTCAs in the United States of America.
On March 2, 2009, PhRMA published the revised version of personal rules governing the
practice of the DTCAs of prescription drug. PhRMA’s members committed, through the
publication of the principles, to convey plausible and true information to both providers
and patients. According to PhRMA’s members, the information from the DTCAs
supported the delivery and utilization of care by the two parties. The principles aimed to
educate patients more about drug, diseases, and treatment options (PhRMA, 2011). The
principles also enabled PhRMA’s members to follow the DTCAs laws and regulations
from the FDA. In fact, the FDA law requires each DTCA to be true, fair in terms of
drug’s risks and benefits presentation, and not to mislead the public. In addition, the
DTCAs should provide information exactly as the information is in the labeling approved
by the FDA (FDA, 2012a; Phrma, 2011). According to PhRMA and Limbu and Torres
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(2009), the DTCAs information did not seek to persuade the consumer to purchase any
drug or products/services after exposure. However, evidence exists and proves that the
DTCAs prompt the utilization of medical services by patients after exposure.
Evidence in Favor of the Correlation Between DTCAs and the Utilization of Medical
Services
There is evidence supporting that exposure to the DTCAs leads to the utilization
of medical services. In that regard, 69.6% of advanced practice nurses (APNs) have
experienced patients specifying the drug they wanted as the result of their exposure to
DTCA (Mackert, Eastin, & Ball, 2010). Furthermore, 57.8% of the APNs claimed
witnessing patients shifting from an usual prescription drug under use to a new one
because of the effect of the DTCAs (Mackert et al., 2010). Also, 63.8% of the APNs
believed that the DTCAs enabled the patients to play more an active role during the
utilization of medical care services while 57.7% recognized that the DTCAs prompted
patient to ask for wrong and avoidable treatments (Mackert et al., 2010). In the same
context, 63.5% of the APNs affirmed having seeing patients exposed to the DTCAs
asking reasonable and logical questions during a medical conversation regarding diseases
or treatments (Mackert et al., 2010). Finally, around 26% of the APNs agreed having seen
patients sticking to the treatment plan under the influence of the DTCAs (Mackert et al.,
2010).
Limbu and Torres (2009) provided other evidence on the impact of the DTCAs
on the utilization of medical care services by Americans in general. Thirty-one percent of
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Americans recognized in 1999 having visited their doctors and having a discussion with
the doctors regarding a prescription drug that they had seen in an advertisement.
Moreover, in 1999, around 25% of a group of Americans surveyed claimed having
visited their doctors to ask more about a condition or illness after an exposure to a helpseeking advertisement (Limbu &Torres, 2009). In the meantime, 44% of another 1999
survey respondents affirmed talking with their doctors about the prescription drug they
saw in a product claim advertisement (Limbu &Torres, 2009). In 2003, a survey
discovered that 2 out of 5 Americans agreed having a high propensity to meet with their
doctors to ask more about a prescription drug after being in contact with a product claim
advertisement (Limbu & Torres, 2009). Another 2003 survey claimed 35% of
respondents agreed that a product claim advertisement prompted them to seek and to gain
more information from their physicians regarding the prescription medicine they saw in
the pharmaceutical advertisement (Limbu & Torres, 2009).
Gap From the Literature and the Need of This Study
The data above showed a sufficient relationship between the DTCAs and the
utilization of medical services by Americans in general. However, none of the data
addressed the question of the relationship between the DTCAs and the utilization of
medical care services amongst the specific group of adult dermatology patients attending
church services at Saint Nicholas Catholic Church or/and receiving primary care services
at MedStar Primary Care clinic in Houston, Texas. MedStar and Saint Nicholas are both
multicultural and multiethnic group communities as described with more details in the
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study sites section of the Chapter 3. Therefore, there is a need to address this gap found in
the literature.
Dermatology disease is frequently listed as the motivation of a visit to a doctor.
Additionally, many of the 10 leading dermatology conditions by prevalence are curable.
Those 10 diseases are herpes simplex and zoster (188.61 million), effects of sun exposure
(123.15 million), contact dermatitis (77.29 million), hair and nail disorders (70.46
million), juman papillomavirus (58.49 million), actinic keratosis(58.08 million), acne
(50.18 million), cutaneous fungal infections (29.37 million), benign neoplasms (29.37
million), and atopic dermatitis (15.17 million) (American Academy of Dermatology
[AAD], 2011). Indeed, herpes simplex’s sores usually disappear without patient
receiving any treatment (AAD, 2014a). Contact dermatitis’s rashes clear simply by the
patient avoiding what has caused them or by following the rash treatment recommended
by a dermatologist (AAD, 2014a). Nonmelanoma skin cancer, one of the conditions
caused by the sun exposure (basal and squamous cell carcinomas), is the most common
and curable type of cancers (American Cancer Society, 2013a, 2013b;
Baghianimoghadam, Noorbala, & Mahmoodabad, 2011; Skin Cancer Foundation,
2013a). Consequently, undertaking this study is a healthy and lifesaving enterprise
through prevention and treatment promotion of dermatology diseases. Patients will use
more medical dermatology services under the influence of the DTCAs. Moreover,
patients will avoid dermatology diseases or have their disease cured. The DTCAs serve as
an informative and educational tool for dermatology patients seeking medical care
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services. DTCA are also informative and educational for the population at risk of
dermatology diseases as it appears in the problem statement of the study.
Problem Statement
The above analysis of the recent literature showed that there is a relationship
between the DTCAs and the utilization of medical services amongst Americans in
general. However, that relationship is not analyzed specifically amongst adult
dermatology patients in the United States. Therefore, the empirical research problem
under investigation is the likely relationship between the DTCAs and the utilization of
medical services amongst adult dermatology patients. The study’s independent variables
of interest are product claim and help-seeking advertisements. They have a probable
relationship with the dependent variables, which are the types and purposes of medical
services utilization by the target population.
A cross-sectional survey method was the methodological support for this study as
described in more detail in Chapter 3 (Creswell, 2009; Frankfort-Nachmia & Nachmias,
2008; Rudestam & Newton, 2007). The study population was all English speaking men
and women with permanent resident or citizen status. The participants had lived
continuously for at least 6 months in Houston, Texas. They were also at least 18 years
old, had seen, heard, or read (exposure) a pharmaceutical DTCA in the past 12 months at
the time of the questionnaire completion, and had used medical dermatology service as
the consequence of that exposure. Moreover, the participants attended church services at
Saint Nicholas Catholic and/or were receiving primary care services at MedStar Primary

13
Care Clinic, both in Houston, Texas. The method consisted of asking a nonprobability
sample of 120 dermatology patients to express their attitudes and views about the
phenomenon under investigation. The selection of the sample was according to my
personal judgment. I used the eligibility questions contained in the questionnaire to
support the judgment and to select only qualified respondents. The respondents expressed
their attitudes and views by responding to a series of questions on a scale of 5 points
using their personal past experiences and backgrounds in the context of medical
dermatology services utilization due to the exposure to the pharmaceutical DTCAs. The
descriptive (frequency and means score) and advance (multiple regression) data analysis
techniques using SPSS 21.0 version helped to organize data, to test the research
hypotheses, and to respond to the research questions and purpose of the study.
Purpose of the Study
The purpose of this quantitative correlation research was to describe the
relationship between the pharmaceutical DTCAs and the utilization of medical services
amongst adult dermatology patients in the United States of America. In other words, I
sought to describe the relationship between dermatology product claim, help-seeking
advertisements, and types and purposes of the utilization of medical dermatology
service(s) amongst adult patients aged 18 years and over. The set of the independent
variables was the DTCAs. The DTCAs of selection were product claim and help-seeking.
The measurement items of product claim and help-seeking were the characteristics from
FDA. In that regard, product claim advertisement specified the name of the drug, stated
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the treated disease, and disclosed the product risks and benefits (FDA, 2012b, 2012d; La
Barbera, 2012). Help-seeking advertisement discussed only the condition or disease of
interest without any drug recommendation for treatment (FDA, 2012b, 2012d; La
Barbera, 2012).
Conversely, the set of the dependent variables were the types and purposes of the
utilization. The type of utilization was the specific medical service(s) that the medical
care seeker has received at a certain point in time and at an identified place (Aday &
Anderson, 1974; Shi & Singh, 2008). The purpose of the utilization referred to the
reason(s) why the medical care seeker has received the medical services (Aday &
Anderson, 1974; Barton, 2010; Shi & Singh, 2008). The measurement items for the types
of medical services used were the medical services found in the literature reviewed on the
utilization of medical services. In terms of the purposes of utilization of the medical
services, the items for the observation also came from the literature reviewed in Chapter
2. The operational definitions section of this chapter offers a clear landscape of the
different measurement items of each set of variable.
The research approach was a cross-sectional survey for the primary data
collection via the administration of questionnaires to the selected sample from the target
population. The research results enabled me to add new knowledge to the existing
knowledge in the field of interest of this study. PT was the theoretical framework or basis
of this study from the literature. PT was the analysis of the individuals’ behavior while
making a decision in a risky situation or condition. An example of a risky condition was
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to decide to seek for treatment or not when dealing with a dermatology disease. The
research approach facilitated the answers of the research questions of this study.
Research Questions and Hypotheses
Main Research Question and Hypothesis
In this quantitative research, I sought to answer the following main research
question: Is there a statistically significant relationship between product claim, helpseeking advertisements, and types and purposes of medical service utilization amongst
adult dermatology patients in the United States of America?
The related hypothesis to this main research question was the following:
Hypothesis 1 (H0): Product claim and help-seeking advertisements do not
significantly prompt the utilization of the types and purposes of medical services amongst
adult dermatology patients in the United States.
Hypothesis 1 (H1): Product claim and help-seeking advertisements significantly
prompt the utilization of the types and purposes of the medical services amongst adult
dermatology patients in the United States.
Secondary Research Questions and Hypotheses
The secondary research questions proceeding from the central question were as
follows:
Is product claim advertisement a predictor of the types of medical services used
amongst adult dermatology patients in the United States?
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Hypothesis 2.1 (H0): Product claim advertisement does not significantly prompt
the utilization of the types of medical services amongst adult dermatology patients in the
United Stated.
Hypothesis 2.1 (H1): Product claim advertisement significantly prompts the
utilization of the types of the medical services amongst adult dermatology patients in the
United States.
Is product claim advertisement a predictor of the purposes of medical services
utilization amongst adult dermatology patients in the United States?
Hypothesis 2.2 (H0): Product claim advertisement does not significantly prompt
the purposes of medical services utilization amongst adult dermatology patients in the
United States.
Hypothesis 2.2 (H1): Product claim advertisement significantly prompts the
purposes of the medical services utilization amongst adult dermatology patients in the
United States.
Is help-seeking advertisement a predictor of the types of medical services utilized
amongst adult dermatology patients in the United States?
Hypothesis 2.3 (H0): Help-seeking advertisement does not significantly prompt
the types of medical services utilized amongst adult dermatology patients in the United
States.
Hypothesis 2.3 (H1): Help-seeking advertisement significantly prompts the types
of the medical services utilized amongst adult dermatology patients in the United States.
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Is help-seeking advertisement a predictor of the purposes of medical services
utilization amongst skin cancer adult patients in the United States?
Hypothesis 2.4 (H0): Help-seeking advertisement does not significantly prompt
the purposes of medical services utilization amongst adult dermatology patients in the
United States.
Hypothesis 2.4 (H1): Help-seeking advertisement significantly prompts the
purposes of the medical services utilization amongst adult dermatology patients in the
United States.
Theoretical Framework for the Study
Theory Identity and Origin: Prospect Theory (PT)
PT is the theoretical framework of this study. PT emerged in 1979 in the context
of decision making in a risky situation. PT focused on individuals’ behavior while
making a decision in a risky situation (Kahneman & Tversky, 1979). Expected utility
theory (EUT), before the PT emergence, was the reference theory in terms of the analysis
of the individual behavior and economic situations when making a decision or choice in a
risky condition (Alghalith, 2010; Kahneman & Tversky, 1979; O'Connell, 2011). EUT’s
foundation was that individuals know most of the time what would be the consequence of
their choice in the context of uncertainty. In other words, individuals made rational
choices frequently. Human beings evaluate the different consequences of the choice
facing uncertainty and opt for only the best options (Kahneman & Tversky, 1979;
Kothiyal, Spinu, & Wakker, 2011; O'Connell, 2011). Kahneman and Tversky (1979), the
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founders of PT, contradicted this well established theory of rational choice and economic
behavior with the results of their experiments study. They claimed that in a situation of
uncertainty, people were not looking for the options that offered the maximum
satisfaction (Kahneman & Tversky, 1979; O'Connell, 2011). People analyzed the results
of their decision as what to gain or to lose compared to the starting condition considered
as the reference point (Kahneman & Tversky, 1979; O'Connell, 2011).
PT Theoretical Foundations/Assumptions
The value and weighting functions are the two assumptions of the PT as analyzed
in Chapter 2. According to the value assumption, individuals create values through the
change that they bring to their assets when deciding under uncertainty (Alghalith, 2010;
Kahneman & Tversky, 1979; Kuo & Chen, 2012). The value creation comes from the
combination of the change and its size. The evaluation of the change is in reference to the
situation of the asset before the change (status quo). When the outcome of the decision
under uncertainty is perceived as a loss, the individual will accept to take the risk to make
the change happen or to create the value. The individual behaved differently when the
outcome is a gain by refusing to take any risk (Alghalith, 2010; Kahneman & Tversky,
1979; Kuo & Chen, 2012; Pfiffelmann, 2011).
The weighting assumption states that each value assigned to each outcome should
be multiplied by the same criterion used to select each prospect. However, the criterion
should not be a probability or a measurement instrument (Kahneman, & Tversky, 1979).
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PT Connection to This Study
PT analyzes the individuals’ behavior when making a decision during uncertainty.
The outcomes of the decision are introduced to the individuals as what to gain or to lose
in reference to an initial point (reference point). The research hypotheses related the
pharmaceutical DTCAs to the types and purposes of the utilization of medical services
amongst adult dermatology patients in the United States. The decision to use the medical
dermatology services or not after an exposure to a DTCA was an uncertainty condition.
The outcomes of the decision to use or not represented a gain or a loss. The gain in case
of the utilization was the dermatology patient recovering from the disease. The loss was
to die because of the dermatology condition in case of nonutilization. The reference
point, in the context of dermatology disease, was the stage of the disease before the use of
the medical services or not due to the exposure to a DTCA. Consequently, PT was in
alignment with this study and helped to place this study in its social context. Chapter 2
provides more details on PT. Before then, I am going to examine the nature of this study.
Nature of the Study
The units or elements of analysis here are the study method, variables, and
methodology. This research was a quantitative correlational design due to the quantitative
nature of the research question and the statement of five hypotheses. The study method
was the cross-sectional survey. The reasons of the selection of the cross-sectional survey
were (a) the quantitative research question, (b) the need of generating numbers to
describe attitudes and views, (c) the random sample, (d) the rapid data collection, (e) the
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statistical analysis and generalization of the results when possible, and (f) the test of the
theory based on hypotheses testing (Creswell, 2009; Frankfort-Nachmias & Nachmias,
2008). In addition, others researches on the prediction of the utilization of medical
services used the cross-sectional survey method (French, Fang, & Balsa, 2011).
The study variables were DTCAs and utilization of medical services.
DTCAs represented the predictor or independent variable through product claim and
help-seeking advertisements. The dependent variable was the utilization of medical
services observed through the types and purposes of the utilization. The empirical
research problem (Creswell, 2009) under investigation was the analysis of the impact of
the pharmaceutical DTCAs on the utilization of medical services amongst adult
dermatology patients.
The study followed a specific methodology. The study population was all men
and women adult dermatology patients living in Houston, Texas. They had all seen, read,
or heard (exposure) a DTCA in the past 12 months from the date of the completion of the
questionnaire and had used medical dermatology services as the consequence of that
exposure. The members of the population were Saint Nicholas Catholic Church
community members and/or MedStar Primary Care Clinic’s patients. G*Power 3.1.2.
software permitted me to determine the nonrandom sample size of 82 individuals
(rounded up to 120 in the final sample) drawn from the study population. The input
parameters for the sample size computerization were two-tailed hypotheses testing, a
Cohen’s d medium conventional effect size = .30, α = .05, and power = .80%. The
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selection of the respondent followed the nonrandom purposive sample scheme rule
(Collins, Onwuegbuzie, & Jiao, 2006; Frankfort-Nachmias & Nachmias, 2008). Thus, my
personal judgment and the screening questions from the questionnaire guided the
selection of the representative statistical unit for the completion of the questionnaire.
Each participant/respondent who accepted voluntarily to participate in the study provided
informed consent using the form duly approved by the Walden University’s Institutional
Review Board (IRB.) office. The primary data collection was from 120 structured
questionnaires completed by the respondents. I developed a structured questionnaire for
the purpose of this study. The questionnaire went through a pilot study for validation
before being used for the final study. The questionnaire has the Likert interval scale of 5
points as the rating instrument. The completion was the face-to-face. All completions
took place at the two study sites: Saint Nicholas Catholic Church and MedStar Primary
Care Clinic both in Houston, Texas. The population size was unknown. A code book
development followed after the completion and approval of the 120 questionnaires. Then,
SPSS 21.0 was the software for the data analysis. Data analysis tools were the descriptive
statistics (frequency and mean scores) used to organize the data. In addition, multiple
regressions analysis was used to test the hypotheses of the study. More detail on the
nature of this study appears in Chapter 3.
Definitions (Operational)
In this section, I define the key terms or concepts of the topic under investigation:
DTCAs, utilization of medical services, medical service, and dermatology disease. Then,
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I define the variables that measure DTCAs and the utilization of medical services that are
respectively the independent and dependent variables of the study. The DTCAs set of
measurement variables are product claim and help-seeking advertisements. The
utilization of medical services set of measurement variables are types and purposes of
utilization. Finally, I provide definitions of each item that permits empirical observation
(the operational definitions) of the variables product claim, help-seeking advertisements,
types, and purposes of the medical services utilization. Those items come from the
literature reviewed in Chapter 2.
Concepts Definitions
Dermatology disease/condition: Disease(s) that attacks skin, hair, and nails
(AAD, 2014b).
DTCAs: Announcements or information about dermatology drug, disease,
treatment options, and devices passed directly to the dermatology patients by
pharmaceutical companies and distributors through the television, radio, newspapers,
telephone, brochures, magazines, or online without any medical professional mediation
(Hall, Jones, & Hoek, 2010; Lee-Wingate & Xie, 2010).
Help-seeking advertisement: Announcement that talks only about the dermatology
disease or condition without any reference to a drug that can treat the condition (FDA,
2012d, 2012f; La Barbera, 2012).
Medical services/physician services: Dermatology healthcare services or supplies
delivered or whose delivery is coordinated by a physician or medical doctor who has a
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medical license to practice medicine or osteopathy (Healthcare Government
[Healthcare.gov], 2013; U.S. Government Printing Office [GPO], 2013).
Product claim advertisement: Announcement that states the dermatology drug
name, the treated condition, and the risks and benefits related to the use of the advertised
drug (FDA, 2012b, 2012f; La Barbera, 2012).
Purpose of medical services utilization: Reason why the dermatology care seeker
uses medical care services. The reason can be disease prevention, treatment of disease,
monitoring, seeking well-being, protection, or alleviating a condition (Aday & Anderson,
1974; Barton, 2010; Shi & Singh, 2008).
Dermatology disease/condition: Disease(s) that attacks skin, hair, and nails
(AAD, 2014b).
Type of medical services utilization: A particular medical service or care provider
that can be a nurse, hospital, surgeon, or a physical therapist used by a dermatology care
seeker (Aday & Anderson, 1974; Shi & Singh, 2008).
Utilization of medical services: Reception of dermatology services provided by or
under the supervision of a state’s licensed dermatologist at a physical place, for an
identified medical reason, and based on a frequency of utilization (Aday & Anderson,
1974; Shi & Singh, 2008).
Operational Definitions
The following is the operationalization of the study variables or presentation of
the measurement items. This study has a total of four set of variables. Product claim and
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help-seeking advertisements are the two sets of independent variables. The types and
purposes of the medical dermatology services utilization after an exposure to a
dermatology pharmaceutical DTCA are the two sets of dependent variables. The
measurement variables of each set of independent and dependent variables are as follows.
Dermatology help-seeking/disease advertisement (characteristics).
Description of the type of dermatology disease without any recommendation of a specific
dermatology drug for treatment: The advertisement presents to the public the disease and
its symptoms without telling what drug can treat the condition (FDA, 2012f).
Encouraging people with the symptoms of the described type of dermatology
disease to talk to their doctor: Recommendation to the public to consult the
dermatologist if the person notices on the skin, hair, or nails any indication/sign of the
advertised disease (FDA, 2012f).
Inclusion of the company's name of the advertised dermatology drug: Designation
of the drug’s manufacturer (FDA, 2012f).
Provision of a telephone number/website to call or to visit for more information
about the advertised dermatology disease (described condition): Communication to the
public of the available telephone number or website to use to collect extra information
regarding the particular advertised dermatology disease if necessary (FDA, 2012f).
Dermatology product claim or prescription drug advertisement
(characteristics). Equal statement of the advantages and possible negative effects of the
dermatology drug use: Presentation to the patients, in a balanced way, of what the
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benefits and potential negative consequences are of using the advertised drug (FDA,
2012d, 2012f).
Equal statement of the benefits and risks associated with the dermatology drug
use: Equitable presentation of the advantages and dangers related to the use of the
advertised drug (FDA, 2012f).
Inclusion in the dermatology print product claim advertisement of the statement
"You are encouraged to report negative side effects of prescription drug to the FDA Visit
MedWatch5 or call 1-800-FDA-1088.": Clear statement of how the patient can
communicate to the FDA office any not desired secondary consequences of the drug
advertised (FDA, 2012f).
Statement by the dermatology broadcast product claim of different sources where
to find the FDA approved prescribing information of the advertised drug (adequate
provision): Statement of where the patient can get additional product information
approved by the FDA.
Statement by the dermatology audio broadcast product claim of the most
important risks of the dermatology drug (major statement): Presentation of the most
serious dangers that the dermatology drug user may encounter.
Statement by the dermatology print product claim of all the drug risks approved
by FDA as prescribing information (brief summary): Presentation of the dangerous
aspects of the drug approved by the FDA and contained in the drug information or label.
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Statement of the most significant dermatology drug’s risks: Presentation of the
very important dangers that the patient may face taking the advertised drug (FDA,
2012f).
Statement of the name of the dermatology drug: Statement of the vulgar
designation of the drug approved by the U.S. government (brand) and the U.S.
government nonapproved drug designation used (generic) to advertise the drug (FDA,
2012f).
Statement of a minimum of one type of dermatology disease (the condition[s])
treated by the advertised dermatology disease drug (approved drug use by the FDA):
Presentation of the form of dermatology disease treated by the advertised drug (FDA,
2012f).
Purposes of medical services utilization after exposure to dermatology helpseeking/disease advertisement. Dermatology disease symptom management: Preventive
measures taken, self-examination of the skin to detect any change that may indicate a
dermatology disease type, identification of the surrounding possible causes for more
prevention and control, and screening test when necessary (Kontos & Viswanath, 2011).
Early detection of the dermatology disease: Diagnosis of the condition at its
very first stage (Kontos & Viswanath, 2011; The University of Texas MD Anderson
Cancer Center [MDACC.], 2013a).
Dermatology disease symptom management: Preventive measures taken, selfexamination of the skin to detect any change that may indicate a dermatology disease
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type, identification of the surrounding possible causes for more prevention and control,
and screening test when necessary (Kontos & Viswanath, 2011).
Tumor/disease clearance: Complete cure of the disease (Samarasinghe et al.,
2011).
Tumor/disease lesion excision: Use of instruments to remove the abnormal part of
the cell or tissue and its surrounding normal cell in order to cure the dermatology
condition (Medical Doctors Guidelines [MDGuidelines], 2013; Samarasinghe et al.,
2011).
Purposes of medical dermatology services utilization after exposure to a
dermatology product claim/drug advertisement. Mohs defect repair using a rhombic
transposition: Rebuilding of the part of the body damaged by the dermatology disease
using Mohs surgery and the rhombic transposition method (Samarasinghe et al., 2011).
Treatment/cure of the dermatology disease looking for well-being: Complete
destruction or removal of the dermatology disease so that the patient will become healthy
(MDACC, 2013a; Samarasinghe et al., 2011; The Skin Cancer Foundation, 2013b).
Tumor/disease clearance: Complete elimination of the dermatology tumor
(Samarasinghe et al., 2011).
Tumor/disease lesion excision: Removal of the abnormal part of the cell and its
surrounding normal tissue (MDGuidelines, 2013; Samarasinghe et al., 2011).
Types of medical dermatology services utilized after exposure to dermatology
help-seeking/disease advertisement. Clinical trial/experimental: Participation in a
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research study that seeks to know how well a dermatology disease treatment approach or
technique works on individuals (American Cancer Society, 2013b; MDACC, 2013a;
NCI, 2013e; The Skin Cancer Foundation, 2013b).
Consulting dermatologist regarding any symptom related to dermatology disease
for early detection: Discussion with the dermatologist about the possible symptoms of the
dermatology disease that the patient has (Kontos & Viswanath, 2011).
Cryotherapy/Cryosurgery: Use of liquid nitrogen to freeze and eliminate skin
tissues affected by the disease (MDACC, 2013a; Samarasinghe et al., 2011; The Skin
Cancer Foundation, 2013b).
Curettage and cautery/Curettage and electrodessiccation/Electrodessiccation and
curettage: Use of an instrument called a curette to scrap off the skin tumor followed by
the destruction of any remaining tumor with the heat generated by the electrocautery
needle (AAD, 2013; American Cancer Society, 2013b; Samarasinghe et al., 2011; The
Skin Cancer Foundation, 2013b).
Dermatology disease screening test: Checkup to diagnose a dermatology disease
before any symptom appears (Kontos & Viswanath, 2011; National Cancer Institute
[NCI], 2013e).
Gene therapy/biological therapy: Destruction of the dermatology disease by
including genes into the patient’s cells affected by the cancer (NCI, 2013a; The Skin
Cancer Foundation, 2013d).
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Clinical trial/experimental. Participation to a research study that seeks to know
how well a dermatology disease treatment approach or technique works on individuals
(American Cancer Society, 2013b; MDACC, 2013a; NCI, 2013e; The Skin Cancer
Foundation, 2013b).
Cryotherapy/Cryosurgery. Use of the liquid nitrogen to freeze and eliminate skin
tissues affected by the disease (Samarasinghe et al., 2011; The Skin Cancer Foundation,
2013b; MDACC, 2013a).
Curettage and cautery/Curettage and electrodessiccation/Electrodessiccation and
curettage. Use of instruments called curette to scrap off the skin tumor followed by the
destruction of any remaining tumor with the heat generated by the electrocautery needle
(AAD, 2013; American Cancer Society, 2013b; Samarasinghe et al., 2011; The Skin
Cancer Foundation, 2013b).
Laser surgery: Removal of the external layers of the cell (epidermis) and the
tissues of the skin affected by the tumor using a laser strong beam light, erbium YAG
laser, or carbon dioxide (MDACC, 2013a; NCI, 2013a ,2013d; The Skin Cancer
Foundation, 2013b).
Lymph node surgery: Operation of the lymph nodes for biopsy to look for
cancerous tumors or for the removal of the lymph nodes in case of the presence of a skin
cancer tumor (American Cancer Society, 2013b).
Mohs micrographic surgery: Excision of a malignant tumor with the help of
staged, intraoperative frozen sections processed in the Mohs technique. Sections excised
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are histologically clear of malignancy (American Cancer Society, 2013b; MDACC,
2013a; Samarasinghe et al., 2011; The Skin Cancer Foundation, 2013b)
Radiotherapy/Radiation: Destruction or treatment of the tumor in the tissue of the
patient using X-ray beams (NCI, 2013d; Samarasinghe et al., 2011; The Skin Cancer
Foundation, 2013b).
Skin grafting and reconstructive surgery: Removal of the skin cancer tumor
followed by the collection of a skin free of tumor from the patient’s body to graft the skin
on the wound. The grafting helps the wounded part to recover completely (American
Cancer Society, 2013b).
Standard surgical excision/resection: Use of anesthesia to paralyze the area of the
skin with tumor for a short time. Then, removal of the tumor surrounded with a certain
normal skin followed by the tumor examination under microscope to make sure the entire
tumor has been removed. Stitches are used to repair the surgical area to end the procedure
(AAD, 2013; American Cancer Society, 2013b; NCI, 2013d; Samarasinghe et al., 2011;
The Skin Cancer Foundation, 2013b).
To search for additional health information outside disease advertisement
(company’s website): Other sources of information are consulted to complete the
information received from the advertisement and to be able to make an informed health
decision (Kontos & Viswanath, 2011).
Types of medical dermatology services utilized after exposure to a
dermatology product claim/prescription drug advertisement. Adherence to the
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dermatology disease treatment regimen: Normal participation to the treatment plan
prescribed by the dermatologist (Frosch, Grande, Tarn, & Kravitz, 2010; Wellington,
2010).
Chemotherapy: Treatment of the patient using the dermatology advertised
prescription drug following the patient’s request (American Cancer Society, 2013b; NCI,
2013a; Samarasinghe et al., 2011; The Skin Cancer Foundation, 2013b)
Dermatology prescription drug refill: Obtainment of another quantity of the same
drug from the pharmacist after running out of the drug (Frosch et al., 2010; Wellington,
2010).
Physician/dermatologist office visit: Meeting with a dermatologist/doctor in
his/her office for medical dermatology reasons (Gray & Abel, 2012).
Request and obtainment of a medical prescription of the dermatology drug
advertised: Meeting with the dermatologist to request and obtain from him/her the
prescription of the advertised dermatology drug (Gray & Abel, 2012).
Chemotherapy: Treatment of the patient using the dermatology advertised
prescription drug following the patient’s request (American Cancer Society, 2013b; NCI,
2013a; Samarasinghe et al., 2011; The Skin Cancer Foundation, 2013b)
Adherence to the dermatology disease treatment regimen: Normal participation to
the treatment plan prescribed by the dermatologist (Frosch et al., 2010; Wellington,
2010).
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Dermatology prescription drug refill: Obtainment of another quantity of the same
drug from the pharmacist after running out of the drug (Frosch et al., 2010; Wellington,
2010).
Skin, hair, and nails health maintenance: Treating the patient to improve his/her
appearance instead of taking care of a specific dermatology disease (AAD, 2014b).
To talk to dermatologist/doctor about dermatology advertised medication:
Meeting with the dermatologist/doctor to discuss the dermatology medicine presented in
the advertisement (Gray & Abel, 2012).
Physician/dermatologist office visit: Meeting with a dermatologist/doctor in
his/her office for medical dermatology reasons (Gray & Abel, 2012).
Skin, hair, and nails health maintenance: Treat the patient to improve his/her
appearance not to take care of a specific dermatology disease (AAD, 2014b).
Assumptions
The achievement of this study required the consideration of three assumptions.
The first assumption was the goodwill of the respondents. It was assumed that the
respondents filled out the questionnaire with true information that represented their
experience with product claim and help-seeking advertisements in the context of the
medical dermatology service utilization. If the answers from the respondents were not
accurate, then the research results would not be accurate and would not represent the
reality from the field. In that case, any decision made using the results of this study would
be wrong.
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The second assumption was that the Likert scale of attitude was appropriate to
measure the attitude and views of adult dermatology patients regarding the impact of
product claim and help-seeking advertisements on the types and purposes of medical
dermatology services used. The Likert scale of attitude was not the only scale in social
sciences research. For instance, there was the Guttman scale that has existed since 1940
as the result of Guttman’s research (Frankfort-Nachmias & Nachmias, 2008). The
Guttman scale is also used for an empirical test of a group of items. However, I assumed
that the Likert scale of attitude would be more appropriate for this study due to the scale’s
validity and effectiveness in past research measuring peoples’ attitudes and views.
The third assumption was the validity of the measurement instrument or
questionnaire. I developed this study’s questionnaire. I used this questionnaire for the
first time in this study after the pilot phase. Consequently, I assumed that the
questionnaire was able to measure the concept under investigation in this study. A bias
from the instrument would affect negatively the research results.
Scope and Delimitations
This research has scope as well as delimitations. The scope of the study was the
description of the relationship between product claim, help-seeking, and the types and
purposes of medical dermatology care services utilization amongst adult dermatology
patients aged 18 years and over and members of Saint Nicholas Catholic Church and/or
patients at MedStar Primary Care Clinic both in Houston, Texas. U.S. dermatology
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patients aged 40 years and above represented 68% of the market in terms of aged (Harris
Williams & Cooperation [Harris Williams & Co.], 2013).
The results of the study identified the FDA’s product claim and help-seeking
characteristics that influenced more than others a type and purpose of the medical
dermatology services used by the target population. Furthermore, for each identified
characteristic, I identified the respective type and purpose of utilization that the identified
characteristic predicted more. The selection of the above scope had multiple motivations.
Indeed, past researchers have claimed that the dermatology DTCAs of prescription drug
and diseases are a reality in the United States. Patients who have seen, read, or heard a
dermatology DTCA have learned about diseases treated by the advertised drug, the
diseases treatment options and symptom control, prevention, adherence to the treatment
regimen, and early detection (Kontos & Viswanath, 2011). Product claim and helpseeking advertisements derived from this study’s results may empower dermatology
patients and the population at risk in general, particularly in Houston, Texas, to know
more about symptoms, treatment options, and purposes.
The study has delimitations. The age bracket of the target population was 18 years
and over. The population was the skin, hair, and nail adult patients (dermatology) who
have used medical services within 1year as the consequence of having seen, heard, or
read (exposure) dermatology DTCAs of prescription drug or disease. The adult
dermatology patient was an American citizen or a legal permanent resident alien living
for at least 6 months in Houston, Texas. While living in Houston, Texas, the patient

35
received primary care services at MedStar Primary Care Clinic or attended church
services at Saint Nicholas Catholic Church. Both organizations were the study sites. In
addition, reminder advertisement, which was the third type of the DTCAs according to
the FDA, was not part of this study. Finally, the site and time interval of the utilization of
dermatology health services from the framework of access (Adey & Anderson, 1974)
were not subject to this investigation. Future researchers may consider focusing on those
variables and populations excluded from this study.
Limitations
This study contained weaknesses or limitations. The limitation of the crosssectional method resided in the difficulty to control the factors that could affect the
internal and external validity of the research. A cross-sectional survey method led to the
use of sophisticated instruments of questionnaire and computer software SPSS 21.0 for
data collection and analysis. A cross-sectional survey permitted data collection only one
time and not continuously as described in Chapter 4 (Creswell, 2009; FrankfortNachmias & Nachmias, 2008). The first threat to validity was the environment and the
time of completion of the questionnaire. The settings of completion were not completely
free of any source of noise or distraction. The parishioners were holding meetings during
the questionnaire completion around the parish hall, which was the completion setting at
Saint Nicholas Catholic Church. The participants heard some noises from time to time
from the meeting attendees. The participants completing the questionnaire at the MedStar
Primary Care Clinic’s meeting rooms heard some noise from the television located in the
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lobby area or from the clinic personal and other patients’ conversations. The doors were
constantly kept closed at the two sites during completion to limit the effect of the noise
on the participant. The questionnaire completion time may have not been appropriate for
the respondent to avoid any bias in the answers (Creswell, 2009; Frankfort-Nachmias &
Nachmias, 2008). The time of completion was after church service or meeting with a
doctor. The participants at that time were possibly thinking about going home. However,
they all agreed on the completion time during recruitment and did not express any rush
until the end of the completion.
The second threat was the construct validity: the use of a new questionnaire. I
designed the questionnaire. It was not sure if the new questionnaire would be capable
exactly of measuring the concepts under investigation. The pilot study results validated
the questionnaire and verified the capability of the questionnaire to measure the concepts
of the DTCAs and the utilization of medical dermatology services. Experts’ opinions of
dermatologists in Houston, Texas, and the DTCAs professionals at the FDA’s Office of
Prescription Drug Promotion (OPDP) validated the questionnaire before the pilot study.
The final study results were consistent with the pilot study.
The last limitation was the sampling bias that could occur during this study due to
the lack of a sample frame and could affect the external validity of the study results. In
that regard, all the final respondents met the study’s inclusion criteria. The inclusion
criteria used in the questionnaire permitted me to filter the respondents during the
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recruitment of each respondent in order to avoid a sampling bias. This study used a
convenient sample not a random sample.
Significance
The study closed the gap and added knowledge to the area of the dermatology
DTCAs and medical utilization. I sought to know if dermatology product claim and helpseeing advertisements prompted the utilization of the types and purposes of medical
services amongst adult dermatology patients in the United States with the application in
Houston, Texas. Therefore, the study results added new knowledge to the DTCAs
influencing the utilization of medical dermatology services in America. The research
showed, in the specific era of dermatology, the FDA’s characteristics of product claim
and help-seeking advertisements that predicted more a type and purpose of medical
services used by the study population. I identified a specific type and purpose of
utilization predicted more by the considered characteristic. Finally, future researchers will
use these results as the source of secondary data for their research.
The study has practice and policy implications. As stated earlier, this study results
provide the DTCAs characteristics that predicted more than other characteristics a
specific type and purpose of utilization of medical dermatology services amongst the
target population. Those characteristics could be the communication axes for new
DTCAs of pharmaceutical companies exclusively targeting the population under
investigation. Indeed, the DTCAs inform and educate patients about drug, diseases, and
treatment options. DTCAs prompt patients to adhere to the drug treatment plan (Phrma,
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2011).Therefore, the statistically significant relationship between the DTCAs and the
utilization of medical dermatology service(s) could lead to the new dermatology product
claim and help-seeking advertisements directed directly to the adult dermatology patients
in Houston, Texas. The target population could benefit from the following values of the
advertisements: education, information, and informed conversation with dermatologists
(PhRMA, 2011). As far as policy is concerned, the FDA as well as Phrma could use the
results of this study to develop new DTCAs regulations, policies, principles, and laws or
to revise the existing one.
The study also has social change impacts. The social change implication is the
health promotion amongst adult dermatology patients in Houston, Texas. In that regard,
help-seeking advertisements from these results will educate and create awareness
amongst patients about dermatology disease, early detection due to screening test, and
skin, hair, and/or nails health maintenance treatment. Conversely, product claim
advertisement created based on these results could promote dermatology prescription
drug requests, educate and inform patients about prescription drug, and prompt doctor
visits amongst the target population. Skin cancer is the driving force of the dermatology
service demand in the United States (Harris Williams & Co., 2013). Health promotion in
the context of skin cancer has various motivations. Early detection and early treatment
can lead to the cure of the skin cancer. From 1992 through 2006, the nonmelanoma skin
cancer treatment increased almost up to 77% (American Cancer Society, 2013a; NCI,
2013a; Skin Cancer Foundation, 2013b).
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Summary
Previous researchers have addressed the relationship between the pharmaceutical
DTCAs and the utilization of medical services. In 1999, 44% of Americans discussed the
prescription drug they saw in a product claim advertisement with their doctors. However,
there was no evidence of the impact of the dermatology DTCAs on the utilization of
medical dermatology services amongst adult patients who live in Houston, Texas and
who receive primary care services at MedStar Primary Care Clinic or attend the church
services at Saint Nicholas Catholic Church. This study filled the gap.
The quantitative correlation design using a cross-sectional survey method was the
research design. The intent of the research was to describe the relationship between the
dermatology pharmaceutical DTCAs and the utilization of medical dermatology care
services amongst skin, hair, and nails adult patients. The independent variables were the
dermatology product claim and help-seeking. The dependent variables were the types and
purposes of the utilization of medical dermatology services. The study has five
hypotheses. PT was the theoretical framework of this study.
Furthermore, I defined the variables of the study in this chapter: product claim
and help-seeking advertisements (independent variables) and types and purposes of
medical services utilization (dependent variables). I also identified and defined the items
used for the empirical observation of the variables. The study has three assumptions: the
respondents’ goodwill to provide with true answers, the validity of the Likert scale of
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attitude to measure adult dermatology patients’ attitudes and views, and the validity of
the questionnaire to be used for the data collection.
The research scope was the description of the relationship between product claim,
help-seeking, and the types and purposes of medical services used exclusively amongst
adult dermatology patients in Houston, Texas. The limitations of the study were the
cross-sectional survey method, the use of a new questionnaire as measurement
instrument, and the possible bias from the sampling procedure. The key social change
value of this study was the health promotion amongst the target population: awareness
and education.
Chapter 2 that follows addresses the literature on the variables of the study in
order to learn about what has been said so far regarding the problem under investigation.
Then, the literature reviewed permits the identification of the gap that justifies the
essence of this research study. Furthermore, Chapter 2 covers PT as the theoretical
framework of the study, the literature search strategy, and the study’s model of the impact
of product claim and help-seeking advertisements on the types and purposes of the
utilization of medical dermatology services. Finally, in Chapter 2, I present the study
model that I elaborated, tested empirically and statistically through hypotheses testing.
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Chapter 2: Literature Review
Introduction
This chapter contains a background, literature review method, approach to the
resources identification used in this literature review, and the theoretical framework (PT)
of the study. In this chapter, I also analyze the independent and dependent variables of
the study and present the explicative model found in the literature of the impact of DTCA
of prescription drug on the utilization of medical services after being exposed to a DTCA.
Finally, Chapter 2 contains the study’s model of the relationship between the
dermatology DTCAs and the utilization of medical dermatology services amongst adult
patients after an exposure to a DTCA.
Background, Problem and Gap
In this section, I describe the evolution of the pharmaceutical DTCAs. The
phenomenon of the DTCAs in the United States goes back up to 1980 as described in
Chapter 1 (Dieringer et al., 2011; FDA, 2012c). The FDA (2012a) revised in 1997 the
policy about the DTCAs and authorized the drug manufacturers to broadcast the branded
products’ advertising (Bradford & Kleit, 2011; Dieringer et al., 2011; Frosch et al.,
2010). This progress of the DTCAs increased in 1999. The FDA required, at that time,
that the marketers provided true information and the right direction to costumers in
marketers advertising (Dieringer et al., 2011; FDA, 2012a).
The pharmaceutical DTCAs represent the information about prescription drug or
diseases mostly that pharmaceutical companies are passing directly to the consumers via
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advertising and not through the pharmacists and physicians (Hall et al., 2010; LeeWingate & Xie, 2010). The expansion of the DTCAs of prescription drug has led to the
recurrent question of the impact on the consumer in terms of the utilization of medical
services after an exposure (Limbu & Torres, 2009). In that regard, researchers have
claimed more than 53 million consumers have talked to their physicians about a
particular prescription drug following their exposure to the drug advertising in the United
of America (Limbu & Torres, 2009). Additionally, approximately 21.2 million consumers
talked to their doctors about an illness because of a drug advertisement (Limbu & Torres,
2009). In the same logic, children consumed more prescription drug between 2007 and
2008. Indeed, amongst five children surveyed, at least one used a minimum of one drug
prescribed by a physician (Gu, Dillon, & Burt, 2010; La Barbera, 2012). These multiple
figures point to the relationship between the DTCAs of prescription drug and disease and
the utilization of medical services in general in the United States (Kim & Park, 2010;
Macias, Lewis, & Baek, 2010). However, little is known about the relationship between
the DTCAs of prescription drug and disease and the utilization of medical services
amongst adult dermatology patients who live in Houston, Texas, and are receiving the
primary care services at MedStar Primary Care Clinic, or attending the church services at
Saint Nicholas Catholic Church. Consequently, this study seeks to address that gap. The
literature review that follows aims to analyze, in relation with the identified gap, the
current publications on the relationship between the DTCAs and the utilization of
medical services to justify the relevance of this etude.
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Literature Review Method and Chapter’s Content
Creswell’s (2009) literature review method (pp. 25-26) guides the present chapter.
According to Creswell, a quantitative literature review has two steps that are:
1.

The researcher creates a thorough outline of the themes of interest and the
gathers the related literature.

2.

The researcher analyzes of the topics in the chapter consecrated to the
literature review.

When analyzing the literature review’s possible approaches, Creswell stated, “Another
approach is to develop a detailed outline of the topics and potential references that will
later be developed into an entire chapter, usually the second, titled “Literature review”,
which runs from 20 to 60 pages or so” (p.26).
Resource Identification Method
The identification of the resources started with the creation of the identifiers or
search terms. The identifiers were prospect theory, Direct-To-Consumer Advertisements,
prescription drug advertising, product-claim advertisement, help-seeking advertisement,
utilization of medical services, medical services, types of medical services, purposes of
the utilization of medical services, dermatology services, dermatology diseases and
treatments, and Direct-To-Consumer Advertisements and dermatology diseases
treatments. The keywords permitted me to search for peer-reviewed articles to identify
the original and current publications about the theoretical framework, and the
independent and dependents variables of the study. The searches were through multiple
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databases at Walden’s virtual library: “Academic Search Complete/Premier”, “ProQuest
Central”, and “Google Scholar”. Primary searches took place on the website of the
United States FDA (2011b) to identify the characteristics of the pharmaceutical DTCAs
of prescription drug and diseases used as independents variables of the study. The
American Cancer Society (2013a) and American Academy of Dermatology’s websites,
and Shi and Singh (2008) provided the dependent variables and operational definitions.
The search for peer-reviewed articles at the Walden library combined three search
modes called “Boolean/Phrase”, “find all my search terms”, and “find any of my search
terms”. The selection of the “Scholarly (Peer-Reviewed) Journals” option during the
search assured the retrieval of only the articles from the peer-reviewed journals. “Ulrich’s
Periodicals Directory” at Walden library permitted me to assure the peer-reviewed nature
of the journal. The “publication date from” option enabled the specification of the desired
5 years to which the retrieved articles should belong. This literature review used only the
relevant articles considering the different topics of interest. These search efforts covered
the period of Summer 2011 through Summer 2014. From January through June 2013, the
review of the retrieved articles permitted to delete and replace the articles older than 5
years with more recent ones.
Theoretical Framework of the Study: PT
Origin
The origin of PT goes back to the year 1979. In fact, PT was a decision making
theory model that permitted an individual to describe how to make a choice when facing
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a risky situation or uncertainty (Kahneman & Tversky, 1979; Kothiyal et al., 2011; Mello
& Cajueiro, 2010; O'Connell, 2011). This theory was the main idea of Kahneman and
Tversky’s works achieved in 1979. It was in reaction to the expected utility theory’s
(EUT) failure (Alghalith, 2010; Kahneman & Tversky, 1979). EUT was the most used
model by researchers and economists during those years to describe individuals’
behaviors and economic phenomena in the risky conditions (Alghalith, 2010; Kahneman
& Tversky, 1979; O'Connell, 2011). EUT’s assumption stated that the probability
associated with the outcome of a possible choice was always known. The reason was that
the subject always compare different outcomes and selected only those that offered a
maximum benefit, satisfaction, or welfare (Kahneman & Tversky, 1979; Kothiyal et al.,
2011; O'Connell, 2011). Conversely, Kahneman & Tversky conducted experiments
study. The study results were a breakthrough because they contradicted the wellestablished EUT (Kahneman & Tversky, 1979; Kothiyal et al., 2011; O'Connell, 2011).
Kahneman & Tversky’s experiments’ results corroborated the idea that people made their
choices in a risky condition after analyzing the different outcomes as what to gain or to
loose based on a referent point of the asset or the condition (Kahneman & Tversky, 1979;
O'Connell, 2011). In other words, agents evaluated the outcomes of their decision as
gains and losses compared to the status quo of the situation or asset (Kothiyal et al, 2011;
O'Connell, 2011).
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Characteristics
PT was a descriptive model initially for a noncomplex prospect. The prospect had
money as outcomes with known probability associated with the results. However, PT was
applied to the multiple choices games with financial results or not (Kahneman &
Tversky, 1979). The following analysis is in the context of noncomplex
prospects/opportunities.
PT has two main assumptions: the value and weighting functions (Alghalith,
2010; Kahneman & Tversky, 1979; Kuo & Chen, 2012). The first assumption or value
stated that the modifications that happened to the subject’s asset/good were the creation
of value for the decision making under uncertainty. Thus, this value should be attributed
both to the change and size of the value. The analysis of the value was about the status
quo of the subject’s good (Kahneman & Tversky, 1979). The value function was near or
concave to the gains and far or convex from the losses as outcomes of the decision made
under uncertainty (Alghalith, 2010; Kahneman & Tversky, 1979; Kuo & Chen, 2012;
Pfiffelmann, 2011). In other words, the subject took or accepted risk when he/she
perceived the outcome of the decision regarding a prospect as losses. Conversely, when
the agent perceived the outcome as gains, he/she would not take any risk (Alghalith,
2010; Kahneman & Tversky, 1979; Kuo & Chen, 2012; Pfiffelmann, 2011). Finally, the
curve of the value function inclined more toward gains than the losses (steeper)
(Kahneman & Tversky, 1979; Pfiffelmann, 2011).
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The second assumption of PT was the weighting. PT weighting referred to the
multiplication of the value attributed to each outcome by the criterion applied to the
selection of each selected opportunity. According to PT, the criterion was neither
probabilities nor measurement instrument for the subject’s belief during the choice.
However, when the agent considered the low probability, the agent always over weighted
the small probability during the choice (Kahneman & Tversky, 1979). There were the
steps applicable to the decision making under uncertainty.
In addition to the assumptions, PT had two key steps applied to a questionable
choice to facilitate the decision making by the subject: the “editing” and the “evaluation”
(Kahneman & Tversky, 1979, p. 274). A subject started making a choice under risk by
trying to comprehend or differentiate the prospects in presence (“editing”). Firstly, the
“editing” efforts of the subject consisted of building a perception of the offers or
prospects regarding what could be the gains or the losses (outcomes) of the decision
(Kahneman & Tversky, 1979; Kothiyal et al, 2011; O'Connell, 2011). The perception of
the decision’s outcomes as gains (quantity or amount to receive) and losses (what to
release) depended on the subject’s current state or condition: he or she had not gained or
lost anything yet. This was the “neutral reference point” in the PT (Kahneman &
Tversky, 1979; Kothiyal et al., 2011; O'Connell, 2011). Secondly, the perception in the
“editing” step led to the reduction phase of the prospect. This reduction consisted of
adding together the probabilities associated with the same opportunity. The addition
yields the new probability (the double of the two added) added to the opportunity
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(Kahneman & Tversky, 1979). Finally, the “editing” continued with the separation of the
part of the prospect that had a risk from the one that did not have any (Kahneman &
Tversky, 1979).
The profiles of the opportunities obtained from the “editing” process enabled the
subject to compare the prospects/opportunities and to opt for the one or those with first
value: “evaluation”. The “evaluation” focused on the overall edited prospect’s global
value (Kahneman & Tversky, 1979).
Two scales permitted to conduct the “evaluation”. The first scale measured the
impact of the prospect’s associated probability on the global value of the considered
prospect. The second scale measured the subjective value of the opportunity based on a
number assigned subjectively to the prospect’s outcomes (Kahneman & Tversky, 1979).
PT has limitations.
Limitations
Regarding the limitations, PT did not integrate the preference variable amongst
the assumptions. Sometimes the agent made a choice when making a decision under
uncertainty because he or she preferred a particular prospect. In other words, the
preference was enough for the agent to select an opportunity without any other
consideration (Kothiyal et al, 2011; Pfiffelmann, 2011). This drawback generated an
evolution of the PT that became cumulative prospect theory (CPT) in 1992. In 1992,
Daniel Kahneman and Amos Tversky added this feature to their original PT model and
created a new model called CPT (Pfiffelmann, 2011). Besides, PT was created to describe
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behavior when dealing with simple prospects and only in the risky conditions (Kothiyal
et al., 2011; Kahneman & Tversky, 1979). PT is applied in the concrete social problems
nowadays.
Contemporary Applications of P T
PT application has occurred in many fields to describe social phenomena.
Morrissette (2010) used PT to facilitate a clearer understanding of Russian President
Boris Yeltsin’s political and international behavior in 1994 under uncertainty. In 1994,
President Yeltsin decided and launched an invasion of the Republic of Chechnya.
Morrissette used PT to analyze Yeltsin’s behavior due to the theory ability to describe
decision taken subjectively under uncertainty. Moreover, PT analyzed the decision
outcomes as gains or losses (Morrissette, 2010). The research question was why did
President Yeltsin launch the military invasion of the Republic of Chechnya in 1994? The
review of the literature was the research method applied to answer the research question.
The study reached the conclusion that President Yeltsin attack or use of force was a risk
as supported by the PT. The attack was risky because of an improper preparation, the
timing was not necessary at that time, and the invasion could not rebuild the Yeltsin’s
domestic tarnished popularity (Morrissette, 2010). Future research will find here an
example of the implementation of the PT to describe contemporary issues. However, the
study lacks empirical results of the application of the PT to the Yeltsin case.
Kuo and Chen (2012) applied PT to the investment phenomenon. Indeed, when
the price of a good or asset changes positively, investors have the high propensity to sell
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them while purchasing those with deteriorated values. Kuo & Chen used the Taiwan
investors’ disposition patterns survey date to answer the research question. The research
question was about the appropriate time for the investors to sell assets with deteriorated
price, and the length of time to keep the assets that have gained value. As the results, the
researchers found that at least 50% respondents have disposition patterns instead of
disposition effect to sell assets that have gained value and to buy goods whose price has
fallen (Kuo & Chen, 2012). This example will inspire future researchers. The research
results shed light on the fact that investors had disposition patterns that were different
from disposition effects in a risky situation of buying deteriorated assets (Kuo & Chen,
2012). However, the reason of that difference was still unclear at the end of the study.
O'Connell (2011) used the lens of PT to analyze and describe the strategies that
presidential candidates used to manage their campaign during primary elections. The
candidates of interest were the following United States presidential candidates: Edward
Kennedy, Jimmy Carter, Ronald Reagan, and Georges H W Bush in the 1980s
(O'Connell, 2011). The researcher discovered that PT’s risk averse and acceptance impact
the management of political campaign by candidates. The study method was the in-depth
interview (O'Connell, 2011). The research question was why each candidate wanted to
become president? The author answered this question by analyzing each candidate’s
strategic options during the campaign regarding riskiness. Therefore, Kennedy in 1979,
Reagan in 1980, and Carter in 1980 were in a situation of loss while choosing options for
their campaign. Carter in 1979/1980, Bush in 1980, and Kennedy in march-april 1980
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perceived the outcomes of their campaign options as gains domain (O'Connell, 2011).
This research has a credit of a successful application of PT to the electoral campaign
management of the candidates. However, the studies failed to tell if the phenomena
considered as losses or gains were due to the nature of the political party and the
personality of the candidate, or were independent of the two variables. This said PT
corresponds with this study.
Matching With This Study
There are many reasons why PT was a match to the present study. The study’s
target population was adult dermatology patients of both sexes, who lived in Houston,
Texas, received primary care services at the MedStar Primary Care Clinic or/and attended
to the church service at the Saint Nicholas Catholic Church. Then, he or she was living
continuously for at least six months in Houston, Texas. They were adults aged 18 years
and over who had seen, heard, or read a dermatology product claim or help-seeking
advertisement (exposure) in the past 12 months and had utilized medical dermatology
service(s) as the consequence of that exposure.
PT, as analyzed earlier, was the analysis of the human behavior when making a
decision in a risky situation. The agent perceived the outcomes of the decision as gains or
losses in relation to a reference point or status quo of the condition. The subject was risk
acceptant when he/she saw the outcomes as benefits. He/she was a risk adverse when the
consequences of the decision were losses (Kahneman & Tversky, 1979; Kothiyal et al,
2011; O'Connell, 2011).
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The condition or reference point for the dermatology patient is his/her health
status: the presence of the dermatology disease. The prospect or risky situation is to
recover/stay alive due to medical dermatology services use after an exposure to the
DTCAs or to lose the life/decease in the case of nonutilization. The decision to make by
the dermatology patient is to use medical services or not after an exposure to a
dermatology product claim or help-seeking advertisement. The dermatology patient who
decides not to use medical dermatology services after an exposure to a product claim or
help-seeking advertisement because he/she perceives the outcome of this decision as a
loss or death is a risk adverse. Conversely, the dermatology patient who decides to utilize
medical services after an exposure to a product claim or help-seeking advertisement
because he/she perceives the outcome of the decision as a gain is a risk acceptant. Thus,
to decide to use medical dermatology services or not is a risky situation. The patient
obtains the restoration of his/her health by seeking medical dermatology services or lost
his/her life by not seeking medical services (Kahneman & Tversky, 1979). The preceding
analysis showed the alignment between PT and this study. Product claim and helpseeking advertisements as are the independent variables.
Analysis of the Independent Variables: Product Claim and Help-Seeking
Advertisements
Product Claim Advertisement’s Regulatory Agency
The United States FDA is the regulatory agency of product claim advertisement.
The FDA is the regulator of the product claim advertisement since 1962 (Dave & Saffer,
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2012; FD A, 2012a, 2012c; Mulligan, 2011). Product claim is the only pharmaceutical
DTCA under the FDA’s regulations (FDA, 2012b; La Barbera, 2012; Rollins et al.,
2010). Conversely, help-seeking and reminder are not under FDA’s regulations giving
that they are not mentioning any drug or device name as required by the law (FDA,
2012b; La Barbera, 2012; Rollins et al., 2010).
In the same context of regulations, Abrams (2011), Dave & Saffer (2012), Eby
(2012), FDA (2012a, 2012c) and senate resolution(S R) 110-85 (2007) addressed the
legal setting. In that regard, The FDA regulates product claim advertisement due to the
law named federal food, drug, and cosmetic act (F DCA) of 1938 (FDA, 2012e), and its
amendment of 2007. Indeed, federal trade commission (FTC) played this role until 1962.
Then, Kefauver-Harris brought modifications to the federal food, drug, and cosmetic act
in 1962 (Dave & Saffer, 2012; FDA, 2012e; Mulligan, 2011). According to the 1962
modifications, each marketer had to prove and support with evidence the fact that the
advertised drug did not represent any danger to the public. Then, the advertised drug was
capable of keeping the manufacturing promises. Moreover, the marketer had to provide in
print advertisements the risks and benefits of using the advertised drug. Finally, the
modifications placed product claim or prescription drug advertising under the FDA’s
regulatory power. In one word, Kefauver-Harris’ modifications of 1962 recognized and
accepted that prescription drug advertising was essential to pharmaceutical companies
(Dave & Saffer, 2012; Mulligan, 2011). However, the FDA amended this law in 2007.
The 2007 amendment gave birth to a new law: food and drug administration amendments
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act (FDAAA) of 2007 (Abrams, 2011; S. Res. 110-85, 2007). The FDCA’s section
502(n) on prescription drug advertisements was amended by adding to the content the
FDAAA’s section 901(d)(3)(A) entitled provision on DTCAs (Abrams, 2011; S. Res.
110-85, 2007). Therefore, the FDA’s oversight of the DTCA of prescription drug
activities followed the FDAAA’s section 901(d)(3)(A) (Abrams, 2011; S. Res. 110-85,
2007).
The office of prescription drug promotion (OPDP) within the center for drug
evaluation and research (CDER) at the FDA implements the supervision strategies of the
drug advertisement activities (Eby, 2012; FDA, 2011c). The OPDP ensures that each
advertisement complies with the law in place or applies sanctions in case of the violation
(FDA, 2011c). Then, the OPDP provides drug advertisers with training opportunities to
get familiar with the law and regulations. Finally, OPDP exhorts drug advertisers to
improve the quality of the communication of the drug selling information to stakeholders
regularly (FDA, 2011c). The office regulates broadcast and printed advertisements such
as mailing, booklets, brochures, posters, and presentations (Eby, 2012).
I clarified in this subsection the regulatory authority (FDA) and the legal setting
of the product claim advertisement as the independent variable of this study (Dave &
Saffer, 2012; FD A, 2011a, 2011c; Mulligan, 2011). However, I did not address the issue
of relationship or not between product claim and the types, and purposes of utilization of
medical dermatology services amongst adult patients in the United States.
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Product Claim Advertisement’s Legal Content
Product claim advertisement’s content is stated by a particular United States
public law. The above referred FDCA law requires in its section 502(n) that the statement
should contain (a) the popular name of the drug, (b) the list of the drug’s ingredients and
their quantity (formula) in conformity with this act, and (c) a quick note on its
contraindications, effectiveness, and side effects (FDA, 2012a). Conversely, other authors
argued that the product claim should have a brief summary (print advertisement), a major
statement, the drug side effects, and contraindications (broadcast advertisement) of the
advertised drug (Dave & Saffer, 2012; FDA, 2012b; Flood, 2010; La Barbera, 2012;
Mendonca et al., 2011). In addition to FDCA’s section 502(n), the FDAAA’s provision
901(d) (3) (A) stipulates that the major statement has to be “clear”, “conspicuous” and
“neutral” (Abrams, 2011; S. Res. 110-85, 2007, p. 940).
Meanwhile, the FDA (2012b), La Barbera (2012), Phrma (2011) shed light on a
different component of printed product claim: a statement motivating the readers to
report to the FDA via MedWatch5 or 1-800-FDA-1088 any drug’s negative side effect.
The statement was the provision 906(a) of FDAAA (S. Res. 110-85, 2007). However,
the FDA and Frosch et al. (2010) argued that the broadcast product claim has to
communicate to the viewers the source of risk related information about the drug
advertised. The sources could be a care provider, a free of charge phone line, a magazine,
or a website. Finally, all product claim announcement most be correct and should not lose
the consumer (FDA, 2011a; 2011c; Phrma, 2011).
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I have identified in this subsection the basic legal components of product claim as
the independent variable of the study: brand name, formula, and quick note (FDA,
2011a).
However, I am still silent on the possible relationship between product claim and the
types and purposes of utilization of medical dermatology services by an adult patient.
There are different types of DTCAs.
DTCAs Typology
There are different types of DTCAs. The FDA distinguishes three kinds of the
DTCAs: (a) product claim, (b) reminder, and (c) help-seeking (FDA, 2012b, 2012d; La
Barbera, 2012; Mendonca, McCaffrey III, Banahan III, Bentle & Yang, 2011). The
product claim announcement has three key features that are (a) drug’s name, (b) the
disease/condition that the drug can treat, and (c) the benefits and risks associated with the
drug use (FDA, 2012d, f; La Barbera, 2012; Mendonca et al., 2011). Al contrary, other
authors claim that reminder advertisement contains only the drug name, while helpseeking advertisement details the disease/condition without any reference to a drug for
the treatment (FDA, 2012d, 2012f; La Barbera, 2012; Mendonca et al., 2011).
The two types of DTCAs are the focuses of this study: product claim and helpseeking that are the sets of independent variables. Product claim and help-seeking were
the two familiar and frequent types in the DTCAs landscape (La Barbera, 2012;
Mendonca et al., 2011). Product claim had an awareness rate of about 80% amongst
Americans (Mendonca et al., 2011). The resources for the analysis of those two types
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were available, and the contents had many features for analysis (FDA, 2012b; La
Barbera, 2012). Conversely, reminder announcement was rare in the practice, and limited
concerning the content (just product name) (FDA, 2012d; La Barbera, 2012). Indeed,
reminder announcement was subject to critiques or calls for banishment because of the
content limitation and lack of accuracy (FDA, 2012d; La Barbera, 2012). Moreover,
reminder announcement did not provide information regarding the advertised drug.
Consequently, reminder announcement could not help the patient to make an informed
medical choice (FDA, 2012b; La Barbera, 2012).
The outcome of this analysis is the three types of DTCAs and their characteristics:
product claim, help-seeking, and reminder. The two independent variables that are
product claim and help-seeking are clear and identified. But, the question of the possible
relationship between product claim and help-seeking, and the types and purposes of the
utilization of medical dermatology services by the adult patient is still without an answer.
At this point, I am going to analyze the current state of cons and pros debate about the
product claim and help-seeking advertisements.
Product Claim and Help-Seeking Advertisements Cons Debate
Product claim advertisement. The authors have condemned product claim
advertisement for many reasons. Dave and Saffer (2012), Frosch et al. (2010), La Barbera
(2012), and Lee and Begley (2010) reproached product claim announcement to
unnecessarily generate an overutilization of medical services. According to the authors,
advertisers seem to have underestimated or ignored the product claim’s capability of
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prompting the consumers’ medical options after exposure (Dave & Saffer, 2012; Frosch
et al., 2010; La Barbera, 2012; Lee & Begley, 2010). Then, Chaar and Lee (2012) and La
Barbera claimed that product claim violates the patient right to make personal medical
decisions: patients sometimes decide about their health based on the influence of the
product claim and not on a personal initiative. The violation could lead to a harmful
choice for the consumer.
Moreover, La Barbera (2012), Kontos and Viswanath (2011), and Willington
(2010) thought that product claim information was capable of empowering the patient to
interpret and to understand the drug’s chemical components and effect side statements.
Indeed, the exposed patient was not knowledgeable enough to manipulate the message of
advertising for proper health decision making (La Barbera, 2012; Kontos & Viswanath,
2011; Willington, 2010). Therefore, the patient still needed the physician’s help for the
utilization of the drug despite the education provided by the product claim announcement
(Kontos & Viswanath, 2011; La Barbera, 2012).
In the same logic of cons debate, Mendonca et al. (2011) conducted experimental
research about new information search after being exposed to the product claim
announcement. They found that product claim had a small capacity of persuading the
exposed patient to seek for additional information about the availability of new medicine
outside of the announcement. Then, the two group posttest experimental design of
Mendonca et al. (2011) concluded that product claim as well as help-seeking
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announcement did not decide asthma patients to gather new information regarding the
possible new drug.
Conversely, Brody and Light (2011) and Willington (2010), in the context of cons
debate analysis, took the discussion to the arena of the patient protection. According to
those two authors, certain approved and advertised drug were risky, unsafe, and
inefficacious for the patient health. They were capable of developing a new condition or
disease to the patient going through a drug therapy for another illness (Brody & Light,
2011). This limitation was evident through the annual consequences of drug therapy in
the United States regarding adverse reactions (46 million), hospitalizations (2.2 millions),
and deaths (111,000). The patient is still not safe from such harms (Brody & Light,
2011).
La Barbera (2012), Kornfield et al. (2013), and Willington (2010) opposed to the
preceding critiques the modification of the physician prescription habit by the product
claim. Indeed, the authors claimed that product claim provoked a change in the familiar
doctor practice of prescribing the drug to patients (La Barbera, 2012; Kornfield et al.,
2013; Willington, 2010). Physician, usually, selected the drug to prescribe to the patient.
Now, the patient requested and obtained from his/her physician an advertised drug. The
patient, by doing so, changed the usual course of medical prescribing (La Barbera, 2012;
Kornfield et al., 2013; Willington, 2010). The physician could create overprescribing by
honoring the patient’s request for the advertised drug (Kontos & Viswanath, 2011).
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Contrarily to La Barbera (2012) and Willington (2010), Hall et al. (2010) and Lee
& Begley (2010) criticized product claim to be a threat to the patient-physician
relationship stability mostly amongst minority groups. In fact, a disagreement between
both parties when the exposed patient would be requesting from the physician the
prescription of a particular advertised drug could break the relationship (Hall et al., 2010;
Lee & Begley, 2010). Patient reacted to the physician’s refusal to prescribe the advertised
drug by selecting a new doctor (Lee & Begley, 2010)
However, Frosch et al. (2010) considered product claim announcement as a health
inequity driver amongst cardiovascular disease patients. According to the authors,
product claim rarely contained African American’s values, beliefs, and cultural elements
when centered on the preventive drug for cardiovascular disease. Moreover, marketers
published less cardiovascular product claim announcement in the magazines accessible to
African Americans.
Lee and Begley (2010) found health disparity due to product claim amongst
Hispanics, African Americans, and Whites after exposure. When exposed to product
claim announcement, the three ethnic groups reacted differently (Lee and Begley, 2010).
Hispanics requested for health care services more than Whites and African Americans.
African Americans met their doctors to discuss a drug seen in product claim
announcement more than other ethnic groups. Whites requested and obtained an
advertised prescription drug from their doctors while the minorities Hispanics and
African Americans saw their request denied by their physicians (Lee & Begley, 2010).
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The preceding authors have the common merit of stating the weaknesses of the
practice of product claim announcement. However, none of those authors has clarified the
characteristics of product claim that decided more the adult dermatology patients to
utilize medical services.
Help-seeking announcement. They were many critiques again help-seeking
announcement. Help-seeking announcement lacked the name of the medicine for the
benefit of the manufacturer’s name (Rollins et al., 2010; FDA, 2012b). Frosch et al.
(2010) and Hall et al. (2010) argued that help-seeking announcement encouraged drug
therapy or medicalization instead of lifestyle change (Frosch et al., 2010; Hall et al.,
2010; O’hara, 2010). Consequently, help-seeking announcement ended up creating a
massive dependence of the people on the medication or drug therapy (Frosch et al., 2010;
Hall et al., 2010; O’hara, 2010).
The above contrasting reflexion again both product claim and help-seeking helped
to shed light on the demerits of the two types of DTCAs. However, I did not answer the
research question of this study presented in Chapter 1. Product claim and help-seeking
announcements did have supports from the literature.
Product Claim and Help-Seeking Advertisements Pros Debate
Product claim advertisement. Many writers supported the product claim
announcement. The product claim advertisement represented an essential source of
information about the drug, treatable conditions, and new treatment options for the
consumers (Chaar & Lee, 2012; Frosch et al., 2010; Hall et al., 2010; La Barbera, 2012;
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O’hara, 2010). According to Frosch et al. (2010); Hall et al. (2010), La Barbera (2012),
and O’hara (2010) product claim announcement helped to build the mental strength of the
consumer through education. The consumer easily adhered to a medical prescription due
to the mental power (Frosch et al., 2010; Hall et al., 2010; La Barbera, 2012; Limbu &
Torres, 2009; O’hara, 2010; Phrma, 2011).
However, the FDA (2012b) and La Barbera (2012) found that product claim
length gave enough time to the announcement to disclose to the patient how the drug
worked, what the drug cured, the dangers of taking the drug, and the potential side
effects. Then, with the product claim, the patient has the choice to meet with his/her
doctor to discuss the appropriateness of the advertised drug to the patient condition. The
discussion permitted to eradicate any possible risk of harm to the patient due to the use of
an advertised drug (FDA, 2012b; La Barbera, 2012).
Willington (2010) thought differently. In fact, product claim restored the natural
health rights of the human being. According to Willington, a human being should have
access to medical care and the related information. The related information is about how
and where to get the right medicine and the possible consequences of using that
medicine. Furthermore, the product claim health information enabled the patient to
exercise his/her right to decide about the right care and best way of taking care of the
personal health (Willington, 2010). In the same logic, Willington recognized that product
claim had the virtue of increasing the number of people aware of a drug as well as those
following their treatment plan rigorously. Finally, Willington claimed that product claim

63
lowers the treatment cost through the appropriate and proper form of drug therapy. The
hospitalization cost in some cases was null with the drug therapy (Willington, 2010).
There are multiple strengths for the product claim such as informing patients,
facilitating patients’ access to health care, and educating patients about drug use and
conditions treated. However, the authors did not state why adult dermatology patients
utilize medical services after an exposure to a product claim and help-seeking
advertisements.
Help-seeking advertisement. The authors have identified various help-seeking
strengths. Help-seeking had the reputation of educating patient about diseases and
possible treatments as well as helping the patient to comply with the medication use
(Chaar & Lee, 2012), Dave and Saffer, 2012; Frosch et al., 2010; Kontos and Viswanath,
2011; Mendonca et al., 2011; O’hara, 2010; Rollins et al., 2010). In the same view with
Frosch et al. (2010) and Mendonca et al. (2011), Rollins et al. (2010) asserted that helpseeking announcement did decide patients to seek for additional information about their
condition. Furthermore, help-seeking empowered consumer to initiate a discussion with
their care provider about not yet diagnosed disease, symptoms, and treatment options of
an existing illness (Dave & Saffer, 2012; Frosch et al., 2010; Mendonca et al., 2011;
Rollins et al., 2010).
However, Hall et al. (2010) found the help-seeking strength in the earlier
diagnosis of a condition sometimes ignored by the patient before an exposure to the
announcement. Help-seeking recommended to the viewers to contact their care provider
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for diagnosis in case of any symptom mentioned in the announcement (Hall et al., 2010;
FDA, 2012d). Frosch et al. (2010) and Hall et al. (2010), contrarily to Mendonca et al.
(2011) and Rollins et al. (2010), identified the help-seeking merit in the patient education,
mainly those with a low level of health literacy. Thus, the exposure to a help-seeking
announcement provided health information to people less educated that enabled them to
utilize medical care as well as those with a high level of health education (Frosch et al.,
2010; Hall et al., 2010). Help-seeking had the positive impact of reducing the health care
utilization disparity between those two groups.
The authors analyzed product claim and help-seeking announcement mostly
concerning the characteristics and capability of motivating exposed patients to seek for
more information about the condition and new drug. However, they did not analyze the
possible relationship between DTCAs and the utilization of medical services amongst the
adult dermatology patients.
Product Claim and Help-Seeking Advertisements’ Regulatory Debate
Product claim advertisement regulatory trend. The regulation of product claim
by United States federal government has been a long and continuing process. In that
regard, Mulligan (2011) focused the attention on the trend analysis of the regulation.
According to Mulligan, the regulatory trend of product claim by FAD went back up to
1969. Indeed, the birth and progress of the product claim regulations had four key
periods: 1969, 1997 through 1999, 2004, and 2007 (Mulligan, 2011).
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The 1969 regulations were four constraints applicable to product claim
announcements (Mulligan, 2011). The first was the truthfulness of the information
conveyed to the population. The communicated information should tell the true about the
product and give the right advice and direction to the target public (Mulligan, 2011). The
second was the constraint of the balanced presentation of what the product represented as
risks and benefits for the consumer (Mulligan, 2011). In other words, the positive and
negative consequences of using the advertised product should have the same weight in
the announcement (Mulligan, 2011). The third principle was about the other utilization
of the product. The regulations required each advertiser to state clearly in the
announcement the essential information for a comfortable and safe use of the drug by the
consumer (Mulligan, 2011). The fourth requirement was about all risk statement that the
consumer incurred during or after the utilization of the product. These risks should appear
clearly in the announcement (Mulligan, 2011).
The second period of 1997 through 1999 was the FDA’s response to the growth of
the broadcast DTCAs in general and product claim in particular (Frosch et al., 2010;
Mulligan, 2011). In fact, stating all or “every risk” (FDA, 2012b) related to the use of the
product of interest in a broadcast announcement, in compliance with the 1969
regulations’ principle number four, was very challenging. This because the advertisers
have to face the time constraint related to the media (Frosch et al., 2010; Mulligan, 2011).
Consequently, the FDA issued new regulations to modify the 1969’s number 4 principle.
In that regard, the FDA gave two choices to the advertisers. The first choice was the
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objective and proper introduction in the announcement of the “major statement”. The
“major statement” referred to the very relevant risk associated with the use of the product
(FDA, 2012b). Furthermore, the advertisers in lieu of the “major statement” could list all
the risks of the product use, or could tell the consumer the additional sources where to
obtain other risks of using the advertised product (Dave & Saffer, 2012; FDA, 2012b;
Flood, 2010; Frosch et al., 2010; Mulligan, 2011).
The third period was 2004 (Frosch et al., 2010; Mulligan, 2011). FAD’s product
claim print announcement was the target. Print advertisers did not satisfy the FDA’s
requirement for the clear communication of the risks information to the public.
According to the FDA, advertisers were using a language not familiar or not accessible to
the readers. Therefore, to reverse this tendency, the 2004’s amendments imposed to the
print advertisers the obligation of communicating product’s risks to the readers using a
popular language known by the public (Frosch et al., 2010; Mulligan, 2011). Moreover,
the announcement should communicate clearly the following to the public: (a) at least
three moderate adverse side effects, (b) warnings, (c) contraindications, and (d) the
necessary precaution related to the product (FDA, 2012b; Mulligan, 2011).
The fourth period was 2007/2008. It was an Act or Public Law named Food and
Drug Administration Amendments Act (FDAAA) of 2007 (FDA, 2012b; Mulligan,
2011). The legislators introduced some changes in the law. The changes aimed to
reinforce the FDA’s control power on the product claim announcement of prescription
drug. The changes were (a) the FDA can ask to review an announcement prior to the
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release to the media by the advertiser (pre-market review); (b) the creation of an ad hoc
program to motivate TV advertisers to participate freely in the FDA’s review prior to the
release (advisory review program), and (c) the requirement of a fee for those willing to
participate to pre-review program (FDA, 2012b; Mulligan, 2011).
The above product claim regulatory efforts were about both broadcast and print
announcements. The 1997 regulation increased the product claim broadcast
announcements. The law makers did not predict how to keep under the Federal
Government’s scrutiny the high and increasing number of the broadcast product claim.
Moreover, the regulatory efforts did not state why product claim influence consumers,
mostly adult dermatology patients, to seek medical care after exposure. Finally, there is a
connection between the preceding product claim regulatory efforts and the
pharmaceutical industry’s efforts for self-regulation.
Pharmaceutical industry’s regulation initiative for product claim and helpseeking. The pharmaceutical companies gathered within PhRMA have undertaken many
regulatory initiatives regarding the DTCAs. Indeed, contrarily to other contributors who
focused on the trend of the regulation of the DTCAs, PhRMA’s members and Marcias et
al. (2010) analyzed the pharmaceutical industry’s efforts for self-regulation. PhRMA is
the group of companies that lead pharmaceutical research and biotechnology aimed to
develop new drug and devices in the United States of America (Marcias et al., 2010;
Phrma, 2011). PhRMA undertook in 2008 the revision of the existing guidelines put in
place by the industry to govern the practice of the DTCAs. The objective of developing
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those principles was to comply with the FDA requirements regarding DTCA of
prescription medicine. Moreover, the aim was to provide the consumers with
communication that was a value added to the public health field (Limbu & Torres, 2009;
Phrma, 2011). In other words, the principles did not seek to influence the consumers’
purchase behavior (Limbu & Torres, 2009). The revised policies became mandatory
within the industry as from March 2, 2009.
The self-regulation effort was a set of 18 principles. The first guiding principle
presented what PhRMA organization believed to be the DTCAs contributions to the
public health field. Those contributions are (a) to make more people to know a disease
by, (b) to make patients be knowledgeable about possible options of treatment for a
condition, (c) to promote meeting between patient and doctor about patient health
problem, (d) to improve the under diagnosed and under treated conditions amongst
patients, (e) and to promote the adherence to drug therapy schedule amongst patients
(Phrma, 2011). The second principle stated the regulatory characteristics of all drug
information conveyed directly to the consumer. Those are (a) accuracy and rightness, (b)
evidence-based claim, (c) balanced presentation of drug risks and benefits, and (d) use of
information from the label approved by the FDA (Phrma, 2011). The principle number
eighteen was an exhortation to the DTCAs advertisers to tell uninsured and underinsured
in the announcements how and where they can obtain help if needed (Phrma, 2011).
I described in the regulatory discussion the different mutations that occurred over time
within the United States’ legal context of the DTCAs. Then, I presented how those
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mutations have impacted the independent variables of the study that were product claim
and help-seeking announcements. Moreover, I shed light on the self-regulatory efforts
that members of the US pharmaceutical industry undertook to facilitate the members’
compliance with the FDA’s laws and regulations of the DTCAs. However, I did not
answer the research question of the possible relationship or not between product claim,
help-seeking, and types and purposes of the utilization of medical dermatology services
by adult patients. Moreover, it is not clear so far how the FDA agents enforced those
regulations to avoid violations or to punish violators.
Product claim regulations: Enforcement.
Enforcement goals and objectives. The FDA’s authorities have assigned
clear and distinctive goals and objectives to the enforcement measures put in place to
force marketers to comply with the product claim announcement law. Thus, conversely to
the above PhRMA organization analysis, Abrams (2010, 2011) and Nguyen, SeoaneVazquez, Rodriguez-Monguio, and Montagne (2013) analyzed the product claim
regulations under the enforcement corner. Enforcement options were possible actions that
the FDA could take against the DTCAs advertisers to ensure compliance with the
FDAAA. The FDA’s authorities measured the enforcement options to prevent and to
punish any violation of the FDAAA law and related regulation (Abrams, 2010, 2011;
Nguyen et al., 2013). The FDA pursued the goal of the protection and promotion of
public health through enforcement. Public health was safe if the medicines for public use
had proven safety and effectiveness (Abrams, 2010; Nguyen et al., 2013). According to
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Abrams (2010) enforcement had multiple objectives that were (a) to assure accurate drug
promotion that did not mislead patients, (b) to assure that the statement in the
announcement of risk and benefit of drug use was fairly balanced, (c) and to contribute to
the dissemination of helpful information to American citizens.
Product claim common violations and enforcement options. There were
certain numbers of violation usually committed by marketers in the context of product
claim announcement. The FDA defined some enforcement strategies to contain and to
limit those violations. In that logic, Abrams (2010, 2011) enumerated the violations that
frequently occur in the DTCAs practice: (a) the risk information were not provided or
were presented in small proportion, (b) lack of the drug efficacy and safety in the
announcement, (c) the announcement did not contain a comparative analysis of claims,
and (d) the advertiser communicated on the drug uses unauthorized by the FDA.
The FDA’s authorities had the following enforcement options when a violation
occurred: (a) untitled letter, (b) warning letters, (c) injections or consent decrees, (d)
seizures, (e) collaborative work with Department of Justice and States Attorney General,
(f) disqualification of the researchers’ clinical trials or studies, (g) recall requests, (h)
market withdrawals, (i) license revocation and suspension, (j) debarment of firm and
individual, and (k) civil penalties in money (Abrams, 2010, 2011; FDA, 2011; Nguyen et
al., 2013).
Civil financial penalties after a product claim law violation. There were
civil financial penalties dictated by the law for marketers who violated the product claim
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law. Indeed, contrarily to Abrams (2010, 2011), FDA (2011), Nguyen
et al. (2013), Senate Resolution 110-85 (2007) analyzed the civil penalties regarding
money applicable when product claim was not right and misled the consumers in any
manner. In that regard, Senate Resolution 110-85 (2007)’s section 901(d)(4) stated that,
within a 3-year period, the first dissemination of a DTCA of a prescription drug that was
false and misleading was liable to a civil monetary penalty of $250,000 maximum. This
amount increased not more than $500,000 in the case of new violations by the same
violator for a 3-year period. The Secretary of Health and Human Services started this
process by notifying in written the violator (S. Res. 110-85, 2007). Then, the violator
must go through a hearing process before the Secretary could assess the applicable civil
monetary penalty. The violator should not face any other penalty from FDAAA (S. Res.
110-85, 2007).
This section clarified the legal measures and financial penalties that the regulatory
agency usually used to prevent or to punish cases of false and misleading product claim
announcements. However, the section was silent about the study’s research question and
the DTCAs spending debate.
Product Claim and Help-seeking Advertisements Spending Debate
The marketers using product claim and help-seeking generated diverse types of
spending within the health care system. In one hand, product claim of a new drug was a
cost driver for medical care. Indeed, new drug were still expensive. Manufacturers
invested enormous amount of money increasingly (Chaar & Lee, 2012; Hall et al., 2010)
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to promote and to sell new drug. The number of patients requesting for a new drug for a
treatment increased over time due to the effect of product claim announcement (Hall et
al., 2010; Willington, 2010). In fact, product claim made patients believe that new drug
were more efficient and safe than existing one (Howard, 2011; Willington, 2010).
In another hand, Dave and Saffer (2012) analyzed the product claim’s cost
regarding the demands and prices of a prescription drug. According to Dave and Saffer,
product claim’s spending growth was due to multiple factors. Marketers were doing more
product claim announcement. The utilization of medical service was frequent. The drug
prices increased regularly. The FDA adjusted the guidelines regarding the broadcast of
the DTCAs through television after 1997. Finally, the components of the drug advertised
changed over time (Dave & Saffer, 2012). Concretely, all DTCAs represented a value of
$150 million for the year 1993 versus $4.24 billion for 2005 (Dave & Saffer, 2012).
Moreover, the sales of the advertised drug in general within the therapeutic classes of the
drug increased due to the effect of the product claim announcement. Thus, Dave and
Saffer (2012) claimed that product claim did create migration of costumers from another
drug to the advertised drug. The movement led to the advertised drug’s market share
increase. Finally, the authors found that the rise of the DTCAs generated 11.8% increase
of the cost per unit of a prescription drug (Dave & Saffer, 2012).
Conversely to Dave and Saffer (2012), Kornfield et al. (2013) conducted a DTCA
spending trend analysis from 2001 through 2010. The DTCAs of interest were both to
consumers and physicians. The data came from IMS Health Integrated Promotional
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Service (all DTCAs, all promotion to care providers, and all sales) and the SDI (Epromotion, meetings, and conferences data). Focusing only on the direct-to-consumer
advertisings to consumers, Kornfield et al. stated that marketers spent UD$46,759,000
over 10 years to promote drug and other pharmaceutical products directly to consumers
through television, print, internet, radio, and outdoor media. 2006 was the year of the
highest spending or the peak period with an amount of $5,891,000 which represented 12,
59% of the overall amount spent in 10 years. In addition, a constant increase of those
direct-to-consumer advertisings to consumers’ spending marked the periods of
2003($4,124,000), and 2004 ($5,151,000), and 2005 ($5,231,000) (Kornfield et al.,
2013). But, after 2006, the spending entered a fluctuating period until 2010. 2001
represented the year of the lowest spending ($3,500,000) in 10 year period (Kornfield et
al., 2013).
Dieringer et al. (2011) differed from Hall et al. (2010), Kornfield et al. (2013),
and Dave and Saffer (2012) by analyzing the reasons why and when DTC Advertising
spending started increasing faster. According to the authors, the FDA issued project
guidelines on broadcast advertisings after 1997 (Bradford & Kleit, 2011; Dieringer et al.,
2011). The guidelines specified the ways marketers should present information regarding
drug and other vital products to the target audience through television and radio. Those
guidelines stimulated more DTCAs and marked the starting point of the fast spending
increase of pharmaceutical advertisings in general (Dieringer et al., 2011).
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I described in this analysis a proven relationship between the DTCAs and the
increase in the cost of care as well as the rise in the drug consumption and price.
However, as the preceding analysis, I did not answer the research question of this study.
Bearing this is mind; I am going to focus now on the state of the debate surrounding the
types and purposes of medical services utilized as the consequence of an exposure to a
product claim or help-seeking announcements.
Analysis of the Dependent Variables: Types and Purposes of Utilization of Medical
Services
The dependent variables of this study were the types and purposes of medical
services utilization.
Types of Medical Services Utilization After Exposure to a Product Claim
Advertisement
The exposure to a product claim advertisement can lead to the use of medical
services. In that regard, Chaar and Lee (2012), Frosch et al. (2010), Kornfield et al.
(2013), and Macias et al. (2010) claimed the patients exposed to a product claim
announcement may request prescriptions of the advertised drug from their health care
provider. Moreover, Frosch et al. (2010) and Wellington (2010) found an exposure to a
product claim created better adherence to the treatment plan and medicalization.
Moreover, the exposure to a product claim prompted a reception of a timely
follow-up care. Then, product claim exposure helped the patient to remember to refill
his/her prescription (Frosch et al., 2010; Wellington, 2010). Chaar and Lee (2012), Flood

75
(2010), Limbu and Torres (2010), and Macias et al. (2010), compared to Frosch et al.
(2010) and Wellington (2010), identified to consult/ask/talk with their doctors about a
particular prescription drug advertised as other medical services used after an exposure to
a product claim. The different authors shed light on the operational variables used to
measure the dependent variable of types of medical services utilized. The limitation of
the analysis was the lack of an answer the research question under investigation.
Types of Medical Services Utilization After Exposure to Help-Seeking
Advertisement
A variety of medical services used after exposure to help-seeking announcement
existed in the literature. Help-seeking exposure persuaded a patient to believe in a
medical solution to his/her condition. Moreover, help-seeking exposure helped the patient
to remember his/her disease (Frosch et al., 2010). In the same logic, Dave and Saffer
(2012), Hall, Jones, and Iverson (2011a, b), Flood (2010), Kornfield et al. (2013), Limbu
and Torres (2010) and Wellington (2010) identified new services. The identified services
were (a) to visit/consult the doctor about symptoms, (b) to talk with the doctor regarding
a condition or illness, (c) to discuss new medical conditions with their physicians, and (d)
to visit more the doctor and talk about the condition treated by the drug advertised.
On the contrary, Bradford and Kleit (2011) and Dave and Saffer (2012) found that
help-seeking advertisement prompted patients to obtain a new diagnosis from their
physicians of a medical condition so far ignored and helped to treat the conditions
undertreated before completely. Hall et al. (2011a), compared to Bradford and Kleit
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(2011) and Dave and Saffer, conducted a survey study of mock advertisements of two
diseases (Fibromyalgia and Osteopenia) amongst 241 women of 48 through 85 years old.
The study identified the following medical services that the women were intending to
search as the consequence of their exposure to the announcement: (a) to ask their doctor
for a referral (49%), (b) to ask their physicians about the tests regarding the condition
advertised, (c) to look for information according to the advertisement orientation, (d) and
to search for information from outside of the announcement (Hall et al., 201b).
These authors identified other operational variables for the measurement of the
dependent variable: types of medical services. However, they did not provide a response
to the research question of this study.
Purposes of Medical Services Utilization After Exposure to a Product Claim
Advertisement
French et al. (2011) stated that patients sought recovery from illness when
utilizing medical services after exposure to a product claim.
Purposes of Medical Services Utilization After Exposure to Help-Seeking
Advertisement
According to French et al. (2011) and Wellington (2010) patients exposed to helpseeking announcement utilized medical services for wellness and wellbeing purposes.
Analysis of the Dependent Variables: the Dermatology Services Context
The dermatology diseases are conditions that attack the human skin, hair, and
nails. Consequently, the medical dermatology services are the services rendered by a
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dermatologist to diagnose, treat, or prevent conditions that affect the skin, hair, and nails
(AAD, 2014b). The effective treatment of the skin conditions requires the use of updated
therapy (Stevens, 2013). Then, the dermatologist should be comfortable applying the
current therapy and should keep the treatment of the chronic skin conditions constant or
continuing (Stevens, 2013). The signs of healthy hair are the length, brilliancy,
smoothness, high quantity, and no loss of hair. Hair treatment using cosmetics aims to
make the hair look beautiful, solid, to grow more, or to maintain the hair. There is a
variety of cosmetics used to treat hairs such as shampoos, detergents, conditioners,
foaming agents, thickeners and opacifiers, gels, and waxes (Madmani, 2013).
According to AAD (2014c), there are different types of nails conditions such as
color change, vertical lines located under nails, white spots, and nails infection due to
bacteria. The nails problems are sometimes the sign of different health issues like liver,
kidney, heart, anemia, and lung diseases. The nails disease(s) treatment(s) varies as well
as conditions (AAD, 2014c). There is a variety of dermatology treatments or medical
services used for different purposes due to the DTCAs exposure as analyzed in the
following subsections.
Types of Medical Services Utilized After Exposure to Dermatology Product Claim
Advertisement
Product claim exposure prompted the utilization of a variety of medical services
amongst dermatology patients. Thus, Gray and Abel (2012) found that 94% of nurse
practitioners working in the cancer field affirmed having received from the patients a
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request of the cancer drug advertised. Patients who were in contact with a cancer
announcement talked/asked their doctor about the medication featured in the
advertisement, or visit a dermatologist office. Besides, the patients requested and
obtained from their physician the prescription of the featured medicine.
However, AAD (2013), American Cancer Society (2013b), NCI, (2013a),
Samarasinghe et al. (2011), and The Skin Cancer Foundation (2013d) compare to Gray
and Abel (2012), identified other drug therapies use after exposure: chemotherapy,
immunotherapies/bio-chemotherapy, chemical peeling, medicated creams and
solution/topical medication, photodynamic therapy, and Imiquimod.
In conclusion, multiple medical dermatology services are available to
dermatology patients who have seen, heard, or read a dermatology product claim
announcement: prescription request, a visit to a dermatologist office, chemical peeling,
and chemotherapy for instance. The services are different from those used due to the
help-seeking advertisement exposure.
Types of Medical Services Utilized After Exposure to Dermatology Help-Seeking
Advertisement
Help-seeking advertisement exposure prompted the utilization of various medical
services. According to Kontos and Viswanath (2011), a patient exposure to a helpseeking cancer advertisement led to consulting a dermatologist regarding any symptom
that could be a sign of the skin cancer. In addition, Kontos and Viswanath added that
help-seeking advertisement helped the skin cancer patients to utilize preventive services
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(chemoprevention medicine), screening/testing services for early detection of the disease
(whole-body imaging and genetic testing), and the search for additional health
information outside of the DTCAs (drug’s company website/online). In the same view,
Narang et al. (2013) found that 59% of American adults searched additional health
information via the internet after exposure to a dermatology help-seeking announcement.
Contrarily to Kontos and Viswanath (2011), Samarasinghe et al. (2011) analyzed
different nondrug therapies in the context of the treatment options for skin cancer named
basal cell carcinoma. In that regard, the authors identified the following surgical and
nonsurgical treatment options available for basal cell carcinoma: (a) surgical
excision/resection, (b) Mohs micrographic surgery, (c) radiotherapy/radiation, (d)
curettage and cautery, and (e) cryotherapy. The Skin Cancer Foundation (2013a) and
MDACC (2013) listed the same treatment options plus laser surgery and
electrodesiccation for the treatment of basal cell carcinoma. Furthermore, American
Cancer Society (2013b), National Cancer Institute [NCI], 2013b, MDACC (2013), and
The Skin Cancer Foundation (2013d) identified the following treatments options
available for skin cancer and another dermatology patients: lymph node surgery, skin
grafting and reconstructive surgery, electrodesiccation, gene therapy/ biological therapy,
clinical trial/experimental.
The value of this section is the obvious relationship between help-seeking
announcement and the medical services utilization in the context of skin cancer and
dermatology care globally. However, the question regarding the same relationship
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amongst study’s target population suffering from dermatology diseases is still without
any answer.
Purposes of Medical Services Utilization After Exposure to Dermatology Product
Claim Announcement
According to Samarasinghe et al. (2011), the exposure to dermatology product
claim led to receiving medical treatment for the tumor clearance and tumor lesion
excision. However, Kontos and Viswanath (2011) found patients utilized medical
dermatology services after an exposure to a dermatology product claim announcement to
detect a skin cancer or other dermatology conditions early.
Purposes of Medical Services Utilization After Exposure to Dermatology HelpSeeking Advertisement
Adult dermatology patients who have seen, heard, or read a dermatology
help-seeking announcement received medical dermatology services to treat the condition
or to manage the diseases symptom (MD Anderson Cancer Center, 2013; Samarasinghe
et al., 2011; The Skin Cancer Foundation, 2013a). Moreover, they received medical
dermatology services to detect the disease early (Kontos & Viswanath, 2011). I have
presented in the preceding analysis the correlation between the DTCAs and utilization of
medical dermatology services by adult patients, in general, however not amongst this
study’s target population. The following model found in the literature and adopted for
this study describes and explained the correlation between the drug DTCA and the
utilization of medical services as the result of the exposure.
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Model of Impact of DTCAs on the Consumer’s Participation in the Medical
Decision Making After Exposure
The following model from the literature was the result, and key summary of the
literature reviewed regarding this research study question. Indeed, patients did play and
continue to play nowadays an important role in the clinical decisions making with the
providers due to the pharmaceutical DTCA of prescription drug exposure. Frosch et al.
(2010) developed the below explicative model (Figure 1.) of the impacts of prescription
drug advertising on the consumer’s participation in the healthcare decision making. The
model was the results of Frosch et al. (2010) research on the policy and practice of drug
advertising in the United States of America.
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Figure 1. Conceptual model of the effects of prescription drug advertising. Reproduced
with copyright official written permission (Appendix Q) from “A Decade of Controversy:
Balancing Policy with Evidence in the Regulation of Prescription Drug Advertising”, by
D.L. Frosch, D. Grande, D.M. Tarn, and R.L. Kravitz, 2010, American Journal of
Public Health, 100, p. 25. Copyright 2010 by American Public Health Association.
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Model Presentation
The model’s underlying principle was that both medical care seekers and
providers make medical decision in a participative way. The physician did listen and
could consider the patient’s opinion/request concerning the possible options for
addressing the clinical situation. Medical care seekers started by being in contact with the
DTCA of a prescription drug. Then, moderating or mediating factors such as patients’
age, sex, education, or medical history influenced the two effects of the exposure to the
patients. The two effects were to request a prescription from the care providers, or to
believe that the condition or behavior could have a medical solution (medicalization).
The information of poor (low) or excellent (high) quality received from the
announcement determined the prescription request effect on the patients. The patients
participated in the clinical care by requiring from the care provider a prescription of the
drug advertised in the DTCA. If the information that drove the patients’ participation was
of poor quality, the outcome of prescription request effect could be a risky medicine to
the patient by the care provider (inappropriate prescribing). The doctor, in this case, could
prevent this dangerous outcome by denying the patient’s prescription request. However,
the physician should be knowledgeable and have a good will to identify and to correct the
patient request deemed medically nonconvenient. When information of excellent quality
determined the prescription request effect, the effect’s outcomes could be sticking to the
advised course of treatment (prescribed regimen) and the obtainment of more medical
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prescriptions from the physician to improve undertreatment. This model has weaknesses
and strengths that are necessary for a review.
Model Critique
The conceptual model has strengths and weaknesses. The model has the merit of
explaining the mechanism of participatory clinical care as the effects of prescription drug
advertising exposure. Indeed, the elements of the participatory clinical care system were
the drug announcement exposure as the starting point. Then, some mediators or
moderators factors were patients’ sex, age, education, and medical history. Other
elements were the information of poor or excellent quality of conveyed by the
announcement, the effects of the patient’s exposure to the drug advertising that are
prescription request and medicalization. Finally, the outcomes in the prescription request
effect could be (a) adherence to the treatment plan, (b) an improvement of the quality of
treatment received so far, (c) or an inappropriateness of the prescribed drug. Those
outcomes depended on the driving types of the quality of the information. All those
components interacted to produce a participatory care between care provider and the
patient who was in contact with As far as this study is concerned, the model has the merit
of demonstrating and confirming the influence of the DTCA (product claim) on the
utilization of medical services amongst the patients in general after exposure.
Conversely, the model’s weakness is the lack of a test and the test results not
presented in the article for the readers’ information and use. In other words, the authors
seem to have not stated in the article if they have tested or not the model empirically and
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statistically before the publication of this article. A test and test results would give more
reliability and validity to the model for future use. Also, medicalization effect has gotten
less attention in the analysis or the development of the model than the prescription
request effect. The model analyzed only one type of the DTCAs: product claim, ignoring
the two others that were help-seeking and reminder announcements. Finally, the model
was silent regarding the drug announcement effect on the utilization of medical services
amongst adult dermatology patients.
The study model that follows (Figure 2.) is an attempt to explain the relationship
between the dermatology DTCAs and the utilization of medical services amongst adult
dermatology patients in the United States. I did create and propose this model after the
literature reviewed. I did empirically and statistically test and validate the model in
Chapter 4.
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Figure 2. Conceptual model of the relationship between dermatology DTCAs and utilization of medical services by adult
dermatology adult patients after exposure to DTCAs, by H. Zouetchou, 2015, “Direct-to-consumer advertisements and medical
services utilization amongst adult dermatology patients in the United States”, dissertation submitted as partial requirements for
the degree of Doctor of Philosophy, Health Services, p. 87, unpublished. Copyright 2015 by Walden University.
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Model Background
The background consists of detailing how this model came to the existence. The
review of the literature in Chapter 2 provided evidence of the relationship between
DTCAs and the use of medical services amongst Americans in general. The existing
evidence from the literature, as well as the model in figure 1, inspired this study’s model
(Figure 2). The study’s model aimed to explain the sequences of the exposure to the
dermatology DTCAs and the utilization of medical dermatology services by the patients
as the consequence of the exposure. The model’s foundation is that an exposure to the
dermatology DTCAs leads to the utilization of the medical dermatology services in the
United States of America. I, empirically tested the model in figure 2 amongst adult
dermatology patients who lived in Houston, Texas, and were receiving primary care
services at MedStar Primary Care Clinic, or/and attending to the church service at Saint
Nicholas Catholic Church. The empirical testing of the study model through the
questionnaire completion enabled to verify that the relationship between the DTCAs and
the utilization of medical services was valid amongst the study’s target population. Then,
the statistical test of the model in figure 2 permitted to examine also the P T, which was
the theoretical framework of this research study. The figure 2 statistical test was through
the research hypotheses statistical testing in the course of the data analysis in Chapter 4.
In fact, the independent (DTCAs exposure) and dependent (types and purposes of the
utilization) variables of the study are the principal components of the model in figure 2.
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Model Presentation
The presentation of the model in figure 2 consists of explaining how an adult
dermatology patients utilized medical services as the consequence of the exposure to the
dermatology product claim, or/and help-seeking announcements. Indeed, an adult
dermatology patient (health status) viewed, heard, or read the dermatology DTCAs
(exposure) that could be product claim, or help-seeking. Product claim and help-seeking
provided the adult dermatology patient with information that had educational values.
Product claim provided information about the advertised drug and the condition treated.
Help-seeking conveyed information on the dermatology condition or disease and the
available treatment options. The information could be complete or incomplete (sufficient
or not to seek and to use medical dermatology services). The adult dermatology patient,
after exposure, uses the full information to seek and to utilize the medical dermatology
service(s). The use of the full information for the medical dermatology services
utilization depends on the mediation or moderation of the patient’s individual factors or
backgrounds such as sex, age, level of education, medical history, and ethnic group. The
medical services utilized vary according to the types of the DTCAs exposure. In that
regard, the dermatology patient in contact with the product claim announcement uses for
example one or more of the following services: (a) to request prescriptions for the
advertised drug from their health care provider, (b) better adherence to the treatment plan
and medicalization/to take medication on a regular basis, (d) to remember to fill his/her
prescription, and (e) to consult/ask/talk with their doctors about a particular prescription
drug advertised. Meanwhile the patient in contact with help-seeking advertisement uses
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one or more of these services: (a) to persuade a patient to believe that his/her disease can
have a medical solution , (b) to remember his/her condition, (c) to visit/consult the doctor
about symptoms, (d) to talk with the physician regarding a condition or illness, (e) to
discuss new medical conditions with their physicians, (f) to visit the doctor and to talk
about the personal disease, (g) to obtain new diagnosis from their doctors of a medical
condition so far ignored, (h) to treat completely conditions undertreated before, (i) to
search additional medical information outside of the announcement, (j) to ask the doctor
for a referral, (k) to ask the physicians about the tests regarding the condition advertised,
and (l) to look for information according to the announcement orientation. When the
information is incomplete, the patient will search for additional information outside of the
dermatology product claim or help-seeking announcements. Then, he/she uses the
complete information to utilize the medical services under the mediation or moderation of
the individual factors and for a particular or many reasons.
Dermatology patients exposed to a DTCA utilize medical services for one or
multiple purposes. The utilization of medical services after an exposure to a product
claim announcement could be for the purpose (s) of (a) to seek recovery from an
illness/tumor clearance, (b) for tumor lesion excision, and (c) to check if the person has
contacted or not dermatology disease/screening test. Contrarily, patient’s exposure to a
help-seeking announcement leads to the utilization of medical services for the purpose (s)
of wellness and wellbeing.
Finally, product claim and help-seeking are the sets of the independent variables
of the study. The types and purposes of utilization of medical dermatology services are
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the sets of the dependent variables. Both independent and dependent variables generated
the hypotheses of this research study.
Model Critique
The model has strengths. In fact, the study’s model explains the possible process
of the exposure to product claim, help-seeking, and the consequent utilization of the
medical dermatology services by the adult patients. In addition, the study’s model
presents the elements of the process, when and how they interact during the process of
exposure-utilization-purpose. Those elements are the health status, product claim, helpseeking, information, mediators, moderators, types, and purposes of medical dermatology
services utilization.
However, the model has weaknesses. Indeed, the study’s model does not tell
which of the dermatology product claim or help-seeking advertisements could prompt
more than others the utilization of the medical services for a purpose by the target
population after exposure. Moreover, the model is silent on which characteristic(s) of the
product claim, and help-seeking advertisements could prompt more the utilization of
which particular medical service and/or purpose. These weaknesses have the solutions in
Chapter 4.
Summary and Conclusion
There are evidence from the analysis in this Chapter 2 that product claim and
health-seeking advertisements prompt the utilization of the medical services for a purpose
or reason amongst Americans in general and specifically the adult dermatology patients.
In that regard, an exposure to a product claim advertisement prompted the request for a
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prescription of the drug advertised to treat a condition. Moreover, an exposure to a
product claim advertisement decided the patients to follow regularly the treatment plans
and to believe that medicine was the solution to the conditions. The dermatology patients
talked about or requested from the physician a drug that treated skin cancer/condition due
to the contact with the advertisement of that drug. The reason for this request was to cure
the tumor/disease through drug therapy. Conversely, help-seeking advertisement
exposure led (a) to a doctor visit about a symptom, (b) to talk to the doctor about the
condition advertised, or (c) to obtain a new diagnosis from the dermatologist. The
patients who utilized the medical services sought wellness and wellbeing. The
dermatology/skin cancer help-seeking advertisements prompted the use of (a)
chemotherapy, (b) preventive services, (c) surgery therapy, (d) screening/testing, and (e)
to consult a dermatologist about new symptoms. Multiple reasons justified the utilization
of those services: (a) tumor clearance, (b) tumor lesion excision, (c) to avoid dermatology
disease, and (d) to check the presence or not of the dermatology disease in the skin.
The relationship between product claim, help-seeking advertisements, and the
utilization of medical services for medical reason sought to increase drug therapy and
disease awareness amongst patients in general and adult dermatology patients in
particular. Indeed, some dermatology diseases were the most curable in the United States.
The exposure to the product claim and help-seeking advertisements prompted the
utilization of the multiple medical dermatology services for medical reason(s). In doing
so, patients could survive from the dermatology disease and could continue to live a
healthy and productive life. However, the question of the prediction between product
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claim, help-seeking advertisements, and the utilization of medical dermatology services
amongst adult patients who lived in Houston, Texas, and were MedStar Primary Care
Clinic’s patients, or/and members of Saint Nicholas Catholic Church was still without
any answer. Therefore, undertaking this study to answer that question was still necessary
and required a precise research method definition.
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Chapter 3: Research Method
Introduction
The purpose of this study was to describe the relationship between dermatology
product claim, help-seeking advertisements, and the types and purposes of the utilization
of the medical dermatology services amongst the adult dermatology patients in the United
States. The adult dermatology patients sampled were those who lived in Houston, Texas,
and were receiving primary care services at MedStar Primary Care Clinic, or/and
attending church services at Saint Nicholas Catholic Church.
Past researchers have claimed the relationship between the DTCAs and the
utilization of medical services in the United States, in general, but not amongst the
specific adult dermatology patient population in Houston, Texas (Limbu & Torres, 2009;
Mackert et al., 2010). Chapter 1 was the introduction of the study with the analysis of the
concepts of the pharmaceutical DTCAs and the utilization of medical services. In Chapter
1, I addressed the background and the gap in the existing literature on the topic, the
problem statement, the purpose of the study, the research questions and hypotheses. Also,
I addressed the theoretical framework (PT), the nature of the study, the operational
definitions of the study variables, the assumptions, the scope and delimitations, the
limitations, and significance of the study. Then, Chapter 2 followed, and I focused on the
review of the publications on the relationship between the independent and dependent
variables and the theoretical framework of the study. In the review, I aimed to clarify and
to understand the state of the problem introduced in Chapter 1. Moreover, I presented the
model from the literature that described the relationship between the independent and
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dependent variables of the study. Finally, I presented in Chapter 2 this study’s model of
the relationship between the dermatology DTCAs and the utilization of the medical
dermatology services amongst this study population. In Chapter 3, I expand on the
Chapters 1 and 2 by analyzing a new component of the study: the methodology used to
investigate the research problem stated in Chapter 1 and clarified in Chapter 2. The key
contents of this chapter are the research design and rationale of the selection, the
methodology focusing on the population, the sampling and sampling procedure, the data
collection procedure and instrument, and the pilot study. Besides, in Chapter 3, I analyze
the threats to the research validity, the ethical procedure, and do the summary and
transition to Chapter 4.
Research Design and Rationale
The Study’s Variables
The study’s independent and dependent variables are the focus of this section. In
this correlation research study, I sought to describe the relationship between dermatology
product claim, help seeking advertisements, and types and purposes of medical
dermatology services utilization amongst the adult patients living in Houston, Texas. The
adult patients were Saint Nicholas Catholic Church members and/or patients at MedStar
Primary Care Clinic. In that regard, the set of independent variables were the
dermatology product claim and help- seeking advertisements that may prompt the
utilization of the medical dermatology services amongst the target population. The items
for the observation of the product claim and help-seeking were the characteristics of each
as defined in general by the FDA (FDA, 2012f). The sets of dependent variables were the
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types and purposes of medical dermatology services used after exposure to the
dermatology product claim or/and help seeking advertisements. The observation of the
types and purposes of the medical dermatology services utilization were the variables
from the current literature reviewed on the topic in Chapter 2. The section of this chapter
entitled operationalization of the variables provides readers with the definition of each
observation item.
Research Design and Connection With the Research Question
The design and rationale. This research study followed the quantitative design.
Social science researchers have the option amongst three complementary types of design,
which are qualitative, mixed method, and quantitative (Creswell, 2009; FrankfortNachmias & Nachmias, 2008). The qualitative design uses an exploratory method aimed
to understand the senses that human beings in a group or individually assign to the
problems in society. Data are words (Creswell, 2009; Frankfort-Nachmias & Nachmias,
2008). The qualitative design is inductive or generates general ideas from those
individuals. The data collection occurs in a setting. This study is about the relationship
between variables and not about the meaning given to the DTCAs and the utilization of
medical services in the context of dermatology care.
The mixed method research design is another research design. The mixed method
makes the use of both quantitative and qualitative strategies to answer the research
question. The combination of the strengths of the two designs leads to a higher strength
for the mixed method. This study has existing literature and a testable theory. Therefore,
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the combination of both quantitative and qualitative designs was not necessary to answer
the research study question.
The quantitative design is the third design available for the social science
research. The quantitative design seeks to test theories based on the description of the
relationship amongst the variables of interest. The observation of the variables is through
the use of instruments that facilitate the generation of numbers for statistical test
purposes. The quantitative design is a deductive approach with the key issues being the
statistical inference and the replication of the research results (Creswell, 2009). This
study falls within the quantitative design given that the purpose is to test the PT by
describing the relationship amongst dermatology product claim and help-seeking
advertisements (independent variables) and the types and purposes of medical
dermatology services utilization (dependent variables). Multiple research methods are
available for the implementation of the quantitative design.
The selected quantitative research method and rationale. A cross-sectional survey
was the quantitative method of selection for this study. The selection of the crosssectional survey approach was due to the quantitative nature of the research question
(Creswell, 2009; Frankfort-Nachmias & Nachmias, 2008). The cross-sectional survey
was not the only quantitative approach. Therefore, other applicable quantitative methods
were subject to a comparative analysis to justify the final selection of the cross-section
survey for this study. In that regard, the classic experimental method was an applicable
quantitative method. The classic experimental method uses two identical groups to
conduct the inquiry: the experimental and control groups.
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The classic experimental allows the assessment of treatment or independent
variable. The researcher randomly assigned the cases to the groups (Frankfort-Nachmias
& Nachmias, 2008). A pretest takes place with the experimental group before the
administration of the treatment. Then, a posttest follows after the same group has gone
through the treatment. The control group does not go through the treatment (FrankfortNachmias & Nachmias, 2008). The experimenter compares the results of the tests
between the two groups. The aim is to see if there are any significant difference between
the two groups that are attributable to the effect of the treatment (Frankfort-Nachmias &
Nachmias, 2008).The strength of this method consists of allowing the establishment of
the cause-en-effect relationship between variables, the manipulation of variables, the
comparison amongst control and experimental groups, and the random assignment of the
cases to each of the groups. The risk of internal invalidity is very limited (FrankfortNachmias & Nachmias, 2008). The limitation is that the generalization of the research
results to the nontested population is impossible (Frankfort-Nachmias & Nachmias,
2008). The classic experimental always rhymes with biological and physical sciences
rather than the social sciences. The structure is rigid and classic experiments cannot
easily fit to study a social phenomenon (Frankfort-Nachmias & Nachmias, 2008). This
research study did not use this method because the aim was not to assess treatment.
The panel was another applicable quantitative method for this study. The panel is
a quasi-experimental method. The panel method is necessary when the researcher wants
to observe changes in the dependent variables over a long period (Frankfort-Nachmias &
Nachmias, 2008). The researcher assesses the same panel on a regular frequency and time
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intervals. In that condition, the researcher has the most accurate assessment of the
situation under investigation before and after the assessment (Frankfort-Nachmias &
Nachmias, 2008). The panel facilitates the identification of the variable that has an effect
on other variables, and the collection of data from the same person is over time
(Frankfort-Nachmias & Nachmias, 2008). The limitation of the panel research is the
difficulty constituting a representative sample of respondents at the beginning of the
research. Then, it is difficult to have the respondents’ approval to participate the research
regularly and for a long time (Frankfort-Nachmias & Nachmias, 2008). The panel is not
appropriate for this research giving that the research question can be answered using data
collected once and not many times.
One-short case study was part of the quantitative methods that could be the
methodological support. The preexperimental one-short case study method refers to the
observation of only one event or a group at a specific moment in time (FrankfortNachmias & Nachmias, 2008). The one-short case study, as another preexperimental
method, does not randomly assign cases to the experimental groups. The one-short case
study does not permit the comparison of both control and experimental groups.
Moreover, the sample is not randomly drawn from the general population. No statistical
technique helps to control the threats to internal validity of the research (FrankfortNachmias & Nachmias, 2008). One-short case study helps in pretesting hypotheses and
conducting exploratory research as the base of future research (Frankfort-Nachmias &
Nachmias, 2008). However, the lack of a random sample does not give equal chance to
all members of the population to appear in the sample. Besides, the lack of random
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assignment of the participants to the groups cannot lead to a representative sample. The
aim of this research is not to test treatment: One-short case study is not appropriate.
The cross-sectional survey was another quantitative method. Cross-sectional
survey research method consists of asking a sample selected randomly or not from the
general population to express the attitude and views about the phenomenon under
investigation. The sample does so by responding to a series of questions related to the
past experiences and backgrounds. The researcher, when appropriate, will infer the
results from the representative sample of the general population (Frankfort-Nachmias &
Nachmias, 2008; Creswell, 2009). Cross-sectional method allows the researcher to
establish a cause-and-effect relationship amongst variables, or to describe the type of
relationship amongst the variables (Frankfort-Nachmias & Nachmias, 2008). The survey
offers a rapid data collection, the economy of time, and the identification of the
characteristics of the general population only in the sample (Creswell, 2009). The
limitation of the cross-sectional method resides in the difficulty to control the factors that
affect the research internal validity and the use of sophisticated instruments like a
questionnaire and computer software (Frankfort-Nachmias & Nachmias, 2008). The
strength of the approach is the rapid data collection and analysis, the statistical inference,
the random sample when possible and the use of statistical analysis to reduce the risk of
internal invalidity (Frankfort-Nachmias & Nachmias, 2008; Creswell, 2009). The crosssectional survey adheres to this study whose purpose is to describe the relationship
amongst the quantitative variables.
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The above review of the applicable quantitative methods led to the conclusion that
cross-sectional research design was appropriate to address this research question. In fact,
the cross-sectional research design allows rapid data collection and analysis, the
statistical analysis and inference when appropriate, the random sample and the test of
theory via hypotheses that establish the relationship amongst independent and dependent
variables (Creswell, 2009; Frankfort-Nachmias & Nachmias, 2008). This study’s
question is about a statistically significant relationship between the independent and
dependent variables. This study's question is in alignment with the cross-sectional design
purpose.
Furthermore, this study tested PT via four hypotheses to describe the relationship
between product claim, help-seeking advertisements, and types and purposes of medical
services utilization in the context of dermatology care (Creswell, 2009; FrankfortNachmias & Nachmias, 2008). Also, the cross-sectional survey uses instruments to
measure the variables and generate quantitative data or numbers for statistical analysis to
answer the research question (Creswell, 2009). The measurement instrument for this
study was a structured questionnaire. The questionnaire enabled the collection of
quantitative data and the use of statistical tools to analyze data and to answer the research
question.
Cross-Sectional Survey Design’s Constraints
The cross-sectional survey has multiple constraints. The limited time is one of the
constraints: data collection occurs at a specific moment in time. In other words, the
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researcher collects data once not over time and at a specific period (Creswell, 2009). The
researcher collected primary data from respondents during one month and 10 days.
Another constraint is the resources necessary to conduct the cross-sectional
survey fully: material and finance. In fact, primary data collection requires instrument or
questionnaire. The researcher can develop one or use an existing one, if possible, with the
written permission of the copyright (Creswell, 2009). The development or the written
permission has a cost. Furthermore, online primary data collection requires a creation or
use of a website to host the survey and for respondents to take the survey. The secondary
data or the use of the existing primary data has a fee. Also, the researcher and other data
collection team person do travel for the data collection. The respondents may have
financial compensations for the participation in the study as well as the research team.
The accommodation and feeding costs for the research team do exist. Then, data analysis
and interpretation both need a computer and statistical software like SPSS (FrankfortNachmias & Nachmias, 2008). Some of those constraints affected this study: use
questionnaire, computer, and SPSS software.
Consistency of the Cross-section Survey Selection With the Designs in Health
Sciences
Health sciences are part of social science. Three designs are dominant in social
sciences for the inquiry as developed earlier. The three designs are quantitative,
qualitative, and mix methods (Creswell, 2009; Frankfort-Nachmias & Nachmias, 2008).
The first tests theories to describe the relationship between variables. The second is the
exploration of the understanding of the meanings assigned to problems by individuals or
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groups. The third combines the quantitative and qualitative designs’ strength to respond
to the research question (Creswell, 2009). Cross-sectional survey belongs to the
quantitative design and has the reputation of being the most common method in social
sciences (Creswell, 2009; Frankfort-Nachmias & Nachmias, 2008). The cross-sectional
survey follows a specific methodology for data collection, analysis, interpretation, and
reporting.
Methodology
Population and Disease of Interest
The Walden University’s Institutional Review Board (IRB) approval number for
this study was # 12-09-14-0177813. The study’s target population was American
residents male and female aged 18 years and over who had skin, hair, and/or nail disease.
He/she was living in Houston, Texas currently receiving primary care treatments at the
MedStar Primary Care Clinic or attending to the church services at Saint Nicholas
Catholic Church. The individual did speak, read, and understand the English language.
The individual resided in Houston, Texas for at least six months continuously. Then, the
person should have seen, viewed, or read a pharmaceutical dermatology advertisement
directed directly to the consumer about a dermatology drug or disease in the past 12
months. The individual should have utilized a medical dermatology service/treatment for
a medical reason as the consequence of having seen, viewed, or read (exposure) a
pharmaceutical advertisement directed to the dermatology patients. The 12 month period
started from the questionnaire completion day. The population size was unknown and
could not be estimated at the time of the study.
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The diseases of interest were skin, hair, and nails diseases (dermatology diseases).
According to the AAD (2014a), dermatology diseases represented the most popular
motivation amongst people who visited a physician’s office in America. Dermatology
diseases are multiple such as Acne, head lice, below-the-belt dermatology conditions,
hair loss, melanoma, psoriasis, eczema, imiquimod, rosacea, scabies, vitiligo, and skin
cancer (AAD, 2014a; University of Texas Medical Branch [UTMB Health], 2014).
Sampling, Sampling Procedures, and Sites of the Study
Sampling and procedures. The study’s sampling strategy was the
nonprobability. The complete list (sampling frame) of the study’s population was not
available for the use of the random sampling method. Consequently, the type of sampling
was a nonprobability sample. The lack of a sampling frame made impossible to select
randomly or to determine the probability of each member of the population to appear in
the sample (Collins et al., 2006; Frankfort-Nachmias & Nachmias, 2008).
The nonrandom purposive sample scheme helped to select from the population
the members of the sample. In fact, the selection of the sample for the study was based on
the use of the pre-determined inclusion criteria (eligibility section of the questionnaire).
The selected respondents were available and willing to participate in the study (Collins et
al., 2006; Frankfort-Nachmias & Nachmias, 2008). The questionnaire contained
eligibility or screening section. The eligibility sections aimed to filter the respondents and
to assure that only those who bore the key characteristics of the population participated in
the study. The screening section was the support to my personal judgment. The selection
or recruitment of the sample took place in the face-to-face encounters with the adult
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dermatology patients at the study sites during their medical appointment and church
service occasions.
Study sites. There were two study’s sites: MedStar Primary Care Clinic and Saint
Nicholas Catholic Church both in Houston, Texas. Houston city had a population of
2,097,217 people in 2010. The Houston’s diversified race make-up was White (50.5%),
Black or African American (23, 7%), American Indian and Alaska Native (0.7%), Asian
(6.0%), Native Hawaiian and Other Pacific Islander (0.1%), Two or More Races (3.3%),
Hispanic or Latino (43.8), and White alone, not Hispanic or Latino (25.6%). Houston city
had three counties: Fort Bend, Harris, and Montgomery (United States Census Bureau,
2014). Houston occupied the fourth position as the largest city in population in the United
States after New York, Los Angeles, and Chicago (The City of Houston, 2014).
The first study’s site was MedStar Primary Care Clinic in Houston, Texas. The
study’s target population received primary care medical services. The selection of this
site was due to the diversity through multicultural and multiethnic groups that
characterized MedStar Primary Care Clinic’s community. Then, MedStar offered
diversified types of community services to a diversified target population. Indeed,
MedStar Primary Care Clinic is a for-profit organization established since 2008 in
Houston, Texas (MedStar Primary Care Clinic [MedStar], 2014). The community
members were African-American, African immigrants, Hispanics, and Whites of all ages
and level of education (MedStar, 2014). The members of the community had different
dermatology services utilization experiences. Indeed, MedStar, in addition to check-ups,
cancer screening, and treatment of chronic diseases (diabetes), offered hypertension,
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weight loss program, smoking cessation, travel medicine, women health, and
hypercholesterolemia treatment/medical services to patients (MedStar, 2014). Some of
those patients were without insurance, had limited insurance, and/or had a full coverage
health insurance plan (MedStar, 2014).
The second study’s group was Saint Nicholas Catholic Church in Houston, Texas.
The target population attended the church services at Saint Nicholas parish. Saint
Nicholas is a multicultural and multi ethnics’ group community. Then, Saint Nicholas
had multiple types of community service rendered to the community. Indeed, Saint
Nicholas Catholics Church was a nonprofit religious organization. Saint Nicholas was the
oldest church for Blacks in Houston area (Saint Nicholas Catholic Church, 2014). The
community members were African-American, African immigrants, and Whites of
different ages and levels of education (Saint Nicholas Catholic Church, 2014). The
members of the community had a variety of experiences regarding dermatology services
utilization. Saint Nicholas Catholic Church offered multiples services to the Houston
community: education, professional skills and financial training, occasional
accommodation in case of disasters, and parenthood teaching (Saint Nicholas Catholic
Church, 2014). The population served was unemployed, sick, and other people going
through any change in their life (Saint Nicholas Catholic Church, 2014).
Eligibility criteria. The selection of the sample followed some criteria. The
eligibility criteria for the inclusion of a member of the population to the sample were (a)
to attend church services at Saint Nicholas Catholic Church or/and to receive primary
care services at MedStar Primary Care Clinic in Houston, Texas, (b) to have been
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diagnosed with a dermatology disease in the past 12 months starting from the
questionnaire completion date, (c) to be at least 18 years old, (d) to have seen, read, or
heard (exposure) a dermatology advertisement about a dermatology prescription drug,
or/and disease directed directly to the dermatology patients, and have received a
treatment for a medical reason because of the exposure to the advertisement within one
year, (e) to speak, read, and understand English language, (f) to be receiving dermatology
treatment at a dermatology facility in Houston, Texas, and (g) to be living in Houston,
Texas for at least six months continuously.
Sample size determination. The power analysis method permitted to determine
the sample size of the study. G*Power 3.1.2 computer software helped to determine the
sample size of 82 individuals for this research study. The test family selected was t-tests.
The statistical test used was Correlation: point biserial model. The type of power analysis
was A priori compute required sample size-given α, power, and effect size. The input
parameters were two-tailed hypotheses testing, a Cohen’s d medium conventional effect
size = .30, α = .05 and the power = .80%. The output parameters were a critical value =
1.99, the degree of freedom = 80 and actual power = .80%. However, by rounding off 82,
120 people were the final sample size. I equally surveyed this sample size within the two
settings: 60 respondents at MedStar (with 50% males and 50% female), and 60
respondents at Saint Nicholas (with 50% males and 50% female). There were no data
available to breakdown proportionally the sample size. I am going to analyze the
recruitment strategy used to form the sample.
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Procedures for Recruitment, Participation, and Data Collection
Respondents’ recruitment, informed consent provision, and participation.
The recruitment of the sample took place at the study’s sites. I was the recruiter of the
sample. I obtained from the authorities of the study’s sites the written permissions to
conduct the study within the facility (see Appendices R and S).Then, each target patient
that I met face-to-face in the lobby of the church or patient waiting area of the clinic
received an A5 format flyer. The A5 flyer introduced the study to the potential
respondent (see Appendix F). Moreover, A3 format flyers were posted in the church’s
lobby and the clinic’s patient waiting areas to create the study awareness amongst the
community (see Appendix D). The patient who accepted to participate in the study
provided the informed consent and participated in the study as described below.
The informed consent provision and participation followed multiple steps. This
study’s informed consent provision started with my completion of the online training
course about protecting human research participants at
http://phrp.nihtraining.com/users/login.php on December 7, 2013. The National Institutes
of Health issued the certificate of completion (See Appendix A) to me as the recognition
of the qualification and ability to conduct research on human participants (National
Institutes of Health, 2011). Then, I prepared and submitted the Informed Consent and
other survey materials to the Walden’s Internal Reviewed Board (IRB) for approval
(Office of Research Integrity and Compliance, 2011).
The participant provided the informed consent and participated in the study as
followed after Walden’s IRB approval and authorization of the study:
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1. After reading the A5 flyer during the recruitment described above, the
patient, who was interested and accepted voluntarily to participate in the study,
received from me the Informed Consent Form (Appendix C). Then, I specified to
the patient the place where to meet for the completion after the church service or
meeting with the physician. The recruit gave the informed consent before the
completion of the questionnaire after he/she attended to the church service or met
with the primary care physician. The recruit had adequate time to review study
information, ask questions if any, before giving an informed consent, and
participate in the study.
2. The patient provided an implied informed consent through the completion of
the questionnaire. The participant did not provide a physical signature on the
Consent Form because of the participant’s privacy protection. Moreover, to
respect the participant’s privacy during the completion, the questionnaire
completion took place at the parish hall behind the closed doors, a different
building within the parish’s perimeter. Besides, the questionnaire completion with
individual participant took place at the clinic meeting room (with the doors
closed) different from the patient waiting area. The recruitment, Informed
Consent provision, and the completion of the questionnaire happened the same
day at the study site during each survey day.
3. The participant answered to the eligibility questions of the questionnaire
(Appendix G), and I recorded the answers to reduce the risk of bias. The
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eligibility questions answer determined if the participant was eligible or not for
the study before the completion of the main questionnaire.
4. The eligible participant answered to the main questionnaire, with me recording
the answers.
5. With a noneligible patient, I terminated the completion, thanked the
participant, and attempted to recruit a new participant or attended to the next
scheduled participant.
6. During the eligibility section completion for recruitment, the participant who
could not continue for any reason merely terminated the completion. I continued
with another recruitment attempt or attended to a next scheduled participant.
7. The participant who could not continue the main questionnaire completion for
any reason merely terminated the completion. I, in that case, attended to the next
scheduled participant.
8. I reviewed, with the participant, the completed questionnaire for validation
using the questionnaire completion guide (Appendix H) and terminated the
specific completion.
9. Finally, at the end of each survey day, I conducted the last review of the entire
completed questionnaire to check the accuracy and the consistency of the
responses. If any mistake or inconsistency noted at that time, I merely eliminated
that questionnaire.
The informed consent form was the summarized information about the nature and
purpose of the study, how to take part to the study, the emphasis on the voluntary
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participation in the study, the risks and what to gain taking part into the study. Also, the
informed consent described the confidentiality measures and the ethical considerations of
the study.
The specific demographics data were necessary to collect during the survey.
Indeed, dermatology disease is of all age, race, ethnic groups, gender, and locations in the
United States (Memorial Sloan-Kettering Cancer Center [MSKCC], 2013; Skin Cancer
Foundation, 2013e). Consequently, the demographic data collected during the survey as
part of the study questionnaire (see Appendix G) were the age, race, ethnic groups,
gender, level of education, yearly income, type of dermatology disease, state, city, and
type of mean of payment of the medical dermatology services received.
Data collection. I used, for the data collection, the face-to-face technique to
survey the target individuals eligible for the study (Creswell 2009; Frankfort-Nachmias &
Nachmias, 2008). According to the literature, the response rate for the face-to-face survey
turns around 95% versus 20 to 40% for the mail survey (Frankfort-Nachmias &
Nachmias, 2008). The projected response rate for this study was 85%. The data collection
following the procedure described earlier lasted a month and 10 days. I coded all the
completed and approved surveys and used SPSS 21.0 to computerize the surveys and to
conduct the data analysis. Then, I did the results interpretation and reporting. The survey
package was (a) a copy of the informed consent (see Appendix C), (b) a copy of the
questionnaire, (c) a questionnaire completion guide for respondent (see Appendix H), (d)
a pencil, and an eraser (Creswell 2009; Frankfort-Nachmias & Nachmias, 2008).
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Survey exit and follow-up. The respondent exited the survey after the joint
review and approval of all the answers by both the respondent and I. No follow-up was
necessary during this study. However, a pilot study was necessary to test, correct, and to
validate the questionnaire before the use for the final study.
Pilot Study for Instrument Validation
Instrument development. The research instrument was a structured
questionnaire. I developed the study questionnaire by the year 2013 end with the
assistance of the dissertation committee members at Walden University (Dr. Kadrie,
Chair and Dr Raj, Methodology Expert), and Dr. Patricia Ann Parker, Associate
Professor at MDACC of Houston, Texas, department of behavioral science. All parties
reviewed the first and second drafts of the questionnaire from me. I used validated health
services research samples questionnaires from Dr. Parker (quality of life survey 2010 in
adult cancer survivors) and Dr. Raj (chronic diseases questionnaire 2007) for inspiration.
Then, Dr. Parker, Dr. Raj, and Dr. Kadrie made recommendations for improvement after
the review of the drafts. I corrected the second draft consequently and resubmitted the
amended copy to the three for final approval. The current study questionnaire was the
final version approved by Dr. Parker (see Appendix N & L), Dr. Raj (see Appendix I)
and Dr. Kadrie (see Appendix J).
This last version of the study questionnaire was first validated using professional
or expert opinions approach as followed. Indeed, the experts took part to the
questionnaire design focusing on the professional accuracy of the study’s variables used
in the questionnaire. In fact, Dr. Mays, dermatologist at MDACC, validated the
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questionnaire after multiple reviews and three sessions of clinical observations (24 hours)
with me at the MDACC’s melanoma and skin center (See Appendix T). He focused on
the dependent variables (types and purposes of treatment). In the same logic, Dr.
Valencia Thomas, Associate Professor at the MDACC, edited the Mohs section
(dependent variables) (see Appendix K). Dr. Thomas recommendations for improvement
were included in the questionnaire.
Regarding the DTCAs, Thomas Abrams, Masters of Business Administration
(MBA) from the Food and Drug Administration’s Office of Prescription Drug Promotion
in Maryland validated the product-claim and help-seeking advertisements characteristics
from the FDA’s website used in this questionnaire (see Appendix O). The product-claim
and help-seeking advertisements characteristics were the independent variables of the
study.
Instrument validation plan. The version of the questionnaire validated through
expert opinion as described above (see Appendix G) went through the pilot study and
reliability test for the second and final validation. The pilot study established the
reliability of the study’s instrument based on the Cronbach’s Alpha α test results. The
final data collection used the validated questionnaire from the pilot study. Indeed, the
questionnaire was new and used for the first time in this study. Consequently, it was
necessary to pilot the instrument before the final data collection (Field, 2009). A reliable
instrument or questionnaire measures most likely the construct under investigation during
each use in the same conditions (Al-Dmour et al., 2013; Creswell, 2009). The objective
of the reliability test was to confirm or not that the study’s findings would be the same
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every time that the researchers repeat the study keeping every condition unchanged
(Field, 2009; Frankfort-Nachmias & Nachmias, 2008; Thatcher, 2010). The reliability
test method was the split-half reliability. This method, using SPSS computer program,
divided into two the data randomly. Then, a high computered correlation between the two
halves of the data indicated the reliability of the questionnaire. In that regard, a
Cronbach’s Alpha α value of .7 through .8 (Field, 2009) or 0 through 1(Al-Dmour et al.,
2013; Green & Salkind, 2011) was valid to establish the internal consistency or reliability
of the scale and consequently, the questionnaire validity (Dedeli & Fadiloglu, 2011;
Green & Salkind, 2011).
The planned and achieved pilot sample size was twelve participants. The pilot
sample was selected identically (six from each study site) from the study sites following
the selection method presented earlier. The twelve pilot study’s respondents were not part
of the final sample. The pilot study was planned to help to identify and correct any
mistake or malfunctioning from the questionnaire regarding questions, format, and scales
before the final study.
The Likert scale of attitude permitted to measure the attitude and views of the
patients regarding the DTCAs of dermatology drug or disease prompting the utilization of
the medical dermatology services for medical reason(s). The questionnaire had six scales:
(a) dermatology product claim advertisement exposure scale (DPCAES), (b) dermatology
help-seeking advertisement exposure scale (DHSAES), (c) types of medical dermatology
treatments utilized after exposure to the dermatology DTCA of prescription drug scale
(TDMTUEPDAS) , (d) types of medical dermatology treatments utilized after exposure
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to the dermatology disease DTCA scale (TDMTUEDDAS), (e) purposes of the utilization
of medical dermatology treatments after exposure to dermatology DTCA of prescription
drug scale (PUDMTEDDAS), and (f) purposes of the utilization of medical dermatology
treatment after exposure to dermatology DTCA of disease scale (PUDMTEDAS). The
scales (a) had 10 items, (b) five items, (c) seven items, (d) 14 items, (e) four items, and
(f) four items.
Instrumentation and Operationalization of Constructs
Identifying instrument and literature supporting the development. I have
identified in this paragraph the instrument, mostly the measurement scales, and presented
the publications that shed light on the instrument development. The quantification of a
concept is the primary purpose of the measurement (Creswell, 2009; Frankfort-Nachmias
& Nachmias, 2008; Likert & Hayes, 1957; Rothmann et al., 2009). Therefore, the study’s
measuring tool was the Likert interval scale of five points included in the questionnaire
which was the main research instrument. This scale existed since 1920 due to Renis
Likert’s work (Likert & Hayes, 1957; Hartleya & Betts, 2010). The scale aimed to
measure the individual’s attitude toward a phenomenon under investigation. In that
regard, the researcher created a list of positive verbal statements to which people
provided their answers to each individual item on a scale (Carifio & Perla, 2007;
Frankfort-Nachmias& Nachmias, 2008; Jamieson, 2004; Likert & Hayes, 1957). The
scale usually was a five-point scale with equal interval. The point five was always
assigned to the positive end and one to the negative end of the scale (Chomeya, 2010;
Hartleya & Betts, 2010; Jamieson, 2004; Likert & Hayes, 1957).
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The Likert interval scale of five points (where one mean Not agree at all, two
means Not agree, three means Agree/Not agree, four means Agree, and five means
Totally agree) served to measure the variables in the questionnaire. Each value from one
through five was the weight and the direction of the respondent’s answer the item
depending on how favorable or not he/she was regarding the item (Frankfort-Nachmias &
Nachmias, 2008). This allowed the generation of the numbered data for the statistical
tests and analysis using SPSS 21.0 computer software (Creswell, 2009; FrankfortNachmias & Nachmias, 2008; Likert & Hayes). The questionnaire had six scales as
described in the pilot section above. Each had a certain number of items or positive
verbal statements on which the respondent expressed his/her attitude about the problem
under investigation.
The questionnaire was a set of 38 questions with 24 closed-ended, six matrix
question/rating, and height open-ended (Frankfort-Nachmias & Nachmias, 2008). The
questions provided information about the following aspects of the research: (a) eligibility
criteria, (b) demographics/background, (c) exposure to the dermatology pharmaceutical
DTCA of prescription drug, (d) exposure to the dermatology pharmaceutical DTCA of
disease, (e) utilization of medical dermatology service(s)/treatment(s) after exposure to a
dermatology pharmaceutical drug announcement, (f) utilization of medical dermatology
service(s)/treatment(s) after exposure to a dermatology pharmaceutical disease
announcement, (g) purpose of the utilization medical dermatology service(s)/treatment(s)
after exposure to a dermatology pharmaceutical drug announcement, and (h) purpose of
the utilization of medical dermatology service(s)/treatment(s) after exposure to a
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dermatology pharmaceutical disease announcement. The length of the questionnaire was
around 30 minutes.
Likert scale reliability and validity critiques. The section addresses the limits
of this study instrument’s reliability and validity method. The reliability and validity of
the questionnaire took place during the pilot study as described earlier. Cronbach’s Alpha
α method allowed in the previous studies to establish the Likert scale’s reliability and
construct validity. In fact, Dedeli and Fadiloglu (2011) in their study on obesity used testretest method to verify the reliability and the content validity of the Likert scale. As
stated in the pilot section above, a reliable and valid instrument permits to obtain the
same findings over time (Frankfort-Nachmias & Nachmias, 2008). However, the Likert
scale’s validity depends on how the researcher creates the positive statement for
measurement. Moreover, the Likert scale’s validity depends on the identification and
control by the researcher of the specific threats to the study validity (Creswell, 2009;
Frankfort-Nachmias & Nachmias, 2008). Finally, the spilt-half reliability or the way the
data set is divided into two determines the results of the test in certain cases (Field, 2009)
independently of the variable measured in the study.
The variables to measure to address the research question. The variables
measured on the interval scale for hypotheses testing were the characteristics of the
pharmaceutical product claim and help-seeking DTCAs as defined in general by the FDA
(independent variables). The other variables for the measurement were the types and
purposes of the medical dermatology services utilized as the consequence of the target
population exposure to a dermatology product claim and help-seeking (dependent
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variables). The complete list of the independent and dependent variables of the study
were in the Chapters 1 and 2, operational definitions sections.
The data to assess these variables in order to answer the research questions were
the primary data collected from the respondents during the face-to-face questionnaire
completions. The measurement instrument was a structure questionnaire with five-point
Likert scale as presented above. The respondents rated on the product claim or helpseeking scales the DTCAs’ characteristics and the medical dermatology services utilized
after an exposure to dermatology DTCA.
The variables measurement required the use of different levels of measurement
that were necessary for this study. The first level was the nominal (use of numbers to
assign modalities or answers to each categorical variable and demographics). The race,
ethnic groups, gender, level of education, type of dermatology disease, state, city, and
type of mean of payment which were categorical variable used this level of measurement
(Frankfort-Nachmias & Nachmias, 2008). The second level was the interval (to measure
the continuous variables respecting the same exact and constant distance between them)
appropriate for the incomes and ages as quantitative variables (Frankfort-Nachmias &
Nachmias, 2008).
The third was the ratio level of measurement (to describe variables with absolute
and fixed natural zero point, or have identical distance between them). This level helped
to calculate the mean age of the respondents (Frankfort-Nachmias & Nachmias, 2008).
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Operationalization of the Variables of the Study
Terminology. DTCAs: Announcements or information about dermatology drug,
disease, treatment options, and devices passed directly to the dermatology patients by
pharmaceutical companies and distributors through the television, radio, newspapers,
telephone, brochures, magazines or online without any medical professional mediation
(Hall, Jones, & Hoek, 2010; Lee-Wingate & Xie, 2010).
Help-seeking advertisement: Announcement that talks only about the dermatology
disease or condition without any reference to a drug that can treat the condition (FDA,
2012d, 2012f; La Barbera, 2012).
Medical services/physician services: Dermatology healthcare services or supplies
delivered or whose delivery is coordinated by a physician or medical doctor who has a
medical license to practice medicine or osteopathy (Healthcare.gov, 2013; GPO, 2013).
Product claim advertisement: Announcement that states the dermatology drug
name, the treated condition, and the risks and benefits related to the use of the advertised
drug (FDA, 2012b, 2012f; La Barbera, 2012).
Purpose of medical services utilization: Reason why the dermatology care seeker
utilizes medical care services. The reason can be the disease prevention, the treatment of
disease, the monitoring, to seek the well-being, the protection or to alleviate a condition
(Aday & Anderson, 1974; Barton, 2010; Shi & Singh, 2008).
Dermatology disease/condition: Disease(s) that attacks skin, hair, and nails
(AAD, 2014b).
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Type of medical services utilization: A particular medical service or care provider
that can be a nurse, hospital, surgeon, or a physical therapist used by a dermatology care
seeker (Aday & Anderson, 1974; Shi & Singh, 2008).
Utilization of medical services: Reception of dermatology services provided by or
under the supervision of a State’s licensed dermatologist at a physical place, for an
identified medical reason, and based on a frequency of utilization (Aday & Anderson,
1974; Shi & Singh, 2008).
Operational definitions. The following were the operationalization of the study
variables.
Dermatology help-seeking/disease advertisement. Description of the type of
dermatology disease without any recommendation of a specific dermatology drug for
treatment: The advertisement presents to the public the disease and its symptoms without
telling what drug can treat the condition (FDA, 2012f).
Encouraging people with the symptoms of the described type of dermatology
disease to talk to their doctor: Recommendation to the public to consult the
dermatologist if the person notices on the skin, hair, or nails any indication/sign of the
advertised disease (FDA, 2012f).
Inclusion of the company's name of the advertised dermatology drug: Designation
of the drug’s manufacturer (FDA, 2012f).
Provision of a telephone number/website to call or to visit for more information
about the advertised dermatology disease (described condition): Communication to the
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public of the available telephone number or website to use to collect extra information
regarding the particular advertised dermatology disease if necessary (FDA, 2012f).
Dermatology product claim or prescription drug advertisement
(characteristics). Equal statement of the advantages and possible negative effects of the
dermatology drug use: Presentation to the patients, in a balanced way, of what are the
benefits and potential negative consequences of using the advertised drug (FDA, 2012d,
2012f).

Equal statement of the benefits and risks associated with the dermatology drug
use: Equitable presentation of the advantages and dangers related to the use of the
advertised drug (FDA, 2012f).
Inclusion in the dermatology print product claim advertisement of the statement.
"You are encouraged to report negative side effects of prescription drug to the FDA Visit
MedWatch5 or call 1-800-FDA-1088.": Clear statement of how the patient can
communicate to the FDA office any not desired secondary consequences of the drug
advertised (FDA, 2012f).
Statement by the dermatology broadcast product claim of different sources where
to find the FDA approved prescribing information of the advertised drug (adequate
provision): Statement of where the patient can get additional product information
approved by the FDA
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Statement by the dermatology audio broadcast product claim of the most
important risks of the dermatology drug (major statement): Presentation of the most
serious dangers that may encounter the dermatology drug user.
Statement by the dermatology print product claim of all the drug risks approved
by FDA as prescribing information (brief summary): Presentation of the dangerous
aspects of the drug approved by the FDA and contained in the drug information or label.
Statement of the most significant dermatology drug’s risks: Presentation of the
very important dangers that the patient may face taking the advertised drug (FDA,
2012f).
Statement of the name of the dermatology drug: Statement of the vulgar
designation of the drug approved by the US government (brand) and the US government
non-approved drug designation used (generic) to advertise the drug (FDA, 2012f).
Statement of a minimum of one type of dermatology disease (the condition[s])
treated by the advertised dermatology disease drug (approved drug use by the FDA):
Presentation of the form of dermatology disease treated by the advertised drug (FDA,
2012f).
Purposes of medical services utilization after exposure to dermatology helpseeking/disease advertisement. Early detection of the dermatology disease: Diagnosis
of the condition at its very first stage (MDACC, 2013a; Kontos & Viswanath, 2011).
Dermatology disease symptom management: Preventive measures taken, selfexamination of the skin to detect any change that may indicate a dermatology disease
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type, identification of the surrounding possible causes for more prevention and control,
and screening test when necessary (Kontos & Viswanath, 2011).
Tumor/disease clearance: Complete cure of the disease (Samarasinghe et al.,
2011).
Tumor/disease lesion excision: Use of instruments to remove the abnormal part of
the cell or tissue and its surrounding normal cell in order to cure the dermatology
condition (MDGuidelines, 2013; Samarasinghe et al., 2011).
Purposes of medical dermatology services utilization after exposure to a
dermatology product claim/drug advertisement. Mohs defect repair using a rhombic
transposition: Rebuilding of the part of the body damaged by the dermatology disease
using Mohs surgery and the rhombic transposition method (Samarasinghe et al., 2011).
Treatment/cure of the dermatology disease looking for well-being: Complete
destruction or removal of the dermatology disease so that the patient will become healthy
(MDACC, 2013a; Samarasinghe et al., 2011; The Skin Cancer Foundation, 2013b).
Tumor/disease clearance: Complete elimination of the dermatology tumor
(Samarasinghe et al., 2011).
Tumor/disease lesion excision: Removal of the abnormal part of the cell and its
surrounding normal tissue (MDGuidelines, 2013; Samarasinghe et al., 2011).
Types of medical dermatology services utilized after exposure to dermatology
help-seeking/disease advertisement. Consulting dermatologist regarding any symptom
related to dermatology disease for early detection: Discussion with the dermatologist
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about the possible symptoms of the dermatology disease that the patient has (Kontos &
Viswanath, 2011).
Dermatology disease screening test: Checkup to diagnose a dermatology disease
before any symptom appears (Kontos & Viswanath, 2011; National Cancer Institute
[NCI], 2013e).
Gene therapy/biological therapy: Destruction of the dermatology disease by
including genes into the patient’s cells affected by the cancer (NCI, 2013a; The Skin
Cancer Foundation, 2013d).
Clinical trial/experimental: Participation to a research study that seeks to know
how well a dermatology disease treatment approach or technique works on individuals
(American Cancer Society, 2013b; MDACC, 2013a; NCI, 2013e; The Skin Cancer
Foundation, 2013b).
Cryotherapy/Cryosurgery: Use of the liquid nitrogen to freeze and eliminate skin
tissues affected by the disease (Samarasinghe et al., 2011; The Skin Cancer Foundation,
2013b; MDACC, 2013a).
Curettage and cautery/Curettage and electrodessiccation/Electrodessiccation and
curettage: Use of instruments called curette to scrap off the skin tumor followed by the
destruction of any remaining tumor with the heat generated by the electrocautery needle
(AAD, 2013; American Cancer Society, 2013b; Samarasinghe et al., 2011; The Skin
Cancer Foundation, 2013b).
Laser surgery: Removal of the external layers of the cell (epidermis) and the
tissues of the skin affected by the tumor using the laser strong beam light, the erbium
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YAG laser or the carbon dioxide (, 2013a; NCI, 2013d; The Skin Cancer Foundation,
2013b).
Lymph node surgery: Operation of the lymph nodes for biopsy to look for
cancerous tumor or for the removal of the lymph nodes in case of the presence of the skin
cancer tumor (American Cancer Society, 2013b).
Mohs micrographic surgery: Excision of a malignant tumor with the help of
staged, intraoperative frozen sections processed in the Mohs technique. Sections excised
are histologically clear of malignancy (American Cancer Society, 2013b; MDACC,
2013a; Samarasinghe et al., 2011; The Skin Cancer Foundation, 2013b)
Radiotherapy/Radiation: Destruction or treatment of the tumor in the tissue of the
patient utilizing X-ray beams (NCI, 2013d; Samarasinghe et al., 2011; The Skin Cancer
Foundation, 2013b).
Skin grafting and reconstructive surgery: Removal of the skin cancer tumor
followed by the collection a skin free of tumor from the patient body to graft it on the
wound. The grafting helps the wounded part to recover completely (American Cancer
Society, 2013b).
Standard surgical excision/resection: Use of the anesthesia to paralyze for a short
time the area of the skin with tumor. Then, removal of the tumor surrounded with a
certain normal skin followed by its examination under microscope to make sure the entire
tumor has been removed. Stitches are used to repair the surgical area to end the procedure
(AAD, 2013; American Cancer Society, 2013b; NCI, 2013d; Samarasinghe et al., 2011;
The Skin Cancer Foundation, 2013b).
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To search for additional health information outside disease advertisement
(company’s website): Other sources of information are consulted to complete the
information received from the advertisement and to be able to make an informed health
decision (Kontos & Viswanath, 2011).
Types of medical dermatology services utilized after exposure to a
dermatology product claim/prescription drug advertisement. Request and obtainment
of a medical prescription of the dermatology drug advertised: Meeting with the
dermatologist to request and obtain from him/her the prescription of the advertised
dermatology drug (Gray & Abel, 2012).
Chemotherapy: Treatment of the patient using the dermatology advertised
prescription drug following the patient’s request (American Cancer Society, 2013b; NCI,
2013a; Samarasinghe et al., 2011; The Skin Cancer Foundation, 2013b)
Adherence to the dermatology disease treatment regimen: Normal participation to
the treatment plan prescribed by the dermatologist (Frosch, Grande, Tarn, & Kravitz,
2010; Wellington, 2010).
Dermatology prescription drug refill: Obtainment of another quantity of the same
drug from the pharmacist after running out of the drug (Frosch et al., 2010; Wellington,
2010).
To talk to dermatologist/doctor about dermatology advertised medication:
Meeting with the dermatologist/doctor to discussion about the dermatology medicine
presented in the advertisement (Gray & Abel, 2012).
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Physician/dermatologist office visit: Meeting with a dermatologist/doctor in
his/her office for medical dermatology reasons (Gray & Abel, 2012).
Skin, hair, and nails health maintenance: Treat the patient to improve his/her
appearance not to take care of a specific dermatology disease (AAD, 2014b).
Scores and interpretation. The calculated scale scores (Likert scale) were the
mean scores. SPSS software helped to calculate the mean scores by adding all the values
in the distribution or all observations and dividing the result by the total number of the
observations (Frankfort-Nachmias & Nachmias, 2008; Green & Salkind, 2011). Each
means score indicated the level of the Likert scale with the higher distribution or
responses for the variable from the respondents. The identified level on the Likert scale
(from one through five) was the respondents’ opinion about the variable (Field, 2009;
Frankfort-Nachmias & Nachmias, 2008; Green & Salkind, 2011).
Data Analysis Strategy
Data analysis software: statistical package for social sciences (spss) 21.0. The
statistical package for the social sciences (SPSS) software version 21.0 was the data
analysis software selected for this study. Windows 7 helped to run SPSS version 21.0 on
a computer. SPSS software served to analyze social sciences data. Furthermore, SPSS
software helped to draw reliable conclusions that helped to solve daily life problems in
the context of medical or health research, market research, pharmaceuticals and
manufacturing (Frankfort-Nachmias & Nachmias 2008; Green & Salkind, 2011;
International Business Machines [I.B.M.], 2011). This research belongs to the health
research category in social sciences.
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Data cleaning and screening procedures. The data cleaning consisted of
multiples tasks before the analysis. The first task was the coding of the data. The coding
was the attribution of number or numeric codes to each observation or variable category.
Then, the numbers enabled the use of the computer and SPSS 21.0 program to
computerize, to edit, to retrieve, and to analyze data (Frankfort-Nachmias & Nachmias,
2008; Green & Salkind, 2011; IBM, 2011). The codebook constituted the coding
outcome (Frankfort-Nachmias & Nachmias, 2008; Laureate Education, 2009). The data
editing during the creation of the codebook was to check and to make sure that each
question had an appropriate answer according to the completion guide for the
respondents, and the appropriate assigned numeric codes for each modality. Then, I
verified that all answers were consistent one another when necessary. I conducted this
task by reviewing all the completed surveys. The development of a codebook took place
after the data collection via questionnaire completion (data preparation). The higher
category of each interval-level of variable had the higher score and vice versa. The
nominal-level variable code assignment followed no rule, but was consistent with all
cases in the study (Frankfort-Nachmias & Nachmias, 2008).
The second task was the data cleaning by me after coded data were in SPSS
format. Thus, I used the codebook to check, to identify, and to correct manually incorrect
and inconsistent codes in the data view windows of the SPSS file. Then, I used the SPSS
data to run the frequency table for each variable in order to track and to replace the code
that did not exist in the codebook (wild codes) (Frankfort-Nachmias & Nachmias, 2008).
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The third cleaning task consisted of tracking and correcting outliers from the
SPSS data before running the multiple regression’s assumptions test. The assumption test
aimed to verify if the assumptions were met or not before any statistical test of
hypotheses (Field, 2009; Laureate Education, 2009). A variable was an outlier if the score
was higher or lower than any other score of the same variable. In other word, each value
that did have a standardized score above the absolute value /3.29/ for the variable was
considered outlier (its standard deviation is more than 3 from the mean score) (Field,
2009; Laureate Education, 2009). I created the standardized scores or z-scores for each
variable using the descriptive table of the SPSS. The frequencies were considered the
new standardized scores. A standardized score with a value higher than the absolute value
of /3.29/ was considered outlier (Laureate Education, 2009). The plan to correct any
outlier found was to make the outlier higher by one unit from the extreme score of the
variable. The new or modified value coming from the correction of the outlier (s) was to
replace the outlier (s) of the variable before any statistical test. I did not plan to delete
outliers, if any found, to avoid reducing the sample size of the study (Laureate Education,
2009). The data analysis did not detect any outlier for this study.
The fourth task was the Multiple Regression’s assumption test. The multiple
regression analysis’ assumptions were the (a) normality, (b) normality of error variances
distribution, (c) independence, (d) linearity, (e) homoscedasticity, (f) independent errors,
(g) predictor variables are quantitative or categorical non-zero variance, (h) no perfect
multicollinearity, and (h) predictors are uncorrelated with external variables (Field, 2009;
Green & Salkind, 2011; Laureate Education, 2009). The testable assumptions were the
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(a) normality of the distribution, (b) normality of error variances distribution, (c)
independence of errors, (d) homoscedasticity and (e) no perfect multicollinearity (Field,
2009). The bottom line of the assumption test was to verify if the assumption was met or
to provide an alternative in case the assumption was not met before any hypothesis test.
Moreover, parameters of the regression model would be free of bias and the external
validity (generalization) would be possible if the assumptions were met. Linear multiple
regression assumption stated that the predictor variables (independent) can be
quantitative or categorical (with two categories codes zero and one) and the outcome
variable (dependent) can be quantitative, continuous and unbounded (Field, 2009; Green
& Salkind, 2011). In addition, more than one predictor would be considered separately as
predicting the type or purpose of medical service utilized.
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Research questions and hypotheses.
Main research question and hypothesis. This quantitative research sought to
answer the following main research question: Is there a statistically significant
relationship between product claim, help-seeking advertisements, and types and purposes
of medical service utilization amongst adult dermatology patients in the United States?
The related hypothesis to this main research question was:
Hypothesis 1 (H0): Product claim and help-seeking advertisements does not
significantly prompt the utilization of the types and purposes of medical services amongst
adult dermatology patients in the United States.
Hypothesis 1 (H1): Product claim and help-seeking advertisements significantly
prompt the utilization of the types and purposes of the medical services amongst adult
dermatology patients in the United States.
Secondary research questions and hypotheses. The secondary research questions
proceeding from the central question were:
Is product claim advertisement a predictor of the types of medical services
utilized amongst adult dermatology patients in the United States?
Hypothesis 2.1 (H0): Product claim advertisement does not significantly prompt
the utilization of the types of medical services amongst adult dermatology patients in the
United States.
Hypothesis 2.1 (H1): Product claim advertisement significantly prompts the
utilization of the types of the medical services amongst adult dermatology patients in the
United States.
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Is product claim advertisement a predictor of the purposes of medical services
utilization amongst adult dermatology patients in the United States?
Hypothesis 2.2 (H0): Product claim advertisement does not significantly prompt
the purposes of medical services utilization amongst adult dermatology patients in the
United States.
Hypothesis 2.2 (H1): Product claim advertisement significantly prompts the
purposes of the medical services utilization amongst adult dermatology patients in the
United States.
Is help-seeking advertisement a predictor of the types of medical services utilized
amongst adult dermatology patients in the United States?
Hypothesis 2.3 (H0): Help-seeking advertisement does not significantly prompt
the types of medical services utilized amongst adult dermatology patients in the United
States.
Hypothesis 2.3 (H1): Help-seeking advertisement significantly prompts the types
of the medical services utilized amongst adult dermatology patients in the United States.
Is help-seeking advertisement a predictor of the purposes of medical services
utilization amongst adult dermatology patients in the United States?
Hypothesis 2.4 (H0): Help-seeking advertisement does not significantly prompt
the purposes of medical services utilization amongst adult dermatology patients in the
United States.
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Hypothesis 2.4 (H1): Help-seeking advertisement significantly prompts the
purposes of the medical services utilization amongst adult dermatology patients in the
United States.
Data analysis plan.
Descriptive and inferential statistics. The first group of analytical tools
was the descriptive statistics. In fact, the descriptive statistics of interest were the mean
scores, standard deviations, and frequencies. The three parameters allowed to organize
and to summarize data. The standard deviation permitted to describe and to measure the
dispersion of the variable distributions from the mean. The frequencies helped to
compute the total number of distribution in favor of each categorical variable that were
the characteristics of each type of advertisements, the types and purposes of medical
services utilization, and the demographics. The mean scores helped to determine the
mean of the interval-level variable exact age (Frankfort-Nachmias & Nachmias, 2008;
Green & Salkind, 2011). Furthermore, the mean score permitted to identify the level of
the Likert scale that had the higher distribution for the variable. The identified level on
the Likert scale (from 1-5) enabled me to read the attitude and views of the respondents
on the scale for the particular item (Field, 2009; Frankfort-Nachmias & Nachmias, 2008;
Green & Salkind, 2011).
The second group of tools was the inferential statistical that enabled to test the
hypotheses: the linear multiple regressions. Linear multiple regression aims to describe
the strength of a linear relationship between one dependent variable and multiple
independent or control variables (Field, 2009; Frankfort-Nachmias & Nachmias, 2008;
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Green & Salkind, 2011). As stated earlier, the research question was about the linear
relationship between product claim and help-seeking advertisements (independent
variables) and the type and purpose (dependent variables) of the utilization of the medical
services amongst dermatology patients aged 18 and older. The dependent and
independent variables were observed on the Likert scale of five points. Consequently,
they were continuous or quantitative. The selection of the predictors to enter into the
model was based on the current literature reviewed and the results of the pilot study
(Field, 2009; Frankfort-Nachmias & Nachmias, 2008). This test was appropriate for the
hypotheses testing of this study.
The parameters for the interpretation of the test of the hypotheses, using linear
multiple regression, were the multiple R or multiple correlation coefficient and the sum of
square R2 or effect size (Field, 2009). The multiple correlation R represented the strength
index of the degree of the correlation between the dependent and independent variables
for the sample (Green & Salkind, 2011). A large multiple R indicated the large
correlation between the product claim and help-seeking advertisements and type sand
purpose of medical services utilization in the sample. Concretely, a multiple R equal to 1
meant that the predictors affected perfectly the outcome or dependent variable: the
overall test or model was positive (Field, 2009). The H0 of the main hypothesis was
rejected to the benefit of H1. Then, the Adjusted R2 was the amount of the variance in the
dependent variable attributed to the set of predictors. In other words, Adjusted R2 was the
level of the overall variance in the outcome explained by a set of the predictors in the
model or equation. The Adjusted R2 represented the amount of variance in a type or
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purpose of the medical dermatology services utilized explained by the set help-seeking or
product claim advertisements variables (Field, 2009). The index of effect size (R2) or
Adjusted R2 ranged in value from -1 to +1 (Frankfort-Nachmias & Nachmias, 2008;
Green & Salkind, 2011).
Confidence level and margin of error for the hypotheses test. The
conventional 95% was the confidence level, and 5% the margin of error or level of
significant (α = .05) for the hypotheses test. Moreover, the test was a two-tailed
hypothesis testing. In that regard, the null hypothesis was rejected if the sample outcome
was among the results that would have occurred by chance not more than 5% time
(Frankfort-Nachmias & Nachmias, 2008). In other words, the null hypothesis was
rejected when the p-value was less or equal to than .05. P-value or probability indicated
how confident I was to say that the observation from the sample was the same in the
population (inference).
Threats to Validity
The paragraph addresses the external validity threats and the solutions for this
research study. The external validity of a research refers to how accurate or until which
degree the researcher can generalize the results from the sample to the entire population,
or can apply those results in a separate context (Frankfort-Nachmias & Nachmias, 2008).
The first threat to the external validity of this research study was the representativeness of
the sample. Indeed, the sample most has the key characteristics of the population for the
statistical inference to be possible. Consequently, the eligibility criteria stated previously
for the statistical unit inclusion to the sample, the demographics, my personal judgment

135
in selecting the final respondents, and the Walden University’s IRB approval of the
questionnaire after reviews permitted to address this study’s threat to external validity. In
addition, the results of this study will not be inferred to any population or setting that was
not part of the study.
The second threat to the external validity was the technical nature of the
independent and dependent variables as well as the items selected for the observation of
the variables. Product claim, help-seeking advertisements, types and purposes of medical
dermatology services utilization, and the observation items described in Chapters 1 and 3
were the language proper to the specific professions. Therefore, the respondent has to
understand the clear meanings of the variables and items to be able to provide with
accurate answers in the questionnaire. In doing so, the items would measure effectively
the intended content or construct (Creswell, 2009; Frankfort-Nachmias & Nachmias,
2008). Indeed, the construct validity is the effectiveness of the items to measure the
concepts stated in the hypotheses (Creswell, 2009). The construct validity threat to this
study can be the selection by me of the inappropriate items for the observation of the
independent and dependent variable of the study. The experts’ opinions about the DTCAs
and the medical dermatology services approved the items and operational definitions
used for the final data collection. The pilot study enabled the test of the target
population’s understanding and familiarity with the constructs or concepts. Then, I used
the pilot study results consequently before the final data collection.
The internal validity threats and solutions are the focus of this paragraph. The
internal validity of a research is the fact that independent variable, not a different factor,
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affect or bring change to the dependent variables effectively (Creswell, 2009; FrankfortNachmias & Nachmias, 2008). The threat to internal validity represents those factors,
different from the independent variable, which can provoke the change in the dependent
variable. This if they are not identified and addressed properly before or during the study.
The threat to the internal validity of this study was the patient’s moral and psychological
conditions due to his/her dermatology condition. Indeed, dermatology diseases such as
skin cancer are a deadly disease if not diagnosed and cured early (Skin Cancer
Foundation, 2013c). The dermatology disease patient participant to this study was
morally and psychologically uncomfortable due to the possible death that he/she could be
a victim (Skin Cancer Foundation, 2013c). Therefore, the information provided during a
completion may not be accurate. In that case, the observed relationship between
dermatology product claim, help-seeking advertisements and types and purposes of
medical dermatology services utilization may not reflect the reality of the field. Two
solutions were used to overcome this threat: the participation and withdrawal at any time
of the patient from the study were free and voluntary.
Ethical Procedures
Access to Data and Research Authorization from the Study Sites and Walden
University
This section provides the answer how I proceeded to obtain primary data from
MedStar and Saint Nicholas Catholic Church communities, the authorization to survey
dermatology patients at those two study sites without harm, and to obtain the Walden
University IRB’s approval to collect data for this study. The two study sites issued to me
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the written permissions to conduct research on the sites (See Appendices R & S). I
completed successfully the US National Institutes of Health’s online training on the
protection of human subject in research on December 7th, 2013 (See Appendix A)
(National Institutes of Health, 2011).
In the same logic, I requested and obtained the study approval from the Walden
University IRB before starting any pilot study and primary data collection. Indeed, I
prepared and submitted to the Walden IRB, after the approval of the committee chair, the
following documents: the Walden IRB application form version 2010A and the
supporting materials. The supporting materials were all the appendixes listed in this
dissertation.
Concerns Regarding Recruitment Materials and Process
The respondents’ recruitment materials that were the flyers A5 and A3 formats
and the screening section of the questionnaire had certain concerns. The concerns
regarding the flyers and the questionnaire were the length, the color, the typography, the
quality of the paper, and the illustrations or images on the flyers (Frankfort-Nachmias &
Nachmias, 2008). The solutions to these concerns were to write short texts for the flyers
and to use a high quality paper and printing selected by the infographic and/or printing’s
professionals, Leeland Designs Company. The questionnaire text was double space, times
news roman, 12 front size for easy and fast readability.
In terms of process, the concern was the level of the dermatology patient’s
receptiveness and corporation during the recruitment at the study sites (to allow me to
talk to him/her or to read the flyers personally about the study). The patient was there to
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honor a medical appointment or to attend a church service. Therefore, it was not easy to
know if the participant would be receptive and corporative in that condition to accept to
have a conversation with me, to read the flyers, and to participate in the study. The
written approval of the study by the study sites’ authorities solved the receptiveness and
corporation concerns. Besides, I made sure that the personal introduction or the first
contact with the potential respondent established a climate of confidence, interest, and
trust between both parties. Furthermore, I told the respondent how the study would be
useful for the dermatology patients. Moreover, I explained to the respondent the aim of
the study, the respondent selection method, and the guarantee of the confidentiality of the
collected information (Frankfort-Nachmias & Nachmias, 2008).
Management of Data Collected
The data collected had no identifier such as name, medical record number, date of
birth, social security number, account number, email address, and home address. The
same code or numerical number identified the answers to the same question. The respect
of confidentiality and respondent privacy was via the no requirement of his/her signature
on the informed consent form. The respondent signed the informed consent form by
completing the survey. I clarified that to the respondent at the beginning of the eligibility
section. Other measures to provide confidentiality of data and respect for the respondent
privacy were an anonymous analysis of the data collected and the study’s results
(Frankfort-Nachmias & Nachmias, 2008).
Furthermore, I stored for five years the data collected on his laptop hard disk,
USB drive, and CD-Rooms with the access protected by a passed word at my discretion. I
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am the only one to have access to the data. The data will be destroyed five years after the
defense and dissemination of the dissertation. In fact, the data will not be current
anymore after five years. I keep the questionnaires, USB drive, and CD-Rooms for the
same number of year in an iron locker secured with a lock and key in my office at home.
Summary and Transition
The quantitative nature of the research question led to the selection of the
quantitative design for this study. The research method was the cross-sectional survey.
The research aim was to describe the relationship between product claim, help-seeking
advertisements, and the types and purposes of medical dermatology service utilization
amongst the target population at a certain point in time. The survey population was
American residents male and female aged 18 years and over, dermatology patients living
in Houston, Texas, receiving primary care services at MedStar and/or attending to church
service at Saint Nicholas Catholic Church. The selection of this population was due to the
diversity of the communities. There was no sampling frame for this study. Consequently,
the nonprobability was the sampling strategy. The constitution of the sample was through
the nonrandom purposive sample scheme. The MedStar and Saint Nicholas Catholic
Church in Houston, Texas were the two sites of the study. The sample size was 82
individuals. G*Power 3.1.2 computer software generated this sample size. The
recruitment of the sample took place at the study sites during their visit to meet with the
primary care physician or to attend to a church service. The respondents received the
informed consent approved by the Walden University’s IRB at the site of the study. Each
participant provided informed consent face-to-face using the Informed Consent Form
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before answering to the eligibility questions. The respondent signed the informed consent
form by completing the survey completely. The pilot study enabled the test of the
reliability and validity of the study instrument before the use of the instrument for the
final study. Twelve individuals from the target population were the pilot sample. They
were excluded from the final sample of the study.
The research instrument was a structured questionnaire of 38 questions with the
Likert scale as the rating scale. The research independent variables were dermatology
product claim and help-seeking advertisements as defined by the FDA. The dependent
variables were the types and purposes of the medical dermatology services utilization
amongst the target population. The data analysis used the Statistical Package for the
Social Sciences (SPSS) software version 21.0. The two groups of analytical tools were
respectively the descriptive statistics for the data organization and the linear multiple
regression for hypotheses testing. The interpretation of the results of the hypotheses test
will be the main focus of the next Chapter 4.
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Chapter 4: Results
Introduction
The intent of this research study was to assess the relationship between
dermatology product claim, help-seeking advertisements, and types and purposes of the
use of medical dermatology service amongst adult patients in the United States. Product
claim and health-seeking advertisements were the two sets of independent variables
(FDA, 2012b, 2012d; La Barbera, 2012). The types and purposes of the medical
dermatology services utilization were the two sets of dependent variables of the study
(Aday & Anderson, 1974; Barton, 2010; Shi & Singh, 2008).
The main research question of this study was to determine if there was a
statistically significant relationship between product claim, help-seeking advertisements,
and types and purposes of medical service utilization amongst adult dermatology patients
in the United States of America. This question led to the following main hypothesis:
Hypothesis 1 (H0): Product claim and help-seeking advertisements do not
significantly prompt the utilization of the types and purposes of medical services amongst
adult dermatology patients in the United States.
Hypothesis 1 (H1): Product claim and help-seeking advertisements significantly
prompt the utilization of the types and purposes of the medical services amongst adult
dermatology patients in the United States.
In Chapter 1, I introduced this study, analyzing the study’s background, problem
statement, purpose, research question(s) and hypotheses, theoretical framework, the
nature of the study, and the operational definitions. Then, in Chapter 2, I examined the
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literature on the study variables and identified the gap as the origin of this research study.
Besides, Chapter 3 was the methodology supporting the investigation of the research
problem. Finally, Chapter 4 aims to present the results of the study. The components of
Chapter 4 are the pilot study, the data collection, the results, and the summary and
transition to Chapter 5. The pilot study results are the object of the following section.
Pilot Study
The research study instrument went through a pilot study as outlined in Chapter 3.
The aim was the final validation of the study instrument before the completion of the
main study. Indeed, as stated in Chapter 3, the research study instrument was a structured
questionnaire with 38 questions. I developed this questionnaire, and by end of the year
2013, I validated the questionnaire using the experts opinion approach presented in
Chapter 3.
The pilot study validated the version of the questionnaire approved by the
research committee. In that regard, Cronbach’s Alpha α statistics allowed me to establish
the questionnaire’s reliability after the pilot study data analysis (Al-Dmour et al., 2013;
Creswell, 2009). The reliability test method was the split-half reliability. This method,
using SPSS computer program, consisted of randomly splitting the data into two. The
Cronbach’s Alpha α test showed a computerized correlation between the two halves of
the data and demonstrated, therefore, the reliability of the questionnaire (Table 2).
Indeed, as stated in Chapter 3, all the Cronbach’s Alpha α value were between zero
through one (Al-Dmour et al., 2013; Green & Salkind, 2011), establishing the internal
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consistency or reliability of the scales and the questionnaire validity (Dedeli & Fadiloglu,
2011; Green & Salkind, 2011).
The pilot study took place from January 12 through 27, 2015 within the two
study’s sites: MedStar Primary care clinic and Saint Nicholas Catholic Church in
Houston, Texas. The pilot sample size was 12 participants, shared equitably in number
and by gender between the study sites (six from each study site with three males and
females) as outlined in Table 1.
Table 1
Summary of Pilot Respondents by Place of Questionnaire Completion and Sex (N = 12)

n

Sex
Male
Female

Place of questionnaire completion
MedStar Primary Care Clinic

6

3

3

Saint Nicholas Catholic Church

6

3

3

Total

12

6

6

The pilot study followed the study research method described in Chapter 3. The
12 pilot study respondents were not part of the main study or final sample. The first
completed and validated 12 questionnaires enabled the pilot study data analysis and
validation of the research instrument. The pilot study results were as follows.
The Pilot Study’s Results
The pilot study generated consistent results that enabled the final validation of the
study instrument. Six scales permitted me to calculate the reliability statistics for the
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validation of the instrument using the split-half reliability method. The six reliability
statistics of the six scales (detailed in Chapter 3) ranged from 0.01 to 0.68, which are
between the Cronbach's Alpha and acceptable range of zero through one (Al-Dmour et
al., 2013; Green & Salkind, 2011). Table 2 shows the reliability statistics of each scale
ranging from 0.01 to 0.68.
Table 2
Instrument’s Cronbach’s & Reliability Statistics per Scale
n

N of
Items

Cronbach's Alpha &

Cronbach's Alpha &
acceptable range

DPCAES

12

10

0.01

0-1

DHSAES

12

5

0.27

0-1

12

7

0.62

0-1

12

14

0.68

0-1

12

2

0.14

0-1

12

4

0.31

0-1

Scale

TDMTUEPDAS
TDMTUEDDAS

PUDMTEDDAS
PUDMTEDAS

Note. DPCAES = dermatology product claim advertisement exposure Scale; DHSAES = dermatology helpseeking advertisement exposure Scale; TDMTUEPDAS = types of medical dermatology treatments utilized
after exposure to dermatology DTCA of prescription drug scale; TDMTUEDDAS = types of medical
dermatology treatments utilized after exposure to the dermatology Disease DTCA Scale; PUDMTEDDAS
= purposes of the utilization of medical dermatology treatments after exposure to dermatology DTCA of
prescription drug scale; PUDMTEDAS = purposes of the utilization of medical dermatology treatment after
exposure to dermatology DTCA of disease scale.

The DPCAES, DHSAES, TDMTUEPDAS, TDMTUEDDAS, PUDMTEDDAS,
and PUDMTEDAS have a Cronbach’s Alpha value between 0 through 1. However, the
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third and fourth scales that are respectively TDMTUEPDAS and TDMTUEDDAS have the
highest Cronbach’s Alpha values of respectively 0.62 and 0.68. Consequently, those two
scales have the high reliabilities while the other four scales have the low reliabilities. In
conclusion and as stated earlier, all six Cronbach’s Alpha α values fell in the region of
zero to one indicated by Al-Dmour et al. (2013) and Green and Salkind (2011) as the
indicator of a good reliability. The pilot study results did not generate any change in the
main study in general, and particularly in the data collection.
Data Collection
Data Collection Time Frame, Recruitment, and Response Rate
The survey or questionnaire completion lasted one month and 10 days, from
January 12 through February 22, 2015. The survey covered the two study sites located in
Houston, Texas, MedStar Primary Care Clinic and Saint Nicholas Catholic Church. The
questionnaire completion took place after the respondent had met with a physician and
from Monday through Friday at MedStar Primary Care Clinic during the clinic’s business
hours from 09:00 AM to 05:30 PM (United States Central Standard Time). The
questionnaire completion at Saint Nicholas took place after church services that started at
09:00 AM or 11:00 AM on Sundays. Each survey day ended approximately until 03:00
PM at Saint Nicholas Catholic Church (United States Central Standard Time). The mean
of the total length of a questionnaire completion for both study sites was 12.03 minutes.
The recruitment strategy applied for the data collection remained the one
described in Chapter 3. Indeed, the data collection tool was a structured questionnaire
with 38 questions. The recruitment and questionnaire completion were face-to-face at
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each study site. I conducted the recruitment and recorded all the respondents’ answers in
the questionnaire to reduce the risk of bias. I selected the sample using the predetermined inclusion criteria (eligibility section of the questionnaire), two recruiting
flyers (A5 or Appendix F and A3 or Appendix D), and the Consent Form (see Appendix
C) as detailed in Chapter 3. The respondent recruitment occurred at the lobby of each
study site before the church services on Sunday at Saint Nicholas, and before the
respondent’s meeting with the primary care physician during a medical visit. The
questionnaire completion occurred at the parish hall or at the clinic meeting rooms. I
reviewed with each participant the completed questionnaire and validated the
questionnaire using the questionnaire completion guide (Appendix H) before terminating
the particular completion. There was no discrepancy noted during the data collection
compared to the strategy stated in Chapter 3.
The study’s projected response rate and the final response rate were different at
the end of data collection. In fact, the study projected response rate based on the literature
was 85%. An existing literature claimed the response rate for the face-to-face survey
turned around 95% versus 20 to 40% for the mail survey (Frankfort-Nachmias &
Nachmias, 2008). I did 335 contacts or attempts to recruit the main or final study’s
respondents at the two study sites. The 335 contacts led to the completion of 120
questionnaires which represented the final sample of this study. The ratio 120 completed
questionnaires and 335 total numbers of contact/attempt gave the study’s response rate of
35.82 %. This response rate represented 42.14 % achievement rate of the projected
response rate (85%). The discrepancy was most likely due to the respondent profile
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detailed through the pre-determined inclusion criteria of the study (See Appendix G).
Indeed, the use of the pre-determined inclusion criteria to select a final respondent for the
completion of the questionnaire limited the possibility of meeting the eligible respondent
during the first contact or recruitment attempt. The final sample has diversified
characteristics.
Sample Characteristics
The final sample has multiple characteristics. I used the G*Power 3.1.2 computer
software, as stated in Chapter 3, to determine the sample size of 82 respondents.
However, by rounding off 82, 100 people were the target final sample size. The final
sample size achieved at the end of the survey was 120 respondents. The 120 respondents
were attending church services at Saint Nicholas Catholic Church or/and receiving
primary care services at MedStar Primary Care Clinic. In addition, the respondents have
received medical dermatology services for a medical reason as the consequence of having
seen, read, or heard a dermatology DTCA of prescription drug or/and disease in the past
12 months starting from the questionnaire completion date. Three hundred and thirty-five
contacts or attempts to recruit a respondent permitted to achieve the 120 final samples.
215 out of 335 contacts were not eligible to complete a questionnaire at the time of the
survey because of one or more of the following reasons: (a) they were not dermatology
patients, (b) have poor English language skills, (c) were concerned about the reason of
their medical visit to the doctor office, (d) did not willing to participate in the study, (e)
were not MedStar’s patients, and (f) did not want to wait after the church service.
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Fifty percent of the 120 respondents were from MedStar clinic (60) and 50%
from Saint Nicholas (60). Moreover, 50% of the sample per study site were male (30) and
50% were female (30). Seventy-one percent of the 120 respondents had skin disease,
24% had hair disease, and 5% had nails disease. The largest proportion of the sample was
skin disease patients. Table 3 shows the achieved sample breakdown by place of
questionnaire completion. Table 4 shows the achieved sample breakdown by sex. Table 5
shows the achieved sample breakdown by type of dermatology diseases.
Table 3
Frequency Distribution of Participant Place of Questionnaire Completion (N = 120)
Place of questionnaire
completion
Valid MedStar Primary Care Clinic

50

Valid
%
50

Cumulative
%
50

60

50

50

100

120

100

100

Frequency

%

60

Saint Nicholas Catholic
Church
Total

Table 4
Frequency Distribution of Participant Sex (N = 120)
Sex
Valid

50

Valid
%
50

Cumulative
%
50

60

50

50

100

120

100

100

Frequency

%

Male

60

Female
Total
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Table 5
Frequency Distribution of Participant Types of Dermatology Disease (N = 120)

Valid

Type of dermatology
disease
Skin disease

71

Valid
%
71

Cumulative
%
71

29

24

24

95

5

5

5

100

120

100

100

Frequency

%

86

Hair disease
Nails disease
Total

The sample of 120 respondents had 50% male and 50% female. The sample is
mostly adults with 44.2% who were 35 to 51 years old while 8.3% were 65 years old and
over. The sample’s mean age was 42 years old with a S D of 13.63. The sample had a
multiracial or ethnic characteristic with the largest portion of 72.5% Black, African
American, or Negro, 14.2% Hispanic, 11.7% white, and the smallest portion of 1.7%
Vietnamese. In terms of highest level of education completed, 25.8% had graduate
degrees while 0.8% completed Less than 9th grade. Sixty percent had an annual
household income of $40, 000 and over, and 0.8% had between $15,000 to $19,999.
Finally, 57.5% of the samples were married and 3.3% separated. Table 6 shows the
descriptive statistics for demographics of the study sample.
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Table 6
Descriptive Statistics for Demographics (N = 120)
Demographics

Frequency
(Valid %)

Mean
score

Standard
deviation

Sex
Male ( = 1)

60 (50%)

Female ( = 2)

60 (50%)

Age
18 to 34 years ( = 1)

31 (25.8%)

35 to 51 years (= 2)

53 (44.2%)

52 to 64 years (= 3)

26 (21.7%)

65 and over (= 4)
Exact age

10 (8.3 %)
42

Race/Ethnicity
White ( = 1)

14 (11.7%)

Black, African American, or Negro ( = 2)

87 (72.5%)

Vietnamese ( = 13)

2 (1.7%)

Some other race: Hispanic ( = 14)

17 (14.2%)

Highest grade of school completed
Less than 9th grade ( = 1)

1 (.8%)

9th to 12th grade, without diploma ( = 2)

6 (5%)

High school graduate ( = 3)

11 (9.2%)

Some college, without degree ( = 4)

25 (20.8%)

Associate’s degree ( = 5)

19 (15.8 %)

Bachelor’s degree ( = 6)

27 (22.5%)

Graduate degree ( = 7)

31 (25.8 %)

Marital status
Married ( = 1)

69 (57.5%)

Divorced ( = 2)

7 (5.8%)

Widowed ( = 3)

8(6.7%)

Separated ( = 4)
Never got married ( = 5)
Unmarried in couple ( = 6)

4 (3.3%)
27 (22.5%)
5 (4.2 %)
(table continues)

13.63
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Demographics

Frequency
(Valid %)

Mean
score

Standard
deviation

Annual household income
Less than $10,000 ( = 1)

3 (2.5 %)

$10,000 to $14,999 ( = 2)

4 (3.3%)

$15,000 to $19,999 ( = 3)

1 (.8 %)

$20,000 to $24,999 ( = 4)

7 (5.8%)

$25,000 to $29,999 ( = 5)

12 (10 %)

$30,000 to $34,999 ( = 6)

10 (8%)

$35,000 to $39,999 ( = 7)

11 (9.2%)

$40, 000 and over ( = 8)

72 (60%)

In terms of sources of exposure to dermatology pharmaceutical prescription
drug(s) announcement, TV channels were the main source (85% of the respondents)
followed by online/websites (56.7%). Then, very few patients heard about drug
announcement from dermatologists giving the lowest percentage of 1.7%. These results
were consistent with dermatology pharmaceutical disease(s) announcement exposure:
90.8% for TV channels, 62.5% for online/websites, and 2.5% as lowest percentage for
both dermatologists and social media.
Sample and Population
The target population size was unknown and a sample frame was not available.
Therefore, the use of a random sample or a proportional sample approach was not
appropriate. In that regards, I used the nonrandom purposive sample scheme to select
from the population the members of the sample based on the pre-determined inclusion
criteria (eligibility section of the questionnaire or Appendix G) as described in Chapter 3.
The selected respondents were available and willing to participate in the study (Collins et
al., 2006; Frankfort-Nachmias & Nachmias, 2008). The predetermined inclusion criteria
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aimed to assure the selection of the individuals who had the key characteristics of the
target population only. In addition, the G*Power 3.1.2 computer software enabled the
determination of this study minimum sample size of 82 respondents capable to provide
with consistent statistical tests or analyses. Furthermore, according to Laureate Education
(2009b) and Andy (2009), a high sample size increases the chance of obtaining an
accurate multiple regression equation. A multiple regression requires a minimum sample
size N of 104 plus M. M represents the number of predictors of the regression (Laureate
Education, 2009b). This study has two sets of predictors for a total of 15 predictors:
dermatology product claim advertisement exposure scale (DPCAES) with 10 predictors
or items, and dermatology help-seeking advertisement exposure scale (DHSAES) with 5
predictors. The final sample achieved of 120 participants met the Laureate Education’s
multiple regression sample size requirement of 104 plus M (Laureate Education, 2009b).
Results
Outliers
The normal box plots of the normality of error variances distribution assumption
(Figures 12 to 20) in the assumptions section below show only suspected outliers (small
empty circles or unfilled). Consequently, this study was free of outliers for the considered
nine criteria (Field, 2009).
Assumptions Evaluation
Multiple Regression has assumptions that require a test before any hypothesis
testing takes place. The testable assumptions listed in Chapter 3 were (a) the normality of
the distribution, (b) normality of error variances distribution, (c) independence of errors,
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(d) homoscedasticity, and (e) no perfect multicollinearity (Field, 2009). The assumption,
when met, ensures the external validity of the research findings, regression model, and a
regression model free of bias. The assumptions test is based on the dependent variables or
criteria of the study.
Selection of the criteria or dependent variables. They were four sets of
dependent variables for a total of 29 criteria for this research study. The predictors were
quantitative and the criteria or outcome variable were quantitative, continuous, and
unbounded (Field, 2009). The first set was TDMTUEPDAS which had seven items. The
second containing 14 items was TDMTUEDDAS. The third was PUDMTEDDAS and
had four items. The fourth was PUDMTEDAS which had four items. A multiple
regression test run between each set of independent variables and each particular
dependent variable showed some nonsignificant test results statistically at 95%
confidence level and 5% margin of error from the model summary tables. Consequently,
the dependent variables retained and used for the assumptions and hypotheses tests were
those with a test result statistically significant (p ≤ .05). The dependent variable retained
from TDMTUEPDAS set were (a) to request and obtain a medical prescription of the
dermatology drug advertised, (b) to receive the advertised drug therapy/chemotherapy,
(c) to talk to the dermatologist/surgeon/doctor about dermatology advertised prescription
drug, (d) to visit a physician/dermatologist office, and (e) to receive skin, hair, and/or
nails health maintenance treatment. Then, the only one from TDMTUEDDAS set was to
go for dermatology disease screening test. PUDMTEDDAS set had to receive
treatment/cure of the dermatology disease in order to excise the tumor lesion. Finally,
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PUDMTEDAS set had (a) to receive dermatology treatment/service to detect/diagnose
early the dermatology disease and (b) to receive treatment/cure of the dermatology
disease in order to clear the tumor/disease. Nine out of 29 criteria are the object of the
following assumptions evaluation.
Normality of the distribution assumption. The result of the normality test run
for the criteria (a) to request and obtain a medical prescription of the dermatology drug
advertised, (b) to receive the advertised drug therapy/chemotherapy, (c) to talk to the
dermatologist/surgeon/doctor about dermatology advertised prescription drug, (d) to visit
a physician/dermatologist office, (e) to receive skin, hair, and/or nails health maintenance
treatment, (f) to go for dermatology disease screening test, (g) to receive treatment/cure
of the dermatology disease in order to excise the tumor lesion, (h) to receive dermatology
treatment/service to detect/diagnose early the dermatology disease, and (i) to receive
treatment/cure of the dermatology disease in order to clear the tumor/disease in SPSS
showed that this assumption was met.
The histograms below show bell shaped curves that indicate the normality of
distribution of each of the criterion listed above: Figure 3 for the criterion (a), Figure 4
for the criterion (b), Figure 5 for the criterion (c), Figure 6 for the criterion (d), Figure 7
for the criterion (e), Figure 8 for the criterion (f), Figure 9 for the criterion (g), Figure 10
for the criterion (h), and Figure 11 for the criterion (i) (Field, 2009; Laureate Education,
2009a).
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Figure 3. Bell shaped curve of the criterion to request and obtain a medical prescription
of the dermatology drug advertised

Figure 4. Bell shaped curve f of the criterion to receive the advertised drug
therapy/chemotherapy
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Figure 5. Bell shaped curve f of the criterion to talk to the dermatologist/surgeon/doctor
about a dermatology advertised prescription drug

Figure 6. Bell shaped curve of the criterion to visit a physician/dermatologist office
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Figure 7. Bell shaped curve of the criterion to receive skin, hair, and/or nails health
maintenance treatment

Figure 8. Bell shaped curve of the criterion to receive treatment/cure of the dermatology
disease in order to excise the tumor lesion
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Figure 9. Bell shaped curve of the criterion to go for dermatology disease screening test

Figure 10. Bell shaped curve of the criterion to dermatology treatment/service to
detect/diagnose early the dermatology disease
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Figure 11. Bell shaped curve of the criterion to receive treatment/cure of the dermatology
disease in order to clear the tumor/disease
Normality of error variances distribution. Multiple regression is convenient for
large sample. The appearance of each box plot of the standardized residual below
(Figures 12 to 20) permitted to observe how the error variances was normally distributed
for each of the nine criteria (Field, 2009).

Figure 12.Normal box plot of the criterion to request and obtain a medical prescription of
the dermatology drug advertised
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Figure 13. Normal box plot of the criterion to receive the advertised drug
therapy/chemotherapy

Figure 14. Normal box plot of the criterion to talk to the dermatologist/surgeon/doctor
about dermatology advertised prescription drug
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Figure 15. Normal box plot of the criterion to visit a physician/dermatologist office

Figure 16. Normal box plot of the criterion to receive skin, hair, and/or nails health
maintenance treatment
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Figure 17. Normal box Plot of the criterion to go for dermatology disease screening test

Figure 18. Normal box plot of the criterion to receive treatment/cure of the dermatology
disease in order to excise the tumor/lesion
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Figure 19. Normal box plot of the criterion to receive dermatology treatment/service to
detect/diagnose early the dermatology disease

Figure 20. Normal box plot of the criterion to receive treatment/cure of the dermatology
disease in order to clear the tumor/disease
Independence of errors and homoscedasticity. The evaluation of these two
assumptions for the nine criteria is through the scatterplots observation. The normal p-p
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plots show no variation in the variance of the residual terms regarding the predictors. The
no variation indicates that the homoscedasticity assumption is met (Field, 2009; Green &
Salkind, 2011). Moreover, the scatterplots show no correlation of residual terms for the
observations. Consequently, the independent of error assumption is met (Field, 2009;
Green & Salkind, 2011). The normal p-p plots for the two assumptions and each criterion
are in Figure 21 for the criterion (a), Figure 22 for the criterion (b), Figure 23 for the
criterion (c), Figure 24 for the criterion (d), Figure 25 for the criterion (e), Figure 26 for
the criterion (f), Figure 27 for the criterion (g), Figure 28 for the criterion (h), and Figure
29 for the criterion (i) (Field, 2009; Green & Salkind, 2011).

Figure 21. Normal p-p plots of regression of the criterion to request and obtain a medical
prescription of the dermatology drug advertised
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Figure 22. Normal p-p plots of regression of the criterion to receive the advertised drug
therapy/chemotherapy

Figure 23. Normal p-p plots of regression of the criterion to talk to the
dermatologist/surgeon/doctor about dermatology advertised prescription drug
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Figure 24. Normal p-p plots of regression of the criterion to visit a
physician/dermatologist office

Figure 25. Normal p-p plots of regression of the criterion to receive skin, hair, and/or
nails health maintenance treatment
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Figure 26. Normal p-p plots of regression of the criterion to go for dermatology disease
screening test

Figure 27. Normal p-p plots of regression of the criterion to receive treatment/cure of the
dermatology disease to excise the tumor/lesion
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Figure 28. Normal p-p plots of regression of the criterion to receive dermatology
treatment/service to detect/diagnose early the dermatology disease

Figure 29. Normal p-p plots of regression of the criterion to receive treatment/cure of the
dermatology disease to clear the tumor/disease
No perfect multicollinearity. The variance inflection factors (VIF) permitted to
assess the multicollinearity amongst predictors in relation with each of the nine
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dependent variables. All the VIF values shown in Table 7 are below 10. A value of 10 or
greater indicates the perfect multicollinearity amongst predictors (Field, 2009). This
assumption was met.
Table 7
Predictors’ Variance Inflection Factors (VIF) for Each Criterion
Criterion

VIF

told to the consumers in a balanced manner the benefits and potential
negative consequences of using the advertised dermatology drug.

2.44

told in a balanced manner about the advantages and dangers
related to the advertised dermatology drug use.

2.56

published in the newspaper, magazines, review, or
the journal contained this statement "you are encouraged to
report negative side effects of prescription drugs to the
US Food and Drugs Administration (FDA) Visit
wmedwatch5 or call 1-800-FDA-1088."
passed on television/radio station (s) told to the
viewer/listener where to get additional prescription drug
information approved by the FDA

1.14

1.22

audio broadcast stated the most serious risks/dangers that the
dermatology drug user may encounter.

1.29

said the drug risk(s)/danger(s) approved by F.D.A and
included in the drug information or label.

2.03

Stated the most important dangers that the dermatology patient
may face taking the advertised drug.

1.9

stated both the vulgar designation/name of the drug approved
(brand) and non-approved (generic) by the U.S. government.

1.61

stated at least one form of dermatology disease treated by
the advertised drug and approved by the FDA

1.4

stated "ask your doctor if [drug name] is right for you.''

1.12

described the type of dermatology disease without any recommendation of a specific
dermatology drug for treatment.
encouraged people with the symptoms of the described type of dermatology disease to
ask/talk to their doctor
(table continues)

1.22
1.19
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Criterion

VIF

had the company's name of the advertised skin cancer drug.

1.37

gave a telephone number/website to call or to visit for more information about the
advertised dermatology disease type/described condition.

1.35

stated "ask your healthcare provider for more information''.

1.06

Hypotheses Testing
Research Question 1: Is product claim advertisement a predictor of the types of
medical services utilized amongst adult dermatology patients in the United States?
Hypothesis 1 (H0): Product claim advertisement does not significantly prompt the
utilization of the types of medical services amongst adult dermatology patients in the
United States.
Hypothesis 1 (H1): Product claim advertisement significantly prompts the
utilization of the types of the medical services amongst adult dermatology patients in the
United States.
Analytical Strategy for the Hypothesis Testing 1. The first hypothesis testing
was product claim advertisement predicting or not the utilization of the types of medical
dermatology services amongst the target population. Question 27 was the set of
predictors, and question 32(5) was the unique criterion used to test the hypotheses and to
answer the related research question. Indeed, question 27 served as the set of predictors
for the forced entries multiple regression test with each of the seven criteria or question
32’s items (set of criteria or measures). Amongst the seven multiple regression tests per
criterion, only five models had the statistically significant P values with 95% confidence
interval (P < .05) from the model summary output tables: (a) question 32(1), P = .000 and
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R = .496, (b) question 32(2), P = .003 and R = .456, (c) question 32(5), P = 0.000 and R =
.512, (d) question 32(6), P = .036 and R = .397, (e) question 32(7), P = .042 and R =
.392. The five models had different multiple correlation coefficients R. Question 32(5)
had the highest multiple correlation coefficient R = .512 amongst the five significant
criteria. Thus, question 32(5) helped to answer this research question.
Answer to Research Question 1. The following multiple regression results
(Table 8) show that product claim advertisement significantly predicts the utilization of
the type of the medical services amongst adult dermatology patients. Indeed, a forced
entry multiple regression analysis was conducted to evaluate how well product claim
advertisement predicted the type of medical dermatology service utilized. The set of
predictors was product claim advertisement with 10 measures or items that were (a) told
to the consumers in a balanced manner the benefits and potential negative consequences
of using the advertised dermatology drug, (b) to told in a balanced manner about the
advantages and dangers related to the advertised dermatology drug use, (c) published in
the newspaper, magazines, review, or journal contained this statement "You are
encouraged to report negative side effects of prescription drug to the U.S. Food and Drug
Administration (FDA) Visit MedWatch5 or call 1-800-FDA-1088", (d) passed on
television/radio station (s) told to the viewer/listener where to get additional prescription
drug information approved by the FDA, (e) audio broadcast stated the most serious
risks/dangers that the dermatology drug user may encounter, (f) said the drug
risk(s)/danger(s) approved by FDA and included in the drug information or label, (g)
stated the most important dangers that the dermatology patient may face taking the
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advertised drug, (h) stated both the vulgar designation/name of the drug approved (brand)
and non-approved (generic) by the U.S. government,(i) stated at least one form of
dermatology disease treated by the advertised drug and approved by the FDA, (j) stated
"Ask your doctor if [drug name] is right for you.'', while the criterion variable was to talk
to the dermatologist/surgeon/doctor about dermatology advertised prescription drug
index. The linear combination of the product claim measures was significantly related to
talk to the dermatologist/surgeon/doctor about dermatology advertised prescription drug,
F (10,109) = 3.87, p < .05. The sample multiple correlation coefficient R was .51,
indicating that approximately 26% of the variance of to talk to the
dermatologist/surgeon/doctor about dermatology advertised prescription drug in the
sample can be accounted for by the linear combination of the set of the predictors product
claim advertisement measures, R2 = .262. The loss of predicted power or shrinkage of
6.7% has been verified with the Adjusted R2 = .195. Consequently, a model from the
population would account for approximately 6.7% less variance by the criterion. Table 8
shows the multiple regression model summary or results.
Table 9 shows the indices of the relative strength of each particular predictor in
relation with the criterion to talk to the dermatologist/surgeon/doctor about a dermatology
advertised prescription drug. Only one out of 10 bivariate correlations between the set of
predictors product claim strength measures and talk to the dermatologist/surgeon/doctor
about a dermatology advertised prescription drug index was negative, and one out of 10
were statistically significant (P < .05). Four out 10 partial correlations between the
product claim strength measures and to talk to the dermatologist/surgeon/doctor about a
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dermatology advertised prescription drug index were significant. Out of the four, only the
partial correlation between the strength measure of stated "Ask your doctor if [drug
name] is right for you'' predictor and to talk to the dermatologist/surgeon/doctor about a
dermatology advertised prescription drug index was positive, p = 0.00. These correlation
analyses may lead to the conclusion that stated "Ask your doctor if [drug name] is right
for you'' is the only useful predictor. However, it alone accounted for only 0.20% of the
variance of to talk to the dermatologist/surgeon/doctor about a dermatology advertised
prescription drug index, while the other variables contributed an additional 25.8% (26% 0.20% = 25.8%). Moreover, predictors were correlated. However, the correlation was not
a source of concern for the multiple regression model giving that all the VIF statistics
were lower than 10.
Table 8
Multiple Regression Model Summaryb

Model

1

R

.512a

R
square

0.262

Adjusted
R square

0.195

Std.
error of
the
estimate

0.844

DurbinWatson

Change statistics

R
Square
change

F
change

df1

df2

Sig. F change

0.262

3.875

10

109

0.000

1.925

Note. a. Predictors: (Constant), DPCAES: "Stated at least one form of dermatology disease treated by the advertised
drug and approved by the FDA ", DPCAES: "Told in a balanced manner about the advantages and dangers related to
the advertised dermatology drug use. ", DPCAES: "Passed on Television/Radio station (s) told to the viewer/listener
where to get additional prescription drug information approved by the FDA ", DPCAES: "Published in the newspaper,
magazines, review, or journal contained this statement " "You are encouraged to report negative side effects of
prescription drug to the US Food and Drug Administration (FDA) Visit MedWatch5 or call 1-800-FDA-1088,
DPCAES: Stated "Ask your doctor if [drug name] is right for you.'', DPCAES: "Stated the most important dangers that
the dermatology patient may face taking the advertised drug. ", DPCAES: "Audio broadcast stated the most serious
risks/dangers that the dermatology drug user may encounter.", DPCAES: "Stated both the vulgar designation/name of
the drug approved (brand) and non-approved (generic) by the U.S. government.", DPCAES: "Said the drug
risk(s)/danger(s) approved by FDA and included in the drug information or label).", DPCAES: "Told to the consumers
in a balanced manner the benefits and potential negative consequences of using the advertised dermatology drug."
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b. Dependent Variable: TDMTUEPDAS: Talk to the dermatologist/surgeon/doctor about dermatology advertised
prescription drug.

Table 9
Bivariate and Partial Correlations between each Predictor and Talk to the
Dermatologist/Surgeon/Doctor About a Dermatology Advertised Prescription Drug Index
Correlation
between
each
predictor
and the
criterion

Correlation
between each
predictor and
the criterion
controlling for
all other
predictors

stated "ask your doctor if [drug name] is right for you.''

0.04*

0.00*

told to the consumers in a balanced manner the benefits and potential
negative consequences of using the advertised dermatology drug

0.06

0.18

told in a balanced manner about the advantages and dangers related to
the advertised dermatology drug use

-0.10

-0.24*

0.20

0.19

passed on Television/Radio station (s) told to the viewer/listener where
to get additional prescription drug information approved by the FDA

0.14

0.15

audio broadcast stated the most serious risks/dangers that the
dermatology drug user may encounter

0.24

said the drug risk(s)/danger(s) approved by the FDA and included in
the drug information or label

0.20

-0.01*

0.40

0.28

Predictors

published in the newspaper, magazines, review, or journal contained
this statement "You are encouraged to report negative side effects of
prescription drug to the US Food and Drug Administration (FDA) Visit
MedWatch5 or call 1-800-FDA-1088

stated the most important dangers that the dermatology patient may
face taking the advertised drug
stated both the vulgar designation/name of the drug approved (brand)
and non-approved (generic) by the U.S. government
stated at least one form of dermatology disease treated by the
advertised drug and approved by the FDA
Note. * P < .05. Confidence interval 95%.

0.07

0.17

-0.01*

0.21

0.06
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Research Question 2: Is product claim advertisement a predictor of the purposes
of medical services utilization amongst adult dermatology patients in the United States?
Hypothesis 2 (H0): Product claim advertisement does not significantly prompt the
purposes of medical services utilization amongst adult dermatology patients in the United
States.
Hypothesis 2 (H1): Product claim advertisement significantly prompts the
purposes of the medical services utilization amongst adult dermatology patients in the
United States.
Analytical Strategy for the Hypothesis Testing 2. The second hypothesis
testing was product claim advertisement predicting or not the purpose of the medical
dermatology services utilization amongst the target population. Question 27 was the set
of predictors, and question 36(4) was the unique criterion used to test the hypotheses and
to answer the related research question. Indeed, question 27 served as set of predictors for
the forced entry multiple regression tests in relation with each of the four criteria or
question 36’s items (set of criteria or measures). Amongst the four multiple regression
tests per criterion, only one model had the statistically significant P values (P ≤ .05) from
the four model summary output tables: question 36(4), P = .05 and R = .386.
Consequently, question 36(4) helped to answer this research question.
Answer to Research Question 2. The following forced entry multiple regression
results (Table 10) show that product claim advertisement significantly predicts the
purpose of the utilization of the medical service amongst adult dermatology patients. In
that regard, a forced entry multiple regression analysis was conducted to evaluate how
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well product claim advertisement predicted the purpose of the medical dermatology
service utilized. The set of predictors was product claim advertisement with 10 measures
or items. The measures were (a) told to the consumers in a balanced manner the benefits
and potential negative consequences of using the advertised dermatology drug, (b) to told
in a balanced manner about the advantages and dangers related to the advertised
dermatology drug use, (c) published in the newspaper, magazines, review, or journal
contained this statement "You are encouraged to report negative side effects of
prescription drug to the U.S. Food and Drug Administration (FDA) Visit MedWatch5 or
call 1-800-FDA-1088", (d) passed on television/radio station (s) told to the
viewer/listener where to get additional prescription drug information approved by the
FDA, (e) audio broadcast stated the most serious risks/dangers that the dermatology drug
user may encounter, (f) said the drug risk(s)/danger(s) approved by the FDA and
included in the drug information or label, (g) stated the most important dangers that the
dermatology patient may face taking the advertised drug, (h) stated both the vulgar
designation/name of the drug approved (brand) and non-approved (generic) by the U.S.
government,(i) stated at least one form of dermatology disease treated by the advertised
drug and approved by the FDA, (j) stated "Ask your doctor if [drug name] is right for
you.'', while the criterion variable was to receive treatment/cure of the dermatology
disease in order to excise the tumor/lesion.
The linear combination of the product claim measures was significantly related to
receive treatment/cure of the dermatology disease to excise the tumor/lesion index,
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F (10,109) = 1.91, P ≤ .05. The sample multiple correlation coefficient R was .40,
indicating that approximately 15% of the variance of to receive treatment/cure of the
dermatology disease to excise the tumor lesion index in the sample can be accounted for
by the linear combination of the set of the predictors product claim advertisement
measures, R2 = .149. The loss of predicted power or shrinkage of 7.8% has been verified
with the Adjusted R2 = .071. Consequently, a model from the population would account
for approximately 7.8% less variance by the criterion. Table 10 shows the multiple
regression model summary or results.
Table 11 shows the indices of the relative strength of each particular predictor in
relation with the criterion to receive treatment/cure of the dermatology disease in order to
excise the tumor/lesion. Height out of 10 bivariate correlations between the set of
predictors product claim strength measures and receive treatment/cure of the dermatology
disease in order to excise the tumor/lesion index were negative, and seven out of 10 were
statistically significant (P < .05). Seven out 10 partial correlations between the set of
predictors product claim strength measures and to receive treatment/cure of the
dermatology disease in order to excise the tumor/lesion index were statistically
significant (P < .05). The partial correlations between the predictors strength measures
(a) told in a balanced manner about the advantages and dangers related to the advertised
dermatology drug use, P = 0.12, (b) published in the newspaper, magazines, review, or
journal contained this statement "You are encouraged to report negative side effects of
prescription drug to the U.S. Food and Drug Administration (FDA). Visit MedWatch5 or
call 1-800-FDA-1088, P = 0.20, (c) stated the most important dangers that the

178
dermatology patient may face taking the advertised drug, P = 0.07, and (d) receive
treatment/cure of the dermatology disease to excise the tumor/lesion index were not
statistically significant, P > .05.
These correlation analyses may lead to the conclusion that the three predictors
strength measures with nonsignificant partial correlations with to receive treatment/cure
of the dermatology disease to excise the tumor/lesion index were relatively not important.
However, this judgment required caution because predictors were correlated. However,
the correlation was not sources of concern for the multiple regression model giving that
all the VIF statistics were lower than 10.
Table 10
Multiple Regression Model Summaryb

Model

1

R

.386a

R
square

.149

Adjusted
R square

.071

Std.
error of
the
estimate

.844

DurbinWatson

Change statistics
R
square
change

F
change

df1

df2

Sig. F
change

.149

1.910

10

109

0.051

1.348

Note. a. Predictors: (Constant), DPCAES: "Stated at least one form of dermatology disease treated by the
advertised drug and approved by the FDA", DPCAES: "Told in a balanced manner about the advantages
and dangers related to the advertised dermatology drug use.", DPCAES: "Passed on Television/Radio
station (s) told to the viewer/listener where to get additional prescription drug information approved by the
FDA", DPCAES: "Published in the newspaper, magazines, review, or journal contained this statement "
"You are encouraged to report negative side effects of prescription drug to the U.S. Food and Drug
Administration (FDA) Visit MedWatch5 or call 1-800-FDA-1088, DPCAES: Stated "Ask your doctor if
[drug name] is right for you.'', DPCAES: "Stated the most important dangers that the dermatology patient
may face taking the advertised drug. ", DPCAES: "Audio broadcast stated the most serious risks/dangers
that the dermatology drug user may encounter." , DPCAES: "Stated both the vulgar designation/name of
the drug approved (brand) and non-approved (generic) by the U.S. government.", DPCAES: "Said the drug
risk(s)/danger(s) approved by FDA and included in the drug information or label).", DPCAES: "Told to the
consumers in a balanced manner the benefits and potential negative consequences of using the advertised
dermatology drug."
b. Dependent Variable: PUDMTEDDAS: Receive treatment/cure of the dermatology disease in order to
excise the tumor lesion.
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Table 11
Bivariate and Partial Correlations Between Each Predictor and to Receive Treatment/Cure of the
Dermatology Disease in Order to Excise the Tumor Lesion Index

Predictors

Correlation between
each predictor and the
criterion

Correlation
between each
predictor and
the criterion
controlling for
all other
predictors

stated "Ask your doctor if [drug name] is right for you.''

-0.04*

-0.03*

told to the consumers in a balanced manner the benefits and potential
negative consequences of using the advertised dermatology drug

-0.25*

-0.25*

told in a balanced manner about the advantages and dangers related to the
advertised dermatology drug use

-0.08*

0.12

0.23

0.20

passed on Television/Radio station (s) told to the viewer/listener
where to get additional prescription drug information approved by the
FDA

-0.12

-0.02*

audio broadcast stated the most serious risks/dangers that
the dermatology drug user may encounter

-0.12

-0.06*

said the drug risk(s)/danger(s) approved by the FDA and
included in the drug information or label

-0.07*

-0.08*

stated the most important dangers that the dermatology patient
may face taking the advertised drug

0.04*

0.07

published in the newspaper, magazines, review, or journal contained
this statement "You are encouraged to report negative side effects
of prescription drug to the US Food and Drug Administration (FDA) Visit
MedWatch5 or call 1-800-FDA-1088

stated both the vulgar designation/name of the drug
approved (brand) and non-approved (generic) by the U.S. government
stated at least one form of dermatology disease treated
by the advertised drug and approved by the FDA
Note. * p < .05. Confidence interval 95%.

-0.01*

0.04*

-0.04*

-0.04*

180
Research Question 3: Is help-seeking advertisement a predictor of the types of
medical services utilized amongst adult dermatology patients in the United States?
Hypothesis 3 (H0): Help-seeking advertisement does not significantly prompt the
types of medical services utilized amongst adult dermatology patients in the United
States.
Hypothesis 3 (H1): Help-seeking advertisement significantly prompts the types of
the medical services utilized amongst adult dermatology patients in the United States.
Analytical Strategy for the Hypothesis Testing 3. The third hypothesis testing
was about help-seeking advertisement predicting or not the type of the medical
dermatology services utilized amongst the target population. Question 30 was the set of
predictors and question 34(2) was the unique criterion used to test the hypotheses and to
answer the related research question. Indeed, question 30 served as the set of predictors
for the forced entry multiple regression tests in relation with each of the fourteen criteria
or question 34’s items (set of criteria or measures). Amongst the fourteen multiple
regression tests per criterion, only one model had the statistically significant P values (P
< .05) from the fourteen model summary output tables: question 34(2), P = .04 and R =
.303. Consequently, question 34(2) helped to answer this research question.
Answer to Research Question 3. The following forced entry multiple regression
results (Table 12) show that help-seeking advertisement significantly predicts the type of
medical services utilized amongst adult dermatology patients. In that regard, a forced
entry multiple regression analysis was conducted to evaluate how well help-seeking
advertisement predicted the type of the medical dermatology service utilized. The set of
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predictors was help-seeking advertisement with five measures. The items were (a)
described the type of dermatology disease without any recommendation of a specific
dermatology drug for treatment, (b) encouraged people with the symptoms of the
described type of dermatology disease to ask/talk to their doctor, (c) had the company's
name of the advertised dermatology drug, (d) gave a telephone number/website to call or
to visit for more information about the advertised dermatology disease type/described
condition, (e) stated "Ask your healthcare provider for more information'', while the
criterion variable was to go for dermatology disease screening test index. The linear
combination of the help-seeking measures was significantly related to go for dermatology
disease screening test index, F (5,114) = 2.31, p < .05. The sample multiple correlation
coefficient R was .30, indicating that approximately 9.2% of the variance of to go for
dermatology disease screening test index in the sample can be accounted for by the linear
combination of the set of the predictors help-seeking advertisement measures, R2 = .092.
The loss of predicted power or shrinkage of 4% has been verified with the Adjusted R2 =
.05. Consequently, a model from the population would account for approximately 4%
less variance by the criterion. Table 12 shows the multiple regression model summary or
results.
Table 13 shows the indices of the relative strength of each particular predictor in
relation with the criterion to go for dermatology disease screening test index. Only one
out of five bivariate correlations between the set of predictors help-seeking strength
measures and to go for dermatology disease screening test index was negative, and the
same one out of five was statistically significant (P < .05). None of the five partial
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correlations between the set of predictors help-seeking strength measures and to go for
dermatology disease screening test index was statistically significant (P > .05).
These correlation analyses may lead to the conclusion that the five predictors’ strength
measures having nonsignificant partial correlations with to go for dermatology disease
screening test index were relatively not important. However, this judgment required
caution because predictors were correlated. However, the correlation was not a source of
concern for the multiple regression model giving that all the VIF statistics were lower
than 10.
Table 12
Multiple Regression Model Summaryb

Model

1

R

.303a

R
square

.092

Adjusted
R square

.052

Std.
error of
the
estimate

.725

DurbinWatson

Change statistics

R
Square
change

F
change

df1

df2

Sig. F change

.092

2.312

5

114

0.048

1.985

Note. a. Predictors: (Constant), DHSAES: Stated "Ask your healthcare provider for more
information''. , DHSAES: Encouraged people with the symptoms of the described type of
dermatology disease to ask/talk to their doctor, DHSAES: Had the company's name of the
advertised skin cancer drug., DHSAES: Described the type of dermatology disease without any
recommendation of a specific dermatology drug for treatment., DHSAES: Gave a telephone
number/website to call or to visit for more information about the advertised dermatology disease
type/described condition.
b. Dependent Variable: TDMTUEDDAS: Go for dermatology disease screening test.
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Table 13
Bivariate and Partial Correlations Between Each Predictor and to Go for Dermatology Disease
Screening Test Index

Predictors

Correlation between each
predictor and the criterion

described the type of dermatology disease without any recommendation of a
specific dermatology drug for treatment.

Correlation
between each
predictor and the
criterion
controlling for all
other predictors

0.15

0.11

-0.02*

-0.08

0.09

0.45

gave a telephone number/website to call or to visit for more information
about the advertised dermatology disease type/described condition.

0.12

0.09

stated "Ask your healthcare provider for more information''.

0.25

0.23

encouraged people with the symptoms of the described type of
dermatology disease to ask/talk to their doctor
had the company's name of the advertised dermatology drug.

Note. * P < .05. Confidence interval 95%.
Research Question 4: Is help-seeking advertisement a predictor of the purposes of
medical services utilization amongst adult dermatology patients in the United States?
Hypothesis 4 (H0): Help-seeking advertisement does not significantly prompt the
purposes of medical services utilization amongst adult dermatology patients in the United
States.
Hypothesis 4 (H1): Help-seeking advertisement significantly determines the
purposes of the medical services utilization amongst adult dermatology patients in the
United States.
Analytical Strategy for the Hypothesis Testing 4. The fourth and last
hypothesis testing was about help-seeking advertisement predicting or not the purpose of
the medical dermatology services utilized amongst the target population. Question 30 was
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the set of predictors and question 38(3) was the unique criterion used to test the
hypotheses and to answer the related research question. Indeed, question 30 served as the
set of predictors for the forced entry multiple regression tests in relation with each of the
four criteria or question 38’s items (set of criteria or measures). Amongst the four
multiple regression tests per criterion, only two models had the statistically significant P
values (P < .05) from the model summary output tables: (a) question 38(1), P = .01 and R
= .347, (b) question 38(3), P = .003 and R = .381. The two models had different multiple
correlation coefficients R. Question 38(3) had the highest multiple correlation coefficient
R = .381. Question 38(3) helped to answer this research question for that reason.
Answer to Research Question 4. The following forced entry multiple regression
results (Table 14) show that help-seeking advertisement significantly predicts the purpose
of medical service utilized amongst adult dermatology patients. In that regard, a forced
entry multiple regression analysis was conducted to evaluate how well help-seeking
advertisement predicted the purpose of the medical dermatology service utilized. The set
of predictors was help-seeking advertisement with five measures or items. The items
were (a) described the type of dermatology disease without any recommendation of a
specific dermatology drug for treatment, (b) encouraged people with the symptoms of the
described type of dermatology disease to ask/talk to their doctor, (c) had the company's
name of the advertised dermatology drug, (d) gave a telephone number/website to call or
to visit for more information about the advertised dermatology disease type/described
condition, (e) stated "Ask your healthcare provider for more information'', while the
criterion variable was to receive treatment/cure of the dermatology disease in order to
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clear the tumor/disease index. The linear combination of the help-seeking measures was
significantly related to receive treatment/cure of the dermatology disease in order to clear
the tumor/disease index, F (5,114) = 3.87, p < .05. The sample multiple correlation
coefficient R was 4, indicating that approximately 14.5% of the variance of to receive
treatment/cure of the dermatology disease in order to clear the tumor/disease index in the
sample can be accounted for by the linear combination of the set of the predictors helpseeking advertisement measures, R2 = .145. The loss of predicted power or shrinkage of
3.7% has been verified with the Adjusted R2 = .108. Consequently, a model from the
population would account for approximately 3.7% less variance by the criterion. Table 14
shows the multiple regression model summary or results.
Table 15 shows the indices of the relative strength of each particular predictor in
relation with the criterion to receive treatment/cure of the dermatology disease to clear
the tumor/disease index. None of the five bivariate correlations between the set of
predictors help-seeking strength measures, and to receive treatment/cure of the
dermatology disease to clear the tumor/disease index was positive, and all the five were
not statistically significant (P > .05). The partial correlations between the strength
measures for (a) described the type of dermatology disease without any recommendation
of a specific dermatology drug for treatment, (b) gave a telephone number/website to call
or to visit for more information about the advertised dermatology disease type/described
condition, and (c) to receive treatment/cure of the dermatology disease in order to clear
the tumor/disease index were statistically significant (P < .05).
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These correlation analyses may lead to the conclusion that the strength measures for (a)
described the type of dermatology disease without any recommendation of a specific
dermatology drug for treatment, (b) gave a telephone number/website to call or to visit
for more information about the advertised dermatology disease type/described condition,
and (d) to receive treatment/cure of the dermatology disease to clear the tumor/disease
are the only useful predictors. However, this judgment required caution because
predictors were correlated. However, the correlation was not a source of concern for the
multiple regression model giving that all the VIF statistics were lower than 10.
Table 14
Multiple Regression Model Summaryb

Model

1

R

.381a

R
square

.145

Adjusted
R square

.108

Std.
error of
the
estimate

1.57

DurbinWatson

Change statistics

R
Square
change

F
change

df1

df2

Sig. F
change

.145

3.88

5

114

0.003

1.19

Note. a. Predictors: (Constant), DHSAES: Stated "Ask your healthcare provider for more
information''. , DHSAES: Encouraged people with the symptoms of the described type of
dermatology disease to ask/talk to their doctor, DHSAES: Had the company's name of the
advertised skin cancer drug., DHSAES: Described the type of dermatology disease without any
recommendation of a specific dermatology drug for treatment., DHSAES: Gave a telephone
number/website to call or to visit for more information about the advertised dermatology disease
type/described condition.
b. Dependent Variable: PUDMTEDAS: receive treatment/cure of the dermatology disease in
order to clear the tumor/disease.
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Table 15
Bivariate and Partial Correlations Between Each Predictor and to Receive Treatment/Cure of the
Dermatology Disease in Order to Clear the Tumor/Disease Index
Correlation between
each predictor and the
criterion

Predictors

described the type of dermatology disease without any recommendation
of a specific dermatology drug for treatment.

Correlation
between each
predictor and the
criterion
controlling for all
other predictors

0.14

-0.02*

0.17

0.12

0.32

0.28

gave a telephone number/website to call or to visit for more information
about the advertised dermatology disease type/described condition.

0.21

0.03*

stated "ask your healthcare provider for more information''.

0.12

0.16

encouraged people with the symptoms of the described type of
dermatology disease to ask/talk to their doctor
had the company's name of the advertised dermatology drug.

Note. * P < .05. Confidence interval 95%.
Additional Findings
Some Predictors and Criteria not Significantly Related
Data analysis showed that the linear combination of product claim advertisement
measures was not significantly related to (did not predict) participate normally to the
dermatology treatment regimen, R2 = .145, F (10,109) = 1.84, p = .06 (not significant)
and to fill the dermatology disease prescription drug, R2 = .091, F (10,109) = 1.08, p =
.378 (not significant) as types of medical dermatology services utilized after exposure.
Additionally, the linear combination of product claim advertisement measures was not
significantly related to the purpose to receive treatment/cure of the dermatology in order
to look for well-being R2 = .078, F (10,109) = .923, p = .515 (not significant). The linear
combination of the help-seeking measures was not significantly related the medical
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service to consult a dermatologist/doctor regarding any symptom/problem related to skin,
hair, or nails, R2 = .060, F (5,114) = .145, p = .212 (not significant) and to the purpose to
receive dermatology treatment/service for the dermatology disease symptom
management, R2 = .003, F (5,114) = .064, p = .997 (not significant).
PT Theory Validation in the Context of This Study
PT is the theoretical framework of this study analyzed in Chapter 2. PT analyzed
individual behaviors while making a decision in a risky situation. As analyzed in Chapter
2, the dermatology patient has to make the decision to utilize medical services or not after
exposure to a dermatology product claim or help-seeking advertisement and as the
consequence of that exposure. In that condition, dermatology patient may lose his/her life
by refusing to use or by using medical services after exposure (risky situation). The risk
consists of losing or saving his/her life by not using or using the medical dermatology
services.
The test and validation of the PT in this study was through the study’s hypotheses
testing, as stated in Chapter 2.The four hypotheses testing (Tables 8, 10, 12, 14) that
preceded showed a statistically significant relationship between the DTCAs (product
claim and help-seeking advertisements) and the utilization of medical dermatology
services (types and purposes) amongst the target population. Consequently, those results
permitted to make the claim PT was verified and applicable in the context of medical
dermatology services utilization prompted by the DTCAs directed directly to consumers.
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Study Model Validation
The literature review enabled me to develop the study model presented in Chapter
2 (Figure 2). Indeed, the model explained, based on the literature, how adult dermatology
patients utilized medical services as the consequence of their exposure to the dermatology
product claim or/and help-seeking advertisements. The model, as stated in Chapter 2,
needed an empirical test and validation amongst the study target population through the
questionnaire completion and hypotheses testing. The hypotheses testing permitted to
review the study model proposed in Chapter 2 (Figure 2). The review consisted of
selecting only the dependent variables (Table 16) with a statistically significant
relationship (P ≤ .05) with independent variables for the illustration and validation of the
model (Figure 30).
In that regard, the dermatology patient in contact with the product claim
advertisement (set of predictors) utilized the following services: (a) to request and obtain
a medical prescription of the dermatology drug advertised (Q32(1)), (b) to receive the
advertised drug therapy/chemotherapy (Q32(2)), (c) to talk to the
dermatologist/surgeon/doctor about dermatology advertised prescription drug (Q32(5)),
(d) to visit a physician/dermatologist office (Q32(6)), and (e) to receive skin, hair, and/or
nails health maintenance treatment (Q32(7)). Meanwhile, the patient exposed to helpseeking advertisement went for dermatology disease screening test or used the screening
test service (Q34 (2)).
In terms of purposes of utilization, the target dermatology patients exposed to a
product claim advertisement utilized medical services in order to excise the tumor/lesion
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(Q36(4)). Al contrary, the dermatology patients in contact with the help-seeking
advertisement received medical services either to detect/diagnose early the dermatology
disease (Q38(1)) or to clear the tumor/disease (Q38(3)).
Table 16
Dependent Variables With Significant P Values for the Study Model Validation
Types and purposes of utilization

P ≤ .05

Product claim types of medical services utilized
to request and obtain a medical prescription of the dermatology drug
advertised (Q32(1))
to receive the advertised drug therapy/chemotherapy (Q32(2))
to talk to the dermatologist/surgeon/doctor about dermatology
advertised prescription drug (Q32(5))
to visit a physician/dermatologist office (Q32(6))
to receive skin, hair, and/or nails health maintenance treatment
(Q32(7))
Help-seeking type of medical service utilized
to go for dermatology disease screening test (Q34(2))
Product claim purpose of utilization
to receive treatment/cure of dermatology disease in order to excise the
tumor/lesion (Q36(4))
Help-seeking purpose of utilization
to detect/diagnose early the dermatology disease (Q38(1))
to receive treatment/cure of dermatology disease in order to clear the
tumor lesion/disease (Q38(3)
Note. P ≤ .05. Confidence interval = 95%.

0.00
0.00
0.00
0.04
0.04

0.04

0.05

0.01
0.00

Exposure to
Dermatology
DTCA (to
view, to hear,
or to read):
Patient’s
health status:
dermatology
disease

DTCA provides
information
about:

Prescription drug
advertised
Product Claim
Advertisement
or

Complete
information
Incomplete
information

or/and
Help-seeking
Advertisement

Product Claim
Advertisement
medical
services types:
Q32 (1), (2),
(5), (6), & (7).
or/and

Condition/disease
advertised
Search of
additional
information

Independent Variables

Mediation/Moderation
of patient’s Sex, age,
ethnic group,
education, medical
trend, revenue, price
of service,
employment status,
mean of payment

Types of
dermatology
medical
services
utilized:

Research Hypotheses

Help-seeking
Advertisement
medical
services type:
Q34 (2).

Purposes of
dermatology
medical
services
utilization:
Product Claim
Advertisement
utilization
purpose: Q36
(4).
or/and
Help-seeking
Advertisement
utilization
purposes: Q38
(1) & (3).

Dependent Variables

Figure 30. Empirical and validated model of the relationship between DTCAs and utilization of medical services by adult
dermatology patients after Exposure to DTCAs, by H. Zouetchou, 2015, “Direct-to-consumer advertisements and medical
services utilization amongst adult dermatology patients in the United States”, dissertation submitted as partial requirements for
the degree of Doctor of Philosophy, Health Sciences, p. 191, unpublished. Copyright 2015 by Walden University.
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The More Predicting Product Claim and Help-seeking Characteristics
The measurement items or independent variables used for product claim and helpseeking advertisements were the characteristics of the advertisements defined by the US
FDA. This research was interested also to know which characteristic applied in a DTCA
could predict more than other characteristics a particular type or purpose of medical
dermatology services utilized amongst the target population. The forced entry simple
regressions were conducted amongst product claim advertisement (question 27) and the
types (question 32) and purposes (question 36) of medical services utilization. Moreover,
the forces entry simple regressions were conducted amongst help-seeking advertisement
(question 30) and the types (question 34) and purposes (question 38) of medical services
utilization.

Then, the simple regressions permitted to identify the particular type or

purpose of medical dermatology service utilized that was prompted significantly more by
a considered product claim or help-seeking characteristic or item. The simple index of
effect size R2 enabled an identification of the characteristics with the highest simple index
of effect size R2 for a considered type or purpose of utilization. The characteristic/item
with the highest simple index of effect size R2 (amongst all variables significantly
predicting the variable) was considered being the one predicting more or explaining more
the variance in a considered type or purpose than other characteristics.
Product claim advertisement characteristics and types of utilization. The
result of the simple regression test showed an independent variable/characteristic told to
the consumers in a balanced manner the benefits and potential negative consequences of
using the advertised dermatology drug having the highest R2 value of 0.11, p = 0.00,

193
regarding the dependent variable to request and obtain a medical prescription for the
dermatology drug advertised. This R2 value meant that the characteristic told to the
consumers in a balanced manner the benefits and potential negative consequences of
using the advertised dermatology drug accounted for 11% of the variance in to request
and obtain a medical prescription for the dermatology drug advertised. This independent
variable significantly predicted more than any other the dependent variable to request and
obtain a medical prescription for the dermatology drug advertised. Moreover, an
independent variable passed on television/radio station (s) told to the viewer/listener
where to get additional prescription drug information approved by the FDA, R2 = 0.04,
p = 0.03, significantly predicted less the dependent variable to request and obtain a
medical prescription for the dermatology drug advertised.
The characteristic told to the consumers in a balanced manner the benefits and
potential negative consequences of using the advertised dermatology drug has the highest
R2 value of 0.08, p = 0.00, regarding the dependent variable to receive the advertised drug
therapy/chemotherapy. Consequently, the independent variable explained 8% of the
variance in to receive the advertised drug therapy/chemotherapy. Also, the characteristic
stated "Ask your doctor if [drug name] is right for you.’’, R2 = 0.04, p =0.03, predicted
significantly less the type of utilization to receive the advertised drug
therapy/chemotherapy. Furthermore, the variable stated both the vulgar
designation/name of the drug approved (brand) and non-approved (generic) by the U.S.
government, R2 = 0.04, p = 0.05, predicted more than the characteristic stated at least one
form of dermatology disease treated by the advertised drug and approved by the FDA
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R2 = 0.04, p =0.02 the dependent variable to talk to the dermatologist/surgeon/doctor
about dermatology advertised prescription drug.
The characteristic stated the most important dangers that the dermatology patient
may face taking the advertised drug, R2 = 0.08, p =0.00, significantly predicted more than
the characteristic published in the newspaper, magazines, review, or journal contained
this statement "You are encouraged to report negative side effects of prescription drug to
the U.S. Food and Drug Administration (FDA) Visit MedWatch5 or call 1-800-FDA1088", R2 = 0.03, p =0.05, the type to visit a physician/dermatologist office. Finally, only
stated at least one form of dermatology disease treated by the advertised drug and
approved by the FDA characteristic, R2 = 0.04, p =0.04, significantly predicted the type to
receive skin, hair, and/or nails health maintenance treatment.
Product claim advertisement characteristics and purposes of utilization. In
terms of purpose of utilization prediction, only the characteristic stated the most
important dangers that the dermatology patient may face taking the advertised drug, R2 =
0.04, p =0.03, explained 4% of the variance in the purpose to receive dermatology
treatment to have rebuilt the part of the body damaged by the dermatology disease.
Moreover, the characteristic stated the most important dangers that the dermatology
patient may face taking the advertised drug, R2 = 0.05, p =0.02, explained 5% of the
variance in the purpose to receive treatment/cure of the dermatology to look for wellbeing. However, the characteristic published in the newspaper, magazines, review, or
journal contained this statement "You are encouraged to report negative side effects of
prescription drug to the U.S. Food and Drug Administration (FDA) Visit MedWatch5 or
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call 1-800-FDA-1088.", R2 = 0.07, p =0.00, the purpose to receive treatment/cure of the
dermatology disease in order to clear the tumor. Finally, the dependent variables told to
the consumers in a balanced manner the benefits and potential negative consequences of
using the advertised dermatology drug.", R2 = 0.06, p =0.01, and published in the
newspaper, magazines, review, or journal contained this statement "You are encouraged
to report negative side effects of prescription drug to the U.S. Food and Drug
Administration (FDA) Visit MedWatch5 or call 1-800-FDA-1088.", R2 = 0.06, p =0.01,
both explained equally 6% of the variance in the purpose of receiving treatment/cure of
the dermatology disease to excise the tumor lesion.
Help-seeking advertisement characteristics and types of utilization. The
simple regression tests indicated that the characteristic described the type of dermatology
disease without any recommendation of a specific dermatology drug for treatment ", R2 =
0.04, p =0.04, accounted for 4% of the variance in the type of utilization to receive gene
therapy/biological therapy, while the variable stated "Ask your healthcare provider for
more information'', R2 = 0.06, p =0.01, explained 6% of the variance in to go for
dermatology disease screening test type of utilization. In the mine time, the simple
regression showed that the variable described the type of dermatology disease without
any recommendation of a specific dermatology drug for treatment, R2 = 0.04, p =0.03,
accounted for 4% of the variation of to receive laser surgery.
Help-seeking advertisement characteristics and purposes of utilization. The
characteristic encouraged people with the symptoms of the described type of dermatology
disease to ask/talk to their doctor, R2 = 0.05, p =0.02, accounted for 5% of the variance in
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to receive dermatology treatment/service to detect/diagnose early the dermatology
disease. Lastly, the variable had the company's name of the advertised dermatology drug,
R2 = 0.10, p = 0.00, predicted more than the characteristic gave a telephone
number/website to call or to visit for more information about the advertised dermatology
disease type/described condition, R2 = 0.04, p =0.02, the purpose of to receive
treatment/cure of the dermatology disease to clear the tumor/disease.
Summary and Transition
Chapter 4 aims to present the pilot study results, to test the multiple regression
assumptions, to test the four hypotheses, the PT, the study model, and to answer the four
research questions. The final sample of this study was 120 respondents. 71% of the 120
had the skin disease, 24% had hair disease, and 5% had nails disease.
The results of the pilot study showed the Cronbach's Alpha & reliability statistics
of the six scales ranging from 0.01 to 0.68 and within the Cronbach's Alpha & acceptable
range of was zero through one. These results enabled the final validation of the research
study instrument (questionnaire) before its use for the final study.
All the four multiple regression assumptions were met. Thus, all the multiple
regressions models of this study were generalizable, free of bias, and the results obtained
from the sample were applied to the entire population of the study.
The findings of the study permitted to reject all the four null hypotheses (H0s) and
to validate all the alternative hypotheses. Therefore, the results of the study showed that
product claim and help-seeking advertisements significantly predicted respectively the
utilization of the following medical services (a) to talk to the
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dermatologist/surgeon/doctor about dermatology advertised prescription drug and (b) to
go for dermatology disease screening test amongst adult dermatology patients attending
church services at the Saint Nicholas Catholic Church or/and receiving primary care
services at MedStar Primary Care Clinic. Besides, product claim and help-seeking
advertisements significantly predicted respectively the following purposes (a) to receive
treatment/cure of the dermatology disease to excise the tumor/lesion and (b) to receive
treatment/cure of the dermatology disease to clear the tumor/disease. The study model
and PT were validated based on the study hypotheses testing.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
Study Purpose, Nature and Motivation
The purpose, nature, and motivation of this study are the content of this section.
The intent of this quantitative correlation study was to describe the relationship between
product claim, help-seeking (independent variables), and types and purposes of medical
dermatology services utilization (dependent variable) amongst patients aged at least 18
years old. The patients were attending church services at Saint Nicholas Catholic Church
or/and receiving primary care services at MedStar Primary Care Clinic in Houston,
Texas. Also, I sought to test PT (Kahneman & Tversky, 1979) based on the description of
the relationship amongst product claim, help-seeking, and types and purposes of medical
dermatology services utilization.
The quantitative nature of this study was due to the research question and the use
of the cross-sectional survey research method. In that regard, a sample of 120 participants
selected based on the predetermined criteria completed a questionnaire of 38 questions.
The forced entry multiple regression analysis of the responses permitted me to address
the research questions. Moreover, all the multiple regression assumptions were met,
enabling the results from the sample inferable to the general population of the study
(Field, 2009).
I undertook this study to fill a gap found in the DTCAs and health services
utilization literature. In fact, previous researchers found that drug and disease DTCAs
prompted the utilization of medical services in general (Limbu & Torres, 2009; Mackert
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et al., 2010). However, those researchers were silent about the question of the
relationship between the product claim, help-seeking DTCAs, and the types and purposes
of utilization of medical services amongst the specific group of adult dermatology
patients attending church services at Saint Nicholas Catholic Church or/and receiving
primary care services at MedStar Primary Care Clinic in Houston, Texas.
Findings Summary
The results of the study presented in Chapter 4 showed that product claim
advertisement significantly prompted the utilization of the following medical
dermatology services: (a) to request and obtain a medical prescription for the
dermatology drug advertised, (b) to receive the advertised drug therapy/chemotherapy,
(c) to talk to the dermatologist/surgeon/doctor about dermatology advertised prescription
drug, (d) to visit a physician/dermatologist office, and (e) to receive skin, hair, and/or
nails health maintenance treatment. The patients exposed to the help-seeking
advertisement used the screening test of the dermatology disease.
Product claim significantly determined the tumor/lesion excision as the purpose of
medical services utilization. Finally, help-seeking advertisement significantly predicted
early disease diagnosis and tumor/disease clearance purposes of medical dermatology
service utilization. Many other types and purposes of medical services utilized had a
nonsignificant relationship with product claim and help-seeking advertisements. An
interpretation of the findings, the limitations of the study, recommendations, and
implications for positive social change are the contents of Chapter 5.
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Interpretation of the Findings
Literature Findings Versus Study Findings
These research findings confirmed, to a certain extent, the literature findings
regarding an impact of the dermatology DTCAs directed directly to consumers on the use
of medical dermatology services.
Research Question 1: Is product claim advertisement a predictor of the types of
medical services used amongst adult dermatology patients in Houston, Texas?
Research Question 1 was about product claim advertisement prompting the types
of medical services that dermatology patients used after exposure. According to the
literature analyzed in Chapter 2, 94% of cancer nurse practitioners have received a
request for the cancer drug advertised from patients (Gray & Abel, 2012). Then, these
cancer patients talked/asked their doctor about the medication featured in the
advertisement or visit a dermatologist office. Furthermore, 69.6% of APNs have seen
patients naming the drug they wanted because of their exposure to the DTCAs (Mackert
et al., 2010). Approximately 26% of the APNs testified that some patients kept their
treatment plan due to the impact of the DTCA (Mackert et al., 2010). Fifty-three million
consumers have talked to their physicians about a particular prescription drug that they
have seen in a DTCA in the United States of America (Limbu & Torres, 2009). Also,
approximately 21.2 million consumers were prompted to talk to their doctors about an
illness in response to a drug advertisement influence (Limbu & Torres, 2009). Thirty-one
percent of Americans claimed in 1999 having discussed with the doctors regarding a
prescription of a drug seen in an advertisement. A 2003 survey showed 35% of
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respondents have sought and gained more information from their physicians regarding
the prescription medicine advertised (Limbu & Torres, 2009).
The study findings follow now. Sixty-eight percent of the respondents totally
agreed having requested and obtained a medical prescription of the dermatology drug
advertised due to their exposure to a dermatology product claim advertisement (P = .000
and R = .496). In the same logic, 47% of the respondents have totally agreed having
received the advertised drug therapy (P = .003 and R = .456). Besides, 67% totally agreed
having talked to the dermatologist/surgeon/doctor about dermatology advertised
prescription drug (P = 0.000 and R = .512). Seventy percent totally agreed having visit a
physician/dermatologist office (P = .036 and R = .397). Finally, 55% of the respondents
agreed having received skin, hair, and/or nails health maintenance treatment under the
influence of the DTCAs of a prescription drug (P = .042 and R = .392). The preceding
study findings supported the above relationship between medical services utilization and
the product claim advertisement from the peer-reviewed literature. However, some
nonsignificant results (P > .05) contradicted the peer-reviewed literature by showing
nonsignificant relationships between product claim and a particular type of the
dermatology medical service. For example, 52% of the respondents agreed to participate
normally in the dermatology treatment regimen due to the DTCAs exposure. However,
the correlation between the variables was statistically nonsignificant (R = .381, P = .06).
Also, 49% agreed to fill the dermatology prescription drug after exposure to a product
claim, but the p value was higher than .05 (R = .301, P = .37).
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The comparative analysis of the literature and study findings demonstrated that
product claim advertisement persuaded, informed, and educated patients to use medical
services in general, and certain medical dermatology services in particular amongst the
study target population. The nonsignificant relationship still showed the presence of the
relationships with R values. However, the relationships were statistically not important,
consequently, did not deserve any consideration before Research Question 2.
Research Question 2: Is product claim advertisement a predictor of the purposes
of medical services utilization amongst adult dermatology patients in Houston, Texas?
Research Question 2 was the relationship between product claim and the purpose
of medical dermatology services utilization. The research findings both confirmed and
disconfirmed the peer-reviewed literature results analyzed in Chapter 2. According to
peer-reviewed literature, a dermatology patient exposed to a dermatology product claim
received medical treatment (a) to clear the tumor, (b) to excise the tumor lesion
(Samarasinghe et al., 201), or (c) to detect early the skin cancer or other dermatology
conditions (Kontos & Viswanath, 2011). Furthermore, patients received treatments to
recover from the dermatology illness or to cure/treat the disease (French et al., 2011).
These research findings showed only 4% of the respondents totally agreeing
having received treatment/cure of the dermatology disease to excise the tumor/lesion
after an exposure to a product claim advertisement. However, the correlation between the
two variables was statistically significant (R = .386, P = .05). Fifty-six percent
respondents agreed to receive dermatology treatment/cure to look for well-being.
However the p value was not statistically significant (R = .279, P = .51).
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This analysis prompted the claim that product claim effectively decided patients
about the considered purpose of the dermatology service utilization within the study
target population. Moreover, product claim effectively decided patients beyond the study
limits as supported by the literature findings. The statistically significant results showed
that the relationship was statistically important and deserved consideration. The
nonsignificant p value meant that the relationship between the product claim and the
considered purpose was real amongst the study population. However, the same
relationship was not statistically important and, therefore, did not deserve any attention
before Research Question 3.
Research Question 3: Is help-seeking advertisement a predictor of the types of
medical services utilized amongst adult dermatology patients in Houston, Texas?
Research Question 3 was about the impact of help-seeking advertisement on the
types of medical dermatology services utilized. The evidence from the literature reviewed
in Chapter 2 stated that the patient exposure to a cancer help-seeking advertisement led
(a) to consult a dermatologist regarding any symptoms observed, (b) to utilize preventive
services, (c) screening/testing services for early detection of the disease, (d) or to search
for additional health information outside of the DTCAs (Kontos &Viswanath, 2011). In
1999, around 25% of survey respondents visited their doctors to ask more about an illness
due to a help-seeking advertisement effect (Limbu and Torres, 2009). Patients exposed to
help-seeking advertisement (a) visited/consulted the doctor about symptoms they had, (b)
talked with the doctor regarding a condition advertised, or (c) discussed new medical
conditions advertised with their physicians (Flood, 2010; Kornfield et al., 2013; & Limbu
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and Torres, 2010). Moreover, help-seeking advertisement prompted patients to search for
information from outside of the advertisement (Hall et al., 201b).
This research finding showed that help-seeking advertisement significantly
prompted 71% patients who totally agreed having gone for dermatology disease
screening test after exposure (R = .303, p = .04). However, help-seeking advertisement
nonsignificant decided 81% patients who totally agreed having consulted a
dermatologist/doctor regarding any symptom/problem related to skin, hair, or nails (R =
.245, p = .21). Seventy-nine percent respondents agree having searched for additional
health information outside of the disease announcement due to their help-seeking
exposure. However, the correlation between help-seeking advertisement and the search of
additional health information outside of the disease announcement was not statistically
significant (R = .082, p = .97).
The preceding analysis led to the claim that help-seeking effectively was
impacting patients about the considered types of the medical dermatology services
utilized within the study target population. Furthermore, help-seeking effectively decided
patients beyond this study sphere as supported by the literature findings. The
nonsignificant p values meant that the relationship between the help-seeking and the
considered types of medical services was factual amongst the study population, however
were not statistically important, therefore, did not deserve any consideration before
Research Question 4.
Research Question 4: Is help-seeking advertisement a predictor of the purposes of
medical services utilization amongst adult dermatology patients in Houston, Texas?
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The Research Question 4 was the impact of help-seeking advertisement on the
purposes of medical dermatology services utilization. According to the literature, skin
help-seeking advertisement exposure led to seek the treatment of the condition or to
manage the diseases symptom (MD Anderson Cancer Center, 2013; Samarasinghe et al.,
2011; The Skin Cancer Foundation, 2013a). Patients sought for early detection, wellness,
and wellbeing when utilizing medical services after an exposure to help-seeking (French
et al., 2011; Kontos & Viswanath, 2011; Wellington, 2010). In addition, help-seeking
advertisement exposure prompted patients to receive medical dermatology services (a) to
treat the condition, (b) to manage the diseases symptom (M D A C C, 2013;
Samarasinghe et al., 2011; The Skin Cancer Foundation, 2013a), or (c) to detect early the
disease (Kontos & Viswanath , 2011).
These study findings showed that help-seeking advertisement significantly
prompted 63% patients who totally agreed having received dermatology
treatment/service to detect/diagnose early the dermatology disease (R = .347, p = .01).
Then, help-seeking advertisement significantly prompted 34% patients who totally agreed
having received dermatology treatment/service to clear the tumor or disease (R = .381, p
= .003). However, help-seeking advertisement nonsignificant prompted 42 % patients
who agreed having received dermatology treatment/service to manage the disease
symptoms (R = .053, p = .99). Sixty-nine percent did not agree at all using dermatology
services to excise the tumor lesion/disease due to help-seeking influence. The p value was
not significant (R = .206, p = .41).
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The preceding analysis prompted the claim that help-seeking effectively was
impacting patients about the considered purposes of the dermatology service utilization
within the study target population. Also, help-seeking effectively decided patients beyond
this study sphere as supported by the literature findings. The nonsignificant p values
meant that the relationship between the help-seeking and the considered purposes of
medical services was real amongst the study population, however, were not statistically
important, and did not deserve any attention.
Finally, the simple regression tests showed that certain single product claim or
help-seeking characteristic significantly predicted or explained more than others the
variance in an outcome variable. Consequently, an advertiser who wants to obtain a
particular outcome or effect on the study population, most use in the advertisement the
specific characteristic shown by this study results as being the variable predicting more
the target outcome. Moreover, according to Phrma (2011) and Limbu and Torres (2009),
the objective of the DTCAs information was not to persuade the consumer to purchase a
drug or products/services after exposure. As presented earlier, the results of this study
showed that the DTCAs significantly prompted the utilization of dermatology medical
services after exposure to a DTCA. The patient using medical dermatology service(s) due
to an exposure to a DTCA paid for or purchased the service(s) (2.5% of the sample
claimed to pay with Medicaid and 97.5% with other means). Therefore, this study results
constitutes a limit to Phrma (2011) and Limbu and Torres (2009) argument: the DTCAs
were not planned to be persuasive. However, the DTCAs ended up being persuasive.
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Study Findings and Theoretical Framework (PT)
The study findings presented in Chapter 4 provided evidence of the product claim
and help-seeking advertisements prompting the types and purposes of medical services
utilization amongst the study population. In that regards, the multiple correlation R of the
forced entry multiple regression analysis represented the strength index of the degree of
the correlation between product claim and help-seeking (dependent variables) and types
and purposes of medical dermatology services utilization (independent variables) for the
sample (Green & Salkind, 2011).
This study was a quantitative correlation study, as stated in Chapter 3. Therefore,
the aim of the study was also to test PT used as the literature foundation of the study and
describe in Chapter 2. The quantitative design tests a theory. The test of the theory
consists of describing the relationship between the dependent and independent variables.
The variables measurement is through the use of instrument or questionnaire to generate
numbers and check statistically the relationship between variables (Creswell, 2009). This
study used a questionnaire with 38 questions to measure the study variables product
claim, help-seeking, types and purposes of medical dermatology services utilization.
Then, forced entry multiple regression analysis permitted to check and to confirm a
correlation between the study variables.
The correlation between the variables led to the claim that PT was valid or
applicable in the context of this study. The validation of PT meant that PT was able to
help to describe the social phenomenon of the medical dermatology services utilization
due to the impact of the dermatology DTCAs amongst adult dermatology patients
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attending church services at the Saint Nicholas Catholic Church or/and receiving primary
medical services at MedStar Primary Care Clinic in Houston, Texas. As stated in Chapter
2, PT is a decision-making theory model that permits to describe how an individual
makes a choice when facing a risky situation or uncertainty (Kahneman & Tversky, 1979;
Kothiyal et al., 2011; Mello & Cajueiro, 2010; O'Connell, 2011). In the context of this
study, the risky situation is to recover/stay alive due to medical dermatology services
utilization after exposure to a DTCA, or to lose the life/decease in the case of
nonutilization. The dermatology patient has to make the decision in the risky condition of
dermatology disease to utilize medical services or not after being in contact with
dermatology product claim or help-seeking advertisement.
Limitations of the Study
The quantitative nature of this study was the first limitation. The cross-sectional
survey method served to conduct this study. The cross-sectional survey method led to the
use of the sophisticated instruments that were a 38-question questionnaire for data
collection, and the computer software SPSS 21.0 for data analysis. The questionnaire
gave less flexibility to the respondents in the expression of their attitudes and views
regarding the problem of the DTCAs and utilization of medical dermatology services.
SPSS 21.0 program required from the user a particular training and familiarity to be able
to operate the program. Also, the cross-sectional survey collected data only one time
from January 12 through February 22, 2015 (one month and 10 days) (Creswell, 2009;
Frankfort-Nachmias & Nachmias, 2008).
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The second limitation and threat to this research internal validity was the
environment and the time of the questionnaire completion. Ideally, the setting of the
completion has to be free of any source of noise or distraction. The time has to be
appropriate for the respondent to avoid any bias in the answers (Creswell, 2009;
Frankfort-Nachmias & Nachmias, 2008). Saint Nicholas Catholic Church’s hall did not
offer a total noise free environment. Faithful carried out usually multiple activities
(sources of noises around the hall) after church services within the parish perimeter.
Then, MedStar Primary Care Clinic’s meeting rooms where the questionnaire completion
took place were exposed, from time to time, to some little noises from other patients in
the lobby area or the television sets. However, the doors were kept closed at the two
locations during questionnaires completion to limit the risk of distraction due to the
noises in the environment. The time of the questionnaire completion was after the church
service or the meeting with the doctor at the respondent convenient. No questionnaire
completion was terminated prematurely due to the noises or time reason.
The third limitation was the use of the new instrument or questionnaire to collect
data for the first time. Indeed, the expert and pilot study validations, as described in
Chapters 3 and 4, did not eliminate completely the risk of the first-time use of the
questionnaire. The questionnaire must be capable of exactly measuring the concepts of
the DTCAs and utilization of medical services under investigation. Only multiple uses of
this questionnaire will give more assurance of the instrument capability of measuring the
concepts of interest, and will eliminate the possible construct validity threat due to the
first time use.
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The fourth limitation is the geographic limit of the study. The data collection took
place only in one city, the Houston city. Then, within the city, the data collection covered
only one church and one clinic. Therefore, the study’s results could not be generalized to
the national population of adult dermatology patients who have used medical services for
a medical reason due to an exposure to a DTCA. In the same logic, this study did not
have a sample frame to avoid sampling bias that could affect the external validity of the
findings. Thus, using a nonrandom purposive sample scheme to select the sample was a
risk for the external validity of the study. However, the predetermined inclusion criteria
in the questionnaire helped to select a representative sample. Then, all the multiple
regression assumptions were met before the hypotheses testing took place. The use of
inclusion criteria and the assumption test enabled, until certain extend, the credibility of
the external validity of this study.
The fifth and last limitation was the lack of the mediators or moderators effect test
regarding product claim and help-seeking advertisements predicting the types and
purposes of medical dermatology services utilization. According to Frosch et al. (2010),
patients’ age, sex, education, or medical history moderate or mediate the effect of an
exposure to a DTCA on the medical services utilization in the process of seeking medical
care. This study failed to test the effect of patients’ sex, age, highest grade of school
completed, type of dermatology disease, race/ethnicity, or annual household income on
the product claim and help-seeking advertisements prompting the types and purposes of
medical dermatology services utilization. Despite the failure, there are recommendations
for the future researches.
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Recommendations for Further Research
This research study offers avenues for further research. F.D.A. (2012b) and LeeWingate and Xie (2010) distinguish three types of the DTCAs that are product claim,
help-seeking, and reminder. This study only focused on product claim, and help-seeking
advertisements. Further research may be interested in the reminder advertisement
prompting medical dermatology services or not. Moreover, a new research could
investigate on the type of the DTCAs prompting more than others the utilization of
medical dermatology services. The bottom line would be to advise pharmaceutical
announcers on the type of the DTCAs that informs, educates, or prompts more (than other
types) the patient to use medical dermatology services. The use of medical dermatology
services as the consequence of the DTCAs exposure could lead to a healthier society.
The geographic limit of this study constituted a source of possible new studies.
This study only was limited to the Houston city. Then, the study sites only were two
locations within Houston city. Finally, the data collection took place amongst 120
participants. A further study covering the 50 States with more than 120 respondents could
generate different interesting results.
It is known from the literature that patients’ age, sex, education, or medical
history were mediators, and moderators of the DTCAs impacting medical services
utilization after exposure (Frosch et al., 2010). This study failed to evaluate the possible
mediation or moderation effect of patients’ sex, age, highest grade of school completed,
type of dermatology disease, race/ethnicity, or annual household income on the
relationship between the DTCAs and the utilization of medical dermatology services
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amongst the study population. A future study focusing on the mediation or moderation
analysis may generate additional information/results regarding the relationship between
product claim, help-seeking, and types and purposes of medical dermatology services
utilization.
The study findings revealed the television and online/websites as the main media
of exposure to the DTCAs amongst the study population. However, the study results did
not specify the television channels and websites of use amongst the population. Further
study could focus on the television and websites viewers’ usage habits to identify the
study population familiar television channels and websites. Pharmaceutical announcers
interested in this study population would select television channels and website
accordingly for the future product claim and help-seeking diffusion or broadcast. This
said, there are several implications for this study that deserve analysis.
Implications
Positive Social Change
I undertook this research study to satisfy related plausible social change
implications. The key study social change implication is the dermatology health
promotion via education, awareness building, and increase amongst patients aged 18 and
over attending church services at Saint Nicholas Catholic Church and/or receiving
primary care services at MedStar Primary Care Clinic in Houston, Texas. In fact,
according to Williams and Co. (2013), skin cancer is the driving force of the dermatology
service demand in the United States. Skin cancer health promotion in particular has
diverse reasons. For instance, an individual victim of skin cancer will have a high chance
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to be healed when the disease is diagnosed at the early stage. In addition, an increase
almost up to 77% occurred in nonmelanoma skin cancer treatment from 1992 through
2006 (American Cancer Society, 2013a; National Cancer Institute, 2013a; Skin Cancer
Foundation, 2013b).
Product claim advertisements enable awareness creation. Product claim created
based on this study results will educate and create awareness amongst patients about (a)
benefits and potential negative effects of the drug advertised use, (b) balanced advantages
and dangers of the drug, (c) how to report the negative side effect of the drug, (d)
additional sources of information about the drug, (e) the FDA approved drug risks, (f) the
most important danger of the drug, (g) the brand and generic drug name, (h) at least one
disease treated by the drug, and (i) the conversation with doctor about the drug
advertised. Patients exposed to the advertisements will, consequently, (a) request and
obtain a prescription of the drug advertised, (b) receive the advertised drug therapy, (c)
adhere to the treatment regimen, (d) have a conversation with the dermatologist regarding
the drug advertised, (e) visit the dermatology office, and (f) use the dermatology help
maintenance treatment. The patients impacted by the education on the most important
danger of the drug advertised will utilize medical dermatology service to rebuild the part of
the body damaged by the dermatology disease or to look for well-being. The education on

the benefits and potential negative effects of the drug advertised use and on how to report
the negative side effect of the prescription drug will prompt the patient to utilize medical
dermatology services for the tumor excision.
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Conversely, help-seeking advertisements from this study results presented in
Chapter 4 will educate and create awareness amongst patients about (a) dermatology
diseases, (b) diseases symptoms and conversation with the doctor regarding the
advertised symptoms, (c) dermatology drug manufacturers, and (d) possible sources of
information about the disease outside the advertisement. In doing so, the help-seeking
advertisements will prompt the study population (a) to use screening test services, (b) to
receive gene therapy/biological therapy, and (c) to receive laser surgery. The diseases
symptoms and conversation with the doctor education will prompt an early diagnosis of
the dermatology disease. The education about the possible sources of information about
the disease outside the help-seeking will lead to the tumor/disease clearance.
Empirical Implication
The empirical implication of the study is from the explanatory study model
empirically, statistically validated, and presented in Chapter 4. The study model
explained how product claim or help-seeking advertisements prompted the types and
purposes of medical dermatology services utilization amongst the specific study target
population. The explanation clarified the process of adult dermatology patient exposure
to the DTCAs and the consequent utilization of medical services. The explanation
provided the types and purposes of medical dermatology services that product claim or
help-seeking advertisements significantly prompted within the study population. Also,
this study results added new knowledge to the field of the DTCAs research.
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Recommendations for Practice
The study has practice and policy implications. Past researchers have claimed an
influence of drug and disease DTCAs on the consumer’s use of medical services.
However, none of them has focused the analysis on the specific characteristics of the
drug and disease advertisements, as defined by the FDA, which influenced consumers
more to utilize medical dermatology services. I run 198 forced entries simple regressions.
Thirty-one out of 198 were statistically significant. The statistically significant simple
regression results in Chapter 4 helped to identify, in the particular era of dermatology
treatment, the FDA’s characteristics of product claim and help-seeking advertisements
that significantly predicted more certain types and purposes of medical dermatology
services utilized. Furthermore, for each significantly predicting characteristic, a specific
predicted type or purpose of utilization was also identified. Consequently, the more
predicting characteristics identified could be the communication axes for the DTCAs of
pharmaceutical companies targeting exclusively the population under investigation.
Indeed, the DTCAs inform and educate patients about drug, diseases, and treatment
options. The DTCAs prompt the patients to adhere to the drug treatment plan (Phrma,
2011). As far as policy is concerned, the FDA as well as Phrma may use the results of
this study to develop the new DTCAs regulations, policies, principles, and laws, or to
revise the existing one.
Conclusion
This research study aimed to describe the statistically significant relationship
between product claim and help-seeking advertisements, and each measurement items of
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the types and purposes of medical dermatology services utilization. The study target
population was the dermatology patients aged 18 years and over living in Houston,
Texas, attending church services at Saint Nicholas Catholic Church, and/or receiving
primary care services at MedStar Primary Care Clinic. A total of 120 participants was the
final sample.
The evidence from the literature reviewed in Chapter 2 showed that product
claim and help-seeking advertisements significantly predicted the types and purposes of
medical services utilization in the United States by the dermatology patients (Limbu &
Torres, 2009; Mackert et al., 2010). I used a cross-sectional survey method to collect data
and to achieve this study objective. I tested the study’s hypotheses using a forced entry
multiple regressions test. The study findings enabled me to make the claim that product
claim and help-seeking advertisements significantly prompted adult dermatology patients
attending church services at Saint Nicholas Catholic Church and/or receiving primary
care services at MedStar clinic in Houston, Texas to receive certain medical dermatology
services for medical reasons. In other words, product claim and help-seeking
advertisements informed, educated, and persuaded patients to utilize certain medical
dermatology services for certain medical reasons as presented in Chapter 4. However, the
patient still needs the physician’s help to use the advertised drug or/and most
dermatology services despite the education provided by the product claim and helpseeking advertisements (Kontos & Viswanath, 2011; La Barbera, 2012). Patients are less
familiar with some of the medical dermatology services.
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Concretely, the set of independent variables product claim significantly prompted
the study population to receive the following medical dermatology services: (a) to request
and obtain a medical prescription of the dermatology drug advertised, (b) to receive the
advertised drug therapy/chemotherapy, (c) to talk to the dermatologist/surgeon/doctor
about dermatology advertised prescription drug, (d) to visit a physician/dermatologist
office, and (e) to receive skin, hair, and/or nails health maintenance treatment. Product
claim significantly prompted only the purpose to receive treatment/cure of the
dermatology disease to excise the tumor/lesion.
Regarding the help-seeking set of independent variables, the only type of
dermatology service significantly prompted was to go for dermatology disease screening
test. Finally, help-seeking set significantly prompted to receive dermatology
treatment/service to detect/diagnose early the dermatology disease, and to receive
treatment/cure of the dermatology disease to clear the tumor/disease as purposes of
medical services utilization.
Besides, forced simple regressions permitted to identify a particular characteristic
of product claim or help-seeking, as defined by the FDA, prompting significantly more
than others a particular type or purpose of medical dermatology services amongst the
study population. For instance, product claim characteristic told to the consumers in a
balanced manner the benefits and potential negative consequences of using the advertised
dermatology drug prompted more than any other characteristic (with the highest R2 value
of 0.11, p = 0.00) patients to request and obtain a medical prescription of the dermatology
drug advertised. Al contrary, the characteristic passed on television/radio station (s) told
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to the viewer/listener where to get additional prescription drug information approved by
the FDA (R2 = 0.04, p = 0.03) predicted significantly less the request and obtainment of a
medical prescription of the dermatology drug advertised. Furthermore, the characteristic
stated both the vulgar designation/name of the drug approved (brand) and nonapproved
(generic) by the U.S. government (R2 = 0.04, p = 0.05) impacted more than the
characteristic stated at least one form of dermatology disease treated by the advertised
drug and approved by the FDA (R2 = 0.04, p =0.02) patients to talk to the
dermatologist/surgeon/doctor about dermatology advertised prescription drug.
Concerning the purposes of utilization, the product claim characteristic stated the most
important danger that the dermatology patient may face taking the advertised drug (R2 =
0.04, p =0.03) determined significantly more a patient to receive dermatology treatment
to rebuild the part of the body damaged by the dermatology disease.
As far as help-seeking advertisement is concerned, the characteristic described the
type of dermatology disease without any recommendation of a specific dermatology drug
for treatment (R2 = 0.04, p =0.04) determined significantly more a patient to receive gene
therapy/biological therapy. Furthermore, the characteristics stated ask your healthcare
provider for more information (R2 = 0.06, p =0.01) predicted more a patient to go for
dermatology disease screening test. In the mine time, the characteristic encouraged
people with the symptoms of the described type of dermatology disease to ask/talk to
their doctor (R2 = 0.05, p =0.02) significantly predicted more a patient to receive
dermatology treatment/service to detect/diagnose early the dermatology disease. Lastly,
the characteristic had the company's name of the advertised dermatology drug (R2 = 0.10,
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p = 0.00), predicted more than the characteristic gave a telephone number/website to call
or to visit for more information about the advertised dermatology disease type/described
condition (R2 = 0.04, p =0.02) a patient to use the medical service for the tumor/disease
clearance.
This study is interesting for the study population for many reasons. Indeed, the
study’s findings provided evidence of the prescription drug and diseases DTCAs
influencing significantly the utilization of medical dermatology services amongst the
target population. The study findings revealed that 71% of the sample had skin diseases,
24% hair diseases, and 5% nails diseases. Skin diseases patients formed the largest
proportion of the sample. Most of skin conditions are curable when detected early as
discovered in the literature. Also, according to the study results, 85% of the samples were
in contact with drug advertisement through television channels versus 56.7% for the
online/websites medium. In addition, 90.8% of the samples were exposed to the
dermatology pharmaceutical disease(s) announcement through television channels versus
62.5% for online/websites medium. Consequently, announcers are encouraged to use the
product claim and help-seeking advertisements characteristics that were statistically
significant predicting or predicted in this study to create the new DTCAs. The announcers
will broadcast the new product claim and help-seeking announcements using television
channels and online/websites to reach the study population. The effect of the new DTCAs
on the population of this study will contribute to more healthy skin, hairs, and nails.
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NB: I have deleted the appendices B, E, M, and P in the course of the dissertation writing
and revisions.
Appendix A: Heribert Zouetchou National Institutes of Health Certificate

Certificate of Completion

The National Institutes of Health (NIH) Office of Extramural Research certifies that

Heribert ZOUETCHOU successfully completed the NIH Web-based training course
“Protecting Human Research Participants”.

Date of completion: 12/07/2013

Certification Number: 1340638
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Appendix C: Informed Consent Form

You are invited to take part in a research study that seeks to learn if patients with skin, hair,
and nails diseases who have seen, read, or heard (exposure) a pharmaceutical drug company's
dermatology advertisement would receive a treatment for a medical reason because of the
exposure to that advertisement. The advertisement should be about dermatology drug(s) or
disease and directed directly to patients.
The researcher is inviting you to be in the study regarding adults of both sexes living in
Houston, Texas. More details about the eligibility criteria are given in the Background
Information section below.
This form is part of a process called “informed consent” to allow you to understand this study
before deciding whether to take part. This study is being conducted by a researcher named
Heribert Zouetchou, who is a doctoral student at Walden University.
Background Information:
The purpose of this research study is to describe the relationship between the dermatology
pharmaceutical direct-to-consumer advertisement (DTCAs) and the utilization of medical
dermatology services amongst adult patients with skin, hair, and/or nails diseases in the
United States of America. In other words, this research’s intent is to describe the relationship
between dermatology product claim, help-seeking advertisements and types and purposes of
the utilization of medical services amongst adult dermatology patients.
Inclusion/eligibility criteria are (a) you attend church services at Saint Nicholas Catholic
Church or receive primary care services at MedStar Primary Care Clinic in Houston, Texas,
(b) you (the participant) have been diagnosed with a dermatology disease, (c) are at least 18
years old, (d) have seen, read, or heard (exposure) a dermatology advertisement about a
dermatology prescription drug or/and disease directed directly to the dermatology patients
and have received a treatment for a medical reason because of the exposure to the
advertisement within one year, (e) speak, read, and understand English language, (f) are
receiving dermatology treatment at a dermatology facility in Houston, Texas, and (g) are
living in Houston, Texas for at least six months continuously.
Be advised that the researcher cannot answer any questions about your current condition. If
you have any question(s) of that nature, please, follow up with your primary care physician.
Procedures:
If you agree to be in this study, you will be asked to:
Complete a questionnaire that asks about some demographic information, your
exposure to a dermatology pharmaceutical company’s advertisement directed directly
to patient regarding skin, hair, and/or nails prescription drug or disease, and the
reception for a medical reason of the medical dermatology service as the consequence
of having seen, heard, or read such advertisement in the past 12 months. The survey
contains 2 sections:
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• an eligibility section of the questionnaire that asks about topics such as your
demographic information (such as race/ethnicity and age), the skin, hair,
and/or nails disease(s), how you pay for treatments, and your exposure to a
skin, hair, and/or nails drug or disease advertisement from dermatology
pharmaceutical companies. Answering the questions should take about 8
minutes.
• Another section called main questionnaire asks about topics such as your
exposure to a skin, hair, and/or nails drug or disease advertisement from
dermatology pharmaceutical companies, and the treatments you have received
after seeing, hearing, or reading such advertisements, and the medical reason
why you receive the service. Completing this section should take about 20
minutes.
Please, respondent, be advised, in order to get accurate results, responses are needed
for each question and if there are questions that you do not want to answer, you may
discontinue the completion of the questionnaire at any time without any penalty,
discontinuation of services, or negative impact of your relationship with the
researcher.
Here are some sample questions:
Q.3. Familiarity with English Language (Please, check only one).
Speak, read and understand.
Do not speak, read and understand (Terminate the Completion)
Q.4. Attending to church service(s) at Saint Nicholas Catholic Church or receiving primary
care services at MedStar Primary Clinic in Houston (Please, check only one).
Yes.
No (Terminate the Completion)
Q.7. Have you been diagnosed with dermatology disease(s) in the past 12 months (check
only one)?
Yes
No (Terminate the Completion)
Other (Specify): (Terminate the Completion)
Q.8. Are you currently receiving dermatology treatment/services (s) here in Houston after
you have been diagnosed with dermatology disease(s) in the past 12 months (check only
one)?
Yes
No (Terminate the Completion)
Other (Specify): (Terminate the Completion)
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Q.19. Race/Ethnicity (Check only one).
White
Black, African American, or Negro
Chinese
American Indian/Alaska Native
Filipinos
Japanese
Other Asians (Specify):
Guamanian

Asian Indian
Native Hawaiian
Other Pacific Islander (Specify):
Korean
Vietnamese
Some Other Race (Specify):
Samoan

Voluntary Nature of the Study:
This study is voluntary. Everyone will respect your decision of whether or not you choose to
be in the study. No one at Saint Nicholas Catholic Church or at MedStar Primary Care Clinic
in Houston will treat you differently if you decide not to be in the study. If you decide to join
the study now, you can still change your mind during or after the study. You may stop at any
time.
Risks and Benefits of Being in the Study:
Being in this type of study involves some risks of the minor discomforts that can be
encountered in daily life, such as fatigue, pain related to eyes, ears and head, stress or
becoming upset. If in the course of the completion you feel any of those, the researchers
recommend that you stop the completion and inform him. In that case, the researcher will
immediately inform the study site’s supervisor on duty and or call the Emergency Services at
911 for immediate medical attention with the participant’s agreement. Being, in this study
would not pose risk to your safety or wellbeing. In addition, the concerns or risks related to
the participant’s physical (eye for instance) regarding the flyers and the questionnaire are the
length, the color, and the typography of the flyers. The solutions to these concerns are that
the flyers are a written in short texts and to use a high quality paper and printing selected by
infographic and/or printing’s professional (Leelanddesigns company). The questionnaire text
is double space, times news roman, 12 front size for easy and fast readability.
The benefit of participating in this study is to contribute to the creation of new knowledge.
The new knowledge will serve to promote dermatology diseases treatment and prevention
amongst patients and populations at risk. Also, the new knowledge will enable the creation of
awareness about dermatology diseases and treatments options through education amongst
patients. In addition, this study will permit the promotion amongst the patients and the
population at risk of a regular skin, hair, and nails check and screening test for an early
diagnosis of a potential dermatology disease.
Payment:
They will be no financial payment to the participants. This is to avoid any bias on the
participant’s willingness to participate to the study and on their answers to the questionnaire.
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Privacy:
Any information you provide will be kept confidential. The researcher will not use your
personal information for any purposes outside of this research project. Also, the researcher
will not include your name or anything else that could identify you in the study reports. Data
will be kept secure by the researcher in locked file or password protected database. Indeed,
the data collected will be stored for 5 years on the researcher’s laptop hard disk, USB drive,
and CD Rooms. The access to those data will be protected by a password at the researcher’s
discretion. Data will be kept for a period of at least 5 years, as required by the university.
Contacts and Questions:
You may ask any questions you have now. Or if you have questions later, you may contact
the researcher via phones numbers (cell) XXX or email addresses:
XXX@waldenu.edu/XXX@yahoo.fr If you want to talk privately about your rights as a
participant, you can call Dr. Leilani Endicott. She is the Walden University representative
who can discuss this with you. Her phone number is 1-800-925-3368, extension 3121210.
Walden University’s approval number for this study is
12-09-14-0177813 and it expires on December 10, 2015.
You may keep the consent form.

Statement of Consent:
I have read the above information and I feel I understand the study well enough to make a
decision about my involvement. By completing the survey in a face-to-face completion
with the researcher, I understand that I am agreeing to the terms described above and
signing the present form.
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Appendix D: A3 Recruiting Flyer
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Appendix F: A5 Recruiting Flyer
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Appendix G: Study Questionnaire
Time Completion started:
Completion:
Date of Completion:
/

Time Completion ends:

Total Length of

/ 2015

Place of Completion (check only one):
MedStar Primary Care Clinic
Saint Nicholas Catholic Church
ELIGIBILITY SECTION
Your answers to the following questions will help to determine if you meet the criteria to
participate in this study or not. Please, answer truthfully, clearly, and consistently during
the completion of this questionnaire.
INCLUSION CRITERIA
Q.1. City of residence.
Houston
Other (Specify)

(Terminate the Completion)

Q.2. Length of Residence in Houston (Check only one).
At least six months.
Less than six months (Terminate the Completion)
Q.3. Familiarity with English Language (Please, check only one).
Speak, read and understand.
Do not speak, read and understand (Terminate the Completion)
Q.4. Attending to church service(s) at Saint Nicholas Catholic Church or receiving
primary care
services at MedStar Primary Clinic in Houston (Please, check only one).
Yes.
No (Terminate the Completion)
Q.5. What is your age (check only one)?
18 to 34 years
35 to 51 years
52 to 64 years
65 years and above
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Q.6. Please, write in number your exact age inside the next box (Optional)
Q.7. Have you been diagnosed with dermatology disease(s) in the past 12 months
(check only one)?
Yes
No (Terminate the Completion)
Other (Specify):
Completion)

(Terminate the

Q.8. Are you currently receiving dermatology treatment/services (s) here in Houston
after you have been diagnosed with dermatology disease(s) in the past 12 months (check
only one)?
Yes
No (Terminate the Completion)
Other (Specify):
(Terminate the Completion)
Q.9. Please, Indicate your dermatology disease(s) that you are currently receiving
treatment for here in Houston (check not more than two)
Skin diseases (Eczema, dry skin, Contact Dermatitis, skin cancer, Actinic
keratosis, effect of sun exposure, acne, atopic dermatitis...)
Hair disease(s) (hair loss)
Nails disease(s) (artificial nails)
Other (Specify):
(If not skin, hair, or nails related,
Terminate the completion).
Q.10. What dermatology treatments/service are you currently receiving at the
medical dermatology facility in Houston (Write down a maximum of 3
treatment(s) for each applicable disease)?
Skin Treatment:
Hair treatment:
Nails treatment:
Don’t Know/ Not sure
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In the past 12 months, have you…
(Terminate completion if "No" for both Q.12.a. and Q.12.b.)

Yes

No

Don't
Know/
Not
sure

Q.11a. Seen, read or heard a pharmaceutical announcement done by pharmaceutical
companies (s) about a prescription drug(s) and directed directly to consumers?
Q.11.b. Seen, read or heard a pharmaceutical announcement (s) done by
pharmaceutical companies about a disease(s) and directed directly to patients?
Q.12.a. Seen, read or heard a pharmaceutical announcement (s) done by
pharmaceutical companies about dermatology prescription drug(s) and directed
directly to dermatology patients?
Q.12.b. Seen, read or heard a pharmaceutical announcement (s) done by
pharmaceutical companies about dermatology disease(s) and directed directly to
dermatology patients?

Q.13. What is/are the reason (s)/expected result (s) of the dermatology treatment that you
are currently receiving at a medical dermatology facility in Houston (Write down
a maximum of 3 reason(s) for each applicable disease)?
Reason for skin treatment:
Reason for hair treatment:
Reason for Nails treatment:
Don’t Know/ Not sure

Dermatology pharmaceutical prescription drug(s) or/and disease(s)
announcement (s) directed directly to consumers seen, read or heard
in the past 12 months. Did the announcement…
(Terminate completion if "No" for both Q.14.a. and Q.14b.)
Q.14.a. State the prescription drug name that treats dermatology
disease,
name the treated disease, and give the risks and benefits
related
to the use of the advertised prescription drug?
Q.14.b. Talk only about the dermatology disease without any
reference to a prescription drug that can treat the condition
(s)?
Q.14.c. Communicate the dermatology prescription drug name
and did not talk about the drug use?

Yes

No

Don't
Know/
Not
sure
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Dermatology treatment (s) currently
received at a medical dermatology
facility in Houston . I have been
PROMPTED by…. (Terminate if
"No" for both Q.15.a. and Q.15 .b.)
Q.15.a. The dermatology
pharmaceutical prescription drug
announcement directed directly
to dermatology patients
that I have seen, read or heard
in the past 12 months.
Q.15.b. The dermatology
pharmaceutical disease announcement
directed directly to
dermatology patients that I have
seen, read or heard in the past
12 months.
Q.15.c. a dermatologist/surgeon’s
prescription.
Q.15.d. Another dermatology patient
with the same disease who
has received or is currently
receiving the same treatment (s).

Don't
Yes No Know/ Not
sure
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Reason (s) of the dermatology
treatment (s) currently received at a
medical dermatology facility in
Houston . I have been PROMPTED
by….
Q.16.a. The dermatology
pharmaceutical prescription drug
announcement directed
directly to dermatology patients that
I have seen, read or heard in
the past 12 months.
Q.16.b. The dermatology
pharmaceutical disease announcement
directed directly to
dermatology patients that I have seen,
read or heard in the past 12
months.
Q.16c. A dermatologist/ surgeon’s
prescription.
Q.16.d. Another dermatology patient
with the same disease who has
received or is currently
receiving the same treatment (s).

Yes No

Don't
Know/
Not sure
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OTHER
Q.17. Indicate your sex.
Male
Female
Q.18. Residence Status (Check only one):
US Citizen
Permanent Resident Alien
Q.19. Race/Ethnicity (Check only one).
White
Black, African American, or Negro
Chinese
American Indian/Alaska Native
Filipinos
Japanese
Other Asians (Specify):
Guamanian

Asian Indian
Native Hawaiian
Other Pacific Islander (Specify):
Korean
Vietnamese
Some Other Race (Specify):
Samoan

Q.20. Indicate the highest grade of school completed (Check only one).
Less than 9th grade
9th to 12th grade, without diploma
High School graduate
Some college, without degree

Associate’s degree
Bachelor’s degree
Graduate degree

Q.21. Current marital status (Please, check only one).
Married
Divorced
Widowed

Separated
Never got married
Unmarried in couple
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Q.22. Current annual household income from all sources (check only one).
Less than $10,000
$10,000 to $14,999
$15,000 to $19,999
20,000 to $24,999

$25,000 to $29,999
$30,000 to $34,999
$35,000 to $39,999
40, 000 and over

Q.23.Write the exact total number of your household members inside the next box:
Q.24. I pay for my current dermatology treatments at medical dermatology facility in
Houston (check not more than one),
With Medicaid insurance only.
With other mean (s) of payment only (private/employer insurance, Medicare,
credit/debit card, cash).
With Medicaid insurance and other mean (s) of payment (Specify other mean(s)):
Please, Continue to the Main Questionnaire or Q.25.
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MAIN QUESTIONNAIRE
Section 1: Dermatology Product Claim Advertisement Exposure Scale (DPCAES)
The set of questions that follow are about the exposure/contact with a dermatology
pharmaceutical drug(s) announcement (Q.14a), directed directly to patients in the past 12
months.
Q.25. Indicate where you have seen, read, or heard dermatology pharmaceutical
prescription drug(s) announcement directed directly to patients in the past 12
months (check all that applies)
Oncology magazines/Journals
Radio stations
TV channels
Pharmacy Journals

Social media (YouTube, Facebook, Twitter,
Skype, Google, LinkedIn, Yahoo)
Newspaper
Online/Website (pharmaceutical,
Companies, U.S. Government, private)
Other (Specify):

Q.26. Please, provide the name/title of the dermatology pharmaceutical prescription
drug(s) announcement (Q.14a) directed directly to patients that you have seen,
read, or heard in the past 12 months. (Write down a maximum of 3
name(s)/title(s) for each applicable disease).
Skin drug announcement:
Hair drug announcement:
Nails drug announcement:
Don’t Know/Not sure
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Q.27. Instructions: I would like to ask you about some things that
dermatology prescription drug pharmaceutical announcements (Q.14a) directed
directly to patients do. Those things can prompt patients to receive dermatology
treatments for particular reason(s) or purpose(s). You will provide your answer for
all statements even if you think some are alike. Below is a scale that ranges from
Not agree at all to Totally agree. Please, indicate the extent to which you agree
with each statement regarding the dermatology drug pharmaceutical
announcement(s) that you have seen, read, or heard in the past 12 months
(Circle one answer for each statement).
DPCAES

Not
Agree
at All

Not
Agree

Agree/
Not agree

Agree

Totally
Agree

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

In the past 12 months, dermatology
prescription drug announcement(s)…
1. Told to the consumers in a balanced manner
the benefits and potential negative consequences
of using the advertised
dermatology drug.
2. Told in a balanced manner about the
advantages and
dangers related to the advertised dermatology
drug use.
3. Published in the newspaper, magazines,
review, or
journal contained this statement "You are
encouraged to
report negative side effects of prescription
drug to the
U.S. Food and Drug Administration (FDA)
Visit
MedWatch5 or call 1-800-FDA-1088."
4. Passed on Television/Radio station (s) told to
the viewer/listener where to get additional
prescription drug
information approved by the FDA
5. Audio broadcast stated the most serious
risks/dangers that the
dermatology drug user may encounter.
6. Said the drug risk(s)/danger(s) approved by
FDA and included in the drug information or
label).
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Not
Agree
at All

Not
Agree

Agree/
Not
agree

Agree

Totally
Agree

1

2

3

4

5

1

2

3

4

5

9. Stated at least one form of dermatology
disease treated by the advertised drug and
approved by the FDA

1

2

3

4

5

10. Stated "Ask your doctor if [drug name] is
right for you.''

1

2

3

4

5

DPCAES

7. Stated the most important dangers that the
dermatology patient
may face taking the advertised drug.
8. Stated both the vulgar designation/name of the
drug approved (brand) and non-approved
(generic) by the U.S. government.

Section 2: Dermatology Help-seeking Advertisement Exposure Scale (DHSAES)
The set of questions that follow are about your contact with dermatology pharmaceutical
disease(s) announcement(Q.14b), directed directly to patients in the past 12 months.
Q.28. Indicate where you have seen, read, or heard dermatology pharmaceutical
disease(s) announcement (Q.14b) in the past 12 months (check all that applies)
Oncology magazines/Journals
Radio stations
TV channels
Pharmacy Journals

Social media (YouTube, Facebook, Twitter,
Skype, Google, LinkedIn, Yahoo)
Newspaper
Online/Website (drug companies, Government,
private)
Other (Specify):

Q.29. Please, provide the name/title of the dermatology pharmaceutical disease(s)
announcement (Q.14b) that you have seen, read, or heard in the past 12 months.
(Write down maximum 3 name(s)/title(s) for each applicable disease).
Skin disease announcement:
Hair disease announcement:
Nails disease announcements:
Don’t Know/Not sure
Q.30. Instructions: I would like to ask you about some things that dermatology
disease(s) pharmaceutical announcements (Q.14b)directed directly to patients do.
Those things can prompt patients to receive dermatology treatments for particular
result(s) or purpose(s).You will provide your answer for all statements even if you
think some are alike.
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Below is a scale that ranges from Not agree at all to Totally agree. Please, indicate the
extent to which you agree with each statement regarding the dermatology
pharmaceutical disease announcement (s) that you have seen, read, or heard in the
past 12 months (Circle one answer for each statement).
DHSAES

Not
Agree
at All

Not
Agree

Agree/Not
agree

Agree

Totally
Agree

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

In the past 12 months, dermatology
pharmaceutical disease announcement (s)…
1.

2.

3.

4.

Described the type of dermatology disease
without any recommendation of a specific
dermatology drug for treatment.
Encouraged people with the symptoms of
the described type of dermatology disease
to ask/talk to their doctor
Had the company's name of the advertised
dermatology drug.
Gave a telephone number/website to call or
to visit for more information about the
advertised dermatology disease
type/described condition.

5. Stated "Ask your healthcare provider for more
information''.

Section 3: Types of Medical Dermatology Treatments Utilized after Exposure to
Dermatology DTCA of Prescription Drug Scale (TDMTUEPDAS)
The questions that follow are about the medical dermatology treatments received after
exposure to dermatology pharmaceutical prescription drug(s) announcement (Q.14a),
directed directly to patients in the past 12 months.
Q.31. What is/are the medical dermatology treatment(s) that you are currently
receiving at a medical dermatology facility in Houston because of the prescription
drug(s) announcement (Q.14a) directed directly to patients that you have seen, read, or
heard in the past 12 months? (Write down a maximum of 3 treatment(s) for each
applicable treatment).
Skin treatment(s):
Hair treatment(s):
Nails treatment(s):
Don’t Know/Not sure
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Q.32. Patients several times affirmed that they have received the following
medical dermatology treatment(s) as the consequence of having seen, heard, or
read dermatology pharmaceutical drug(s) announcement (Q.14a) directed directly
to patients. Below is a scale that ranges from Not agree at all to Totally agree.
Please,
indicate the extent to which you agree with each statement
regarding the pharmaceutical prescription drug announcement(s) that you
have seen, read, or heard in the past 12 months (Circle one answer for each
statement).

Not
Agree
at All

Not
Agree

Agree/Not
agree

Agree

Totally
Agree

1

2

3

4

5

Receive the advertised drug
therapy/Chemotherapy.

1

2

3

4

5

Participate normally to the dermatology
treatment regimen.

1

2

3

4

5

Fill the dermatology disease
prescription drug.

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

TDMTUEPDAS
In the past 12 months, dermatology
prescription drug announcement (s) prompted
me to…

1.

2.

3.

4.

5.

Request and obtain a medical
prescription of the dermatology drug
advertised.

Talk to the
dermatologist/surgeon/doctor about a
dermatology advertised prescription
drug.

6.

Visit a physician/dermatologist office.

7.

Receive Skin, hair, and/or nails health
maintenance treatment.
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Section 4: Types of Medical Dermatology Treatments Utilized after Exposure to the
Dermatology Disease DTCA Scale (TDMTUEDDAS)
The questions that follow are about the medical dermatology treatments received after
exposure to dermatology pharmaceutical disease(s) announcement (Q.14b), directed
directly to patients in the past 12 months.
Q.33. What is/are the medical dermatology treatment(s) that you are currently
receiving at a medical dermatology facility in Houston because of the
pharmaceutical disease(s) announcement (Q.14b) directed directly to consumers
that you have seen, read, or heard in the past 12 months? (Write down a
maximum of 3 treatment(s) for each applicable disease).
Skin disease treatment(s):
Hair disease treatment(s):
Nails disease treatment(s):
Don’t Know/Not sure
Q.34. Patients several times affirmed that they have received the following
medical dermatology treatment(s) as the consequence of having seen, heard, or
read dermatology pharmaceutical disease(s) announcement directed directly to
patients (Q.14b). Below is a scale that ranges from Not agree at all to Totally agree.
Please, indicate the extent to which you agree with each statement regarding the
dermatology pharmaceutical disease announcement(s) that you have seen,
read, or heard in the past 12 months(Circle one answer for each statement).

TDMTUEDDAS

Not
Agree
at All

Not
Agree

Agree/Not
agree

Agree

Totally
Agree

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

In the past 12 months, dermatology
pharmaceutical disease announcement (s)
prompted me to…

1. Consult a dermatologist/doctor regarding any
symptom/problem related to skin, hair, or
nails.
2. Go for dermatology disease screening test.
3. Receive gene therapy/biological therapy.
4. Participate to dermatology clinical
trial/experimental
treatment.
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1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

12. Go through skin grafting and reconstructive
surgery.

1

2

3

4

5

13. Go through a standard surgical
excision/resection.

1

2

3

4

5

1

2

3

4

5

5. Receive cryotherapy/Cryosurgery
6. Receive curettage and cautery/Curettage and
electrodessiccation/Electrodessiccation and
curettage.
7. Receive an electrodessication /"scraping and
burning”.
8. Receive laser surgery.
9. Go through lymph node surgery.
10. Go through a mohs micrographic surgery
11. Go through a radiotherapy/radiation.

14. Search for additional health information
outside of the
disease announcement.

Section 5: Purposes of the Utilization of Dermatology Medical Treatments after
Exposure to Dermatology DTCA of Prescription Drug Scale (PUDMTEDDAS)
The questions that follow are about expected result(s)/reason(s) of the medical
dermatology treatments received after exposure to dermatology pharmaceutical
prescription drug(s) announcement (Q.14a), directed directly to patients in the past 12
months.
Q.35. What is/are the expected result(s)/reason(s) why of your medical dermatology
treatment(s) that you are currently receiving at a medical dermatology facility in
Houston because of the pharmaceutical prescription drug(s) announcement
(Q.14a) directed directly to patients that you have seen, read, or heard in the past
12 months? (Write down a maximum of 3 reason(s) for each applicable disease).
Reason(s) skin disease treatment(s):
Reason(s) hair disease treatment(s):
Reason(s) nails disease treatment(s):
Don’t Know/Not sure
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Q.36. Patients several times affirmed that they have received the medical dermatology
treatment(s) for the following expected result(s)/reason(s), as the consequence of
having seen, heard, or read dermatology pharmaceutical prescription drug
announcement(s) directed directly to patients. Below is a scale that ranges from Not agree
at all to Totally agree.
Please, indicate the extent to which you agree with each statement regarding the
Dermatology pharmaceutical prescription drug announcement(s) that you have
seen, read, or heard in the past 12 months (Circle one answer for each statement).

PUDMTEDDAS

Not
Agree
at All

Not
Agree

Agree/Not
agree

Agree

Totally
Agree

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

In the past 12 months,
dermatology pharmaceutical
prescription drug announcement
(s) prompted me to…
1. Receive dermatology

treatment to have rebuilt
the part of the body
damaged by the
dermatology disease.
2. Receive treatment/cure of

the dermatology in order to
look for well-being.
3. Receive treatment/cure of

the dermatology disease in
order to clear the tumor.
4. Receive treatment/cure of

the dermatology disease in
order to excise the tumor
lesion.
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Section 6: Purposes of the Utilization of Medical Dermatology Treatment after
Exposure to Dermatology DTCA of Disease Scale (PUDMTEDAS)
The questions that follow are about expected result(s)/reason(s) of the medical
dermatology treatments received after exposure to dermatology pharmaceutical disease(s)
announcement (Q.14b), directed directly to patients in the past 12 months.
Q.37. What is/are the expected result(s)/reason(s) why of your medical dermatology
treatment(s) that you are currently receiving at a medical dermatology facility in
Houston because of the dermatology pharmaceutical disease(s) announcement (Q.14a)
directed directly to patients that you have seen, read, or heard in the past 12 months?
(Write down maximum 3 reason(s) for each applicable treatment).
Reason(s) skin disease treatment(s):
Reason(s) Hair disease treatment(s):
Reason(s) Nails disease treatment(s):
Don’t Know/Not sure
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Q.38. Patients several times affirmed that they have received the medical dermatology
treatment(s) for the following expected result(s)/reason(s), as the consequence of
having seen, heard, or read dermatology pharmaceutical disease announcement(s)
(Q.14b) directed directly to patients. Below is a scale that ranges from Not agree at all to
Totally agree.
Please, indicate the extent to which you agree with each statement regarding the
dermatology pharmaceutical disease announcement(s) that you have seen, read,
or heard in the past 12 months (Circle one answer for each statement).

PUDMTEDAS

Not
Agree
at All

Not
Agree

Agree/Not
agree

Agree

Totally
Agree

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

In the past 12 months,
dermatology pharmaceutical
disease announcement (s)
prompted me to…
1. Receive dermatology

treatment/service to
detect/diagnose early the
dermatology disease.
2. Receive dermatology

treatment/service for the
dermatology disease
symptom management.
3. Receive Treatment/cure of

the dermatology disease in
order to clear the
tumor/disease.
4. Receive Treatment/cure of

the dermatology disease in
order to excise the tumor
lesion/disease.

You have come to the end of this survey. I thank you very much for your valuable
contribution and precious time.
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Appendix H: Questionnaire Completion Guide

This Guide provides the researcher with the necessary help to check the answer each
question. Also, the guide provides with the help to check consistency amongst answers
for several related questions. This is to be used by the researcher to approve each
completed questionnaire.
ELIGIBILITY SECTION

Your answers to the following questions will help to determine if you meet the criteria to
participate in this study or not. Please, answer truthfully, clearly, and consistently.
INCLUSION CRITERIA
Q.1. City of residence.
Houston
Other (Specify)

(Terminate the completion)

Q.2. Length of Residence in Houston (Check only one).
At least six months.
Less than six months (Terminate the Completion)
Q.3. Familiarity with English Language.


If you check the first answer, continue with the completion.



If you check the second answer, terminate the completion because you cannot
participate in this study if you cannot speak, read, and understand English
language which is the language of this survey.

Q.4. Attending to church service(s) at Saint Nicholas Catholic Church in Houston or
receiving primary care services at MedStar Primary Clinic in Houston (Please, check
only one).



Yes, continue to Q.5.
No, Terminate the completion.
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Q.5. What is your age?


Please, only one answer be checked.

Q.6. Please, write in number your exact age inside the next box (Optional)


This answer is optional.



However, if you choose to provide it, use a two digit number (00) to give your
exact age at the time of the completion.

Q.7. Have you been diagnosed with dermatology disease (s) in the past 12 months?
 Only one answer be checked, and if you check “No”, terminate the completion
completely because the study is designed to survey dermatology disease patients.
 If you choose “Other” as answer, specify the name of the disease and terminate
the completion.
Q.8. Are you currently receiving dermatology disease treatment at a dermatology
facility in
Houston after you have been diagnosed with dermatology disease in the past 12
months?
 Only one answer be checked.
 If “No”, terminate the completion completely because the study is designed to
survey dermatology patients who are receiving treatment at a dermatology
facility in Houston at the time of the completion as the consequence of their
exposure to dermatology DTCAs in the past 12 months. Then, they attend church
services at Saint Nicholas Catholic Church in Houston or receiving primary care
services at MedStar Primary Care Clinic of Houston, Texas.
 Also, if you choose “Other” as answer, terminate the completion.
Q.9. Please, Indicate your dermatology disease that you are currently receiving
treatment for in
Houston.
 There should not be more than three answers checked for this question.
 If you choose “Other” as answer, terminate the completion.
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Q.10. What dermatology treatments are you currently receiving at
the dermatology facility in Houston ?


Write down a maximum of 3 treatment(s) for each applicable disease if your
answer is different from “Don’t Know/Not Sure”.

Q.11:


It is about both pharmaceutical prescription drug/disease announcements in
general seen, read, or heard in the past 12 months. Check only one answer for
each statement.

Q.12:
 It is about dermatology pharmaceutical prescription drug/disease announcement
in particular seen, read, or heard in the past 12 months.
 Check only one answer for each statement. Terminate the completion if "No" for
both Q.12.a. and Q.12.b. because the target population for this study is the
dermatology patients who have seen, read, or heard in the past 12 months
dermatology pharmaceutical prescription drug/disease announcement and have
received treatment as the consequence of that exposure.
 If you answer “Yes” for Q12a, Q.11a should also be “Yes” too.
 If you answer “Yes” for Q12b, Q.11b should also be “Yes” too.
Q.13. What is/are the reason (s)/expected result (s) of the dermatology treatment that you
are currently receiving at a dermatology facility in Houston?


Write down a maximum of 3 treatment(s) for each applicable disease.

Q.14.: It is about exposure or contact with dermatology pharmaceutical prescription
drug, disease, and reminder announcements in particular seen, read, or heard in the
past 12 months.
 Check only one answer for each statement. (Terminate completion if "No" for
both Q.14.a. and Q.14.b.)
Q.15.: It is about the factors that prompted the patients to receive current
dermatology treatment(s) at a dermatology facility in Houston (Terminate if "No"
for both Q.15.a. and Q15.b.).
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Check only one answer for each statement.

Q.16.: It is about the factors that prompted the patients to go for the expected
results/reasons of dermatology treatment currently received in Houston .
Check only one answer for each statement.
OTHER
Q.17. Indicate your sex.
Please, only one answer be checked.
Q.18. Residence Status (Check only one):
US Citizen
Permanent Resident Alien
Q.19. Race/Ethnicity.
 Please, do not check more than one answer for this question.
Q.20. Indicate the highest grade of school completed.
 There should not be more than one answer checked.
 The checked answer should be the highest grade of school completed by the
participant
at the time of the completion.
Q.21. Current marital status?


There should not be more than one answer checked.



The checked answer should be the participant’s marital status at the time of
completion.

Q.22. Current annual household income from all sources.


Do not check more than one answer here.



The checked answer should be the overall income of participant’s household
made last year.

Q.23. Write the exact total number of your household members inside the next box:
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Use a two digit number (00) to give your exact total number of your household’s
members.



The exact total number of the participant’s household members at the time of the
completion should not include visitors, however only those who are living
permanently/at least six months continuously in the household.



The researcher will use this information to check the consistency with question 8.

Q.24. I pay for my current dermatology treatments …


They should not be more than one answer checked for this question.

MAIN QUESTIONNAIRE
Section 1: Dermatology Product Claim Advertisement Exposure Scale (DPCAES)
Q.25. Indicate where you have seen, read, or heard dermatology pharmaceutical
prescription drug(s) announcement directed directly to patients in the past 12
months


Please, check all answers that apply to you. If you have an answer that is not
listed, provide or specify that answer as “other”.

Q.26. Please, provide the name/title of the dermatology pharmaceutical
prescription drug(s) announcement directed directly to patients that you have
seen, read, or heard in the past 12 months.


Write down a maximum of 3 name(s)/title(s) for each applicable disease, if your
answer is different from “Don’t Know/Not Sure”.

Q.27. Instructions: We would like to ask you about some things that
dermatology prescription drug pharmaceutical announcements directed
directly to patients do. Those things can prompt patients to receive
dermatology treatments for particular reason(s) or purpose(s). You will
provide your answer for all statements even if you think some are alike. Below is
a scale
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that ranges from Not agree at all to Totally agree. Please, indicate the extent to
which you agree with each statement regarding the dermatology drug
pharmaceutical announcement(s) that you have seen, read, or heard in the past 12
months.


Circle only one answer for each statement.

Section 2: Dermatology Help-seeking Advertisement Exposure Scale (DHSAES)
Q.28. Indicate where you have seen, read, or heard dermatology pharmaceutical
disease(s) announcement in the past 12 months.


Please, check all answers that apply to you. If you have an answer that is not
listed, provide or specify that answer as “other”.

Q.29. Please, provide the name/title of the dermatology pharmaceutical
disease(s) announcement that you have seen, read, or heard in the
past 12 months.


Write down a maximum of 3 name(s)/title(s) for each applicable disease.

Q.30. Instructions: We would like to ask you about some things that dermatology
disease(s) pharmaceutical announcements directed directly to patients do. Those
things can prompt patients to receive dermatology treatments for particular result(s)
or purpose(s).You will provide your answer for all statements even if you think
some are alike. Below is a scale that ranges from Not agree at all to Totally agree. Please,
indicate the extent to which you agree with each statement regarding the
dermatology pharmaceutical disease announcement (s) that you have seen, read, or
heard in the past 12 months.


Respondent should answer this question by circling one number that represents
the selected answer for each statement.

Section 3: Types of Medical Dermatology Treatments Utilized after Exposure to the
Dermatology DTCA of Prescription Drug Scale (TDMTUEDDAS)
Q.31. What is/are the medical dermatology treatment(s) that you are currently
receiving in Houston because of the dermatology prescription drug(s)
announcement directed directly to patients that you have seen, read, or heard
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in the past 12 months?


Write down a maximum of 3 treatments for each applicable disease, if your
answer is different from “Don’t Know/Not Sure”.



Your answer should be appropriate for Q.9. (dermatology disease that you are
currently receiving treatment for in Houston ).



Your answer should be listed also at Q.10. (the dermatology treatment that you
are currently receiving at a dermatology facility in Houston).



Your answer should be appropriate for Q.13. (the expected result/reasons for the
dermatology treatment that you are currently receiving at a dermatology facility
in Houston).

Q.32. Patients several times affirmed that they have received the following
medical dermatology treatment(s) as the consequence of having seen, heard,
or read dermatology pharmaceutical drug(s) announcement directed directly
to patients. Below is a scale that ranges from Not agree at all to Totally agree.
Please, indicate the extent to which you agree with each statement regarding the
dermatology pharmaceutical prescription drug announcement(s) that you have
seen, read, or heard in the past 12 months.


Respondent should answer this question by circling one number that represents
the selected answer for each statement.



Your “Agree/Totally agree” answer should be appropriate for Q.9. (dermatology
disease that you are currently receiving treatment for at a dermatology facility in
Houston).



Your answer should be listed also at Q.10. (the dermatology treatment that you
are currently receiving at a dermatology facility in Houston).



Your “Agree/Totally agree” answer should be appropriate for Q.13. (the expected
results/reasons of the dermatology treatment that you are currently receiving at a
dermatology facility in Houston in Houston ).
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Your answer should be “Yes” for Q.33.2. (the dermatology pharmaceutical
prescription drug announcement prompted you to receive the current dermatology
treatment).



If you agree with Q.32.2 (Receive the advertised drug therapy) and Q.32.4 (Fill
the dermatology prescription drug), you should have a type of drug treatment
listed as one of your answers in Q.31. above (the medical dermatology
treatment(s) that you are currently receiving in Houston because of the
dermatology prescription drug(s) announcement directed directly to patients that
you have seen, read, or heard in the past 12 months).

Section 4: Types of Medical Dermatology Treatments Utilized after Exposure to
Dermatology DTCA of Disease Scale (TDMTUEDAS)
Q.33. What is/are the medical dermatology treatment(s) that you are currently
receiving at a dermatology facility in Houston because of the dermatology
pharmaceutical disease(s) announcement directed directly to consumers that you
have seen, read, or heard in the past 12 months?


Write down a maximum of 3 treatments for each applicable disease, if your
answer is different from “Don’t Know/Not Sure”.



Your answer should be consistent with Q.9. (dermatology disease that you are
currently receiving treatment for at a dermatology facility in Houston).



Your answer should be listed also at Q.10. (the dermatology treatment that you
are currently receiving at a dermatology facility in Houston).



Your answer should be consistent with Q.13. (the expected result/reasons for the
dermatology treatment that you are currently receiving at a dermatology facility
in Houston ).

Q.34. Patients several times affirmed that they have received the following
medical dermatology treatment(s) as the consequence of having seen, heard,

or

read dermatology pharmaceutical disease(s) announcement directed directly to
patients. Below is a scale that ranges from Not agree at all to Totally agree. Please,
indicate the extent to which you agree with each statement regarding the
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dermatology pharmaceutical disease announcement(s) that you have seen,
read, or heard in the past 12 months.


Respondent should answer this question by circling one number that represents
the selected answer for each statement.



Your “Agree/Totally agree” answer should be appropriate for Q.9. (dermatology
disease that you are currently receiving treatment for at a dermatology facility in
Houston ).



Your “Agree/Totally agree” answers should be consistent with for Q.10. (the
dermatology treatment that you are currently receiving at a dermatology facility
in Houston).



Your answer should be “Yes” for Q.15.b. (the dermatology pharmaceutical
disease announcement prompted you to receive the current dermatology
treatment).

Section 5: Purposes of the Utilization of Medical Dermatology Treatments after
Exposure to Dermatology DTCA of Prescription Drug Scale (PUDMTEPDAS)
Q.35. What is/are the expected result(s)/reason(s) why of your dermatology
medical treatment(s) that you are currently receiving at a dermatology facility in
Houston because of the pharmaceutical prescription drug(s) announcement
directed directly to patients that you have seen, read, or heard in the past 12 months?


Write down a maximum of 3 treatments for each applicable disease, if you answer
is different from “Don’t Know/Not Sure”.



Your answer should be consistent with for Q.9. (dermatology disease that you are
currently receiving treatment for at a dermatology facility in Houston).



Your answer should be listed also at Q.10. (the dermatology treatment that you
are currently receiving at a dermatology facility in Houston).



Your answer should be listed also at Q.13. (the expected results/reasons of the
dermatology treatment that you are currently receiving at a dermatology facility
in Houston).
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Your answer should be “Yes” for Q.15.a. (dermatology pharmaceutical
prescription drug announcement prompted you to receive the current dermatology
treatment).



Verify that if you Agreed/Totally agreed with Q.32.2 (Receive the advertised drug
therapy) and Q.32.4 (Fill the dermatology disease prescription drug), you should
have a type of drug treatment listed as one of your answers in Q.31. above (the
medical dermatology treatment(s) that you are currently receiving at a
dermatology facility in Houston because of the dermatology pharmaceutical
prescription drug(s) announcement directed directly to patients that you have
seen, read, or heard in the past 12 months).

Q.36. Patients several times affirmed that they have received the dermatology
medical treatment(s) for the following expected result(s)/reason(s), as the
consequence of having seen, heard, or read dermatology pharmaceutical
prescription drug announcement(s) directed directly to patients. Below is a scale
that ranges from Not agree at all to Totally agree. Please, indicate the extent to
which you agree with each statement regarding the dermatology
pharmaceutical prescription drug announcement(s) that you have seen, read,
or heard in the past 12 months.


Respondent should answer this question by circling one number that represents
the selected answer for each statement.



Your “Agree/Totally agree” answer should be appropriate for Q.9. (dermatology
disease that you are currently receiving treatment for at a dermatology facility in
Houston).



Your “Agree/Totally agree” answers should be listed also at Q.13. (the expected
results/reasons of the dermatology treatment that you are currently receiving at a
dermatology facility in Houston).

273
Section 6: Purposes of the Utilization of Medical Dermatology Treatment after
Exposure to dermatology DTCA of Disease Scale (PUDMTEDAS)
Q.37. What is/are the expected result(s)/reason(s) why of your medical dermatology
treatment(s) that you are currently receiving at a dermatology facility in Houston
because of the dermatology pharmaceutical disease(s) announcement directed
directly to patients that you have seen, read, or heard in the past 12 months?


Write down a maximum of 3 treatments for each applicable disease, if your
answer is different from “Don’t Know/Not Sure”.



Your answer should be consistent with Q.9. (dermatology disease that you are
currently receiving treatment for at a dermatology facility in Houston).



Your answer should be consistent with Q.10. (dermatology treatment that you are
currently receiving at a dermatology facility in Houston ).



Your answer should be listed at Q.13. (the expected result/reasons for the
dermatology treatment that you are currently receiving at a dermatology facility
in Houston ).



Your answer should be listed at Q.33. (What is/are the medical dermatology
treatment(s) that you are currently receiving at a dermatology facility in Houston
because of the pharmaceutical disease(s) announcement directed directly to
consumers that you have seen, read, or heard in the past 12 months?).

Q.38. Patients several times affirmed that they have received the dermatology
medical treatment(s) for the following expected result(s)/reason(s), as the
consequence of having seen, heard, or read dermatology pharmaceutical disease
announcement(s) directed directly to patients. Below is a scale that ranges from
Not agree at all to Totally agree.
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Please, indicate the extent to which you agree with each statement regarding
the dermatology pharmaceutical disease announcement(s) that you have seen, read,
or heard in the past 12 months.


Respondent should answer this question by circling one number that represents
the selected answer for each statement.



Your “Agree/Totally agree” answers should be consistent with Q.9. (dermatology
disease that you are currently receiving treatment for at a dermatology facility in
Houston ).



Your answer should be consistent with Q.10. (dermatology treatment that you are
currently receiving at a dermatology facility in Houston ).



Your “Agree/Totally agree” answers should be listed also at Q.13. (expected
results/reasons of the dermatology treatment that you are currently receiving at a
dermatology facility in Houston ).



Your “Agree/Totally agree” answers should be consistent with Q.33. (What is/are
the medical dermatology treatment(s) that you are currently receiving at a
dermatology facility in Houston because of the dermatology pharmaceutical
disease(s) announcement directed directly to consumers that you have seen, read,
or heard in the past 12 months?.
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Appendix I: Dr. Raj Final Approval of the Study Questionnaire
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Appendix J: Dr. Kadrie Final Approval of the Study Questionnaire
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Appendix K: Dr. Thomas’ Edit of the Mohs Section of the Study Questionnaire
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Appendix L: Ann Parker First Draft Questionnaire Recommandations After Review
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Appendix N: Dr Parker Final Approval of the Study
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Appendix O: Thomas Abrams Approval of the DTCAs Variables of the Questionnaire
TELEPHONE CONVERSATION WITH THOMAS ABRAMS
Date: 08/29/2013
Time: 13: 36 (USCST) – 13:41:13 (0:05:13)
His phone number: XXX
Topic: DTCA Characteristics
Heribert: My name is Heribert from Walden University. Thank you for returning
my call. I am working on my dissertation and the topic is DTCAs of prescription drug
and disease. I would like to request for your expertise to review the sections of my
dissertation on DTCAs written based on the FDA’s website resources and your
PowerPoint presentations. If you don’t mind, is it possible to have your email address so
that I can send you an email clarifying my request?
T. Abram: I do apologize for the voice mail, this is the first one that I have
received and I don’t know what went wrong with my answering machine. All the
resources on our website are accurate and updated. You can use them for your
dissertation. Unfortunately I don’t have resources and time to review external documents.
We spend a lot of time reviewing internal documents. However, if you have any question,
call me I can answer for you.
Thank you! Bye bye!
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Appendix Q: American Journal of Public Health’s Zouetchou Permission
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Appendix R: Dr Rachel Kientcha-Tita Letter of Consent
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Appendix S: Rv. Fr Desmond Ohankwere Letter of Consent
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Appendix T: Dr Mays Letter on Questionnaire Development and Approval

